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Pulmonary fungal infections in the transplant recipient
After their introduction in the early 1960s, solid organ and bone marrow transplantation have 
now become established treatment options for a wide range of potentially fatal disorders. 
This advance in the field of medicine also heralded a new era in the field of prevention, di-
agnosis and treatment of opportunistic fungal infections. Prior to this time, these infections 
were encountered infrequently in patients receiving intensive chemotherapy, suffering from 
malnourishment or from congenital or acquired immunological disorders [1, 2]. Because of 
the relatively low incidence of diseases caused by these pathogens, interest in exploration of 
the specific fungal host-pathogen interactions was limited. This however changed along with 
the rising numbers of patients with a severely compromised immune system and the parallel 
increase in the incidence of fungal infections. It soon became recognized that this emerging 
class of pathogens was responsible for a high morbidity and mortality in the transplanted 
population [3-5].
The timing and type of fungal infection correlates with the specific immunodeficiency 
imposed by underlying disease or treatment modalities received by the patient [6]. Pneumo-
cystis pneumonia (PCP), caused by infection with the fungus Pneumocystis jirovecii, may only 
develop under the condition of T-cell lymphocyte depletion or dysfunction. After the spread 
of the HIV epidemic in the 1980s, increasing attention was drawn to this infection as the PCP 
incidence climbed to >50% in patients presenting with AIDS [7, 8]. Although progress has 
been made with regard to unraveling of the biology and lifecycle of Pneumocystis in the past 
decades, a more profound understanding of the pathogenicity, transmission and epidemiol-
ogy has been severely hampered by the lack of available in-vitro culture methods. With the 
advent of highly active antiretroviral therapy (HAART) in 1996 and the protocolized use of 
chemoprophylaxis, the incidence of PCP in HIV-infected patients dropped dramatically [9]. In 
contrast, the number of patients at risk for PCP due to solid organ or hematopoietic stem cell 
transplantation continues to increase. Chemoprophylaxis also proved effective in preventing 
PCP in solid organ transplant recipients [10, 11]. However, deficits in our understanding of 
risk factors and mode(s) of transmission preclude the identification of patients at high risk 
and settings in which outbreaks of PCP may occur [12]. Hence, PCP has remained to be a fre-
quently considered diagnosis in transplant recipients presenting with interstitial pneumonia.
For patients subject to myeloablative chemotherapy or hematopoietic stem cell transplan-
tation, the peak incidence of fungal infection is found during episodes of neutropenia [13]. 
In this setting Aspergillus (a filamentous fungus belonging to the family of Trichocomaceae) 
is recognized as the most important cause of severe pulmonary fungal infection [14]. After 
inhalation into the small airways and alveoli, infectious conidia that overcome the innate 
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immune defenses germinate and form hyphae. If unchallenged by the host’s cellular immune 
response (i.e., neutrophilic granulocytes), angioinvasive hypheal growth leads to pulmonary 
hemorrhage and respiratory failure. Even in the era of effective antifungal drugs, a large 
proportion of severely immunocompromised patients diagnosed with invasive aspergillosis 
experience treatment failure, which carries a mortality of approximately 30% [15]. The rever-
sal of immune suppression, e.g., by engraftment of hematopoetic stem cells and return in the 
blood of neutrophilic granulocytes, has remained the best predictor of control of invasive 
aspergillosis and recovery of the patient [16].
Pneumocystis pneumonia
Pneumocystis
The Pneumocystis genus consists of multiple individual species that each require a specific 
mammalian host [17]. Accompanying this selective infectivity, morphological and biological 
differences between separate species have been demonstrated. At the electron microscopic 
level, individual Pneumocystis species show distinctive morphology of the filopodia as well as 
different densities of the membrane-limited cytoplasmatic granules [18, 19]. The species that 
causes pneumonia in humans has been renamed Pneumocystis jirovecii, but was previously 
known as Pneumocystis carinii or Pneumocystis carinii f. sp. hominis [20, 21].
For a long time Pneumocystis was considered a protozoa by the majority of the medical com-
munity involved in Pneumocystis research and treatment of PCP. This was due to morphological 
characteristics, the lack of growth in various fungal culture media and the apparent inability 
to cure patients with the classical anti-fungal agents Amphotericin B and Ketoconazole. In 
contrast, other drugs like Trimethoprim-Sulfamethoxazole and Pentamidine, commonly used 
in the treatment of protozoan infections, were used with marked success in the treatment 
and prevention of PCP. These drugs inhibit metabolic pathways partially common to protozoa 
and fungi. The lack of responsiveness to polyenes and triazoles is now known to be due to the 
lack of ergosterol in the cell membrane of Pneumocystis, which is replaced by cholesterol [22]. 
At present, Pneumocystis is classified as a fungal organism on the basis of DNA analyses [23].
Transmission and Susceptibility
The primary source of Pneumocystis causing infection in humans has been heavily debated, 
and it was thought for a long time that it had an environmental origin [24]. In animal models 
it was convincingly demonstrated that host-to-host transmission could occur via the airborne 
route [25]. In humans however, observations point to the possibility of either endogenic reac-
tivation or an exogenous source being the major cause of infection [26]. Studies performing 
serology for Pneumocystis showed that the fungus is contacted already early in life, with over 
50% of 8-month-old and 85-100% of 2-year-old children having specific anti-Pneumocystis 
antibodies [27, 28]. In recent years over 20 studies reported the asymptomatic carriage of 
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P. jirovecii in all kinds of human subpopulations consisting of healthy or immunocompro-
mised adults [29-32]. Together with recent information derived from genotypic studies of 
Pneumocystis organisms isolated during PCP outbreaks in hospitals this strongly indicates 
that interhuman transmission is the major route of infection. At present, the predominant 
hypothesis comprises that groups at risk for carriage provide the main species-specific res-
ervoir of P. jirovecii and that environmental reservoirs may contemporary co-exist through 
exhalation of Pneumocysts in the air [33]. Host at risk then become infected by inhalation 
and develop PCP (figure 1).
The CD4+ T-cell count is the best predictor of risk for PCP In HIV-positive patients. Recent 
work further suggest additional but independent influence of HIV replication itself [35]. 
Though, the CD4+ T-cell count is more difficult to use as a reliable cut-off for the need of 
PCP chemoprophylaxis in HIV-negative immunocompromised populations [36]. Only a few, 
small studies explored the clinical risk factors for PCP in transplant recipients. In general, 
superimposed degrees of iatrogenic immune suppression due to intensive maintenance im-
munosuppression, treatment for graft rejection and concurrent CMV infection are probably 
predictive for development of PCP in this population [37-39].
Immune response to Pneumocystis
In the majority of patients the primary immune impairment is T-lymphocyte depletion or 
dysfunction. The central and crucial role of CD4+ T-cells in the defense against Pneumocystis 
has been appreciated ever since the association with advanced HIV infection became clear. 
Figure 1. Potential model and routes of transmission of Pneumocystis, modified from Peterson and Cushion, reference [34]. Arrows indicate 
transmission routes. *Mild infection with flu-like symptoms may occur during primary infection in, for Pneumocystis naïve, children.
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Additional research showed that colonization was associated with low CD4+ T-cell counts and 
CD4+/CD8+ T-cell ratio’s <1 [40, 41]. Besides the established role of CD4+ T-cells, uncertainty 
exist about the role of CD8+ T-cell subsets [42]. Nonetheless, the actions of T-lymphocytes do 
not stand alone but mediate a complex immune response that involves components of the 
innate, humoral and cellular immunity [43, 44]. The inflammatory response to P. jirovecii not 
only promotes the essential clearance of this microorganism from the lungs but also causes 
the collateral damage to the lung tissue. This results in decreased efficacy of gas exchange 
and associated symptoms of respiratory distress [45].
Pneumocysts are initially recognized by alveolar macrophages through Dectin-1 and other 
receptors, which interact with glycoprotein moieties (β-D-glucan, glycoprotein A and the 
Pneumocystis major surface antigen) [46, 47]. This process is enhanced by binding of fibro-
nectin and vitronectin to the Pneumocystis cell wall and counteracted by down regulation of 
both surfactant protein A and B and up-regulation of surfactant protein D [48]. The relevance 
of these components that operate in the initial encounter with Pneumocystis has been con-
firmed in animal and in-vitro models. For example, Toll-like receptor 2 or 4 were found to 
be important mediators of the immune response in animal models with induced P. murina 
pneumonia [49, 50]. However, in another study, no direct effect on the phagocytosis capacity 
of alveolar macrophages was noted [51]. This is likely due to redundancy of the signalling 
pathways to NF-kB activation, since a single deficiency of one of the recognition ‘molecules’ 
did not exclude an effective activation of this pathway [52-54]. NF-kB propagates the release 
of pro-inflammatory cytokines, IL-1, IL-8 and TNF. The latter molecule stimulates alveolar 
epithelial cells (Pneumocytes type I) to increase cytokine production and recruits monocytes, 
CD8+ cytotoxic lymphocytes as well as neutrophils into the alveolar space. Among the 
other cytokines investigated, IFN-γ in particular is noteworthy because of its ability to induce 
macrophage activation and to exert inflammatory effects by T-cells. Neutralization of IFN-γ 
reduced survival in a rat model for Pneumocystis pneumonia [55]. Because P. jirovecii cannot 
be cultured in vitro, the study of the pathogenesis of PCP largely has largely been restricted 
to animal models [56, 57].
Diagnosis of Pneumocystis pneumonia
The diagnosis of PCP is currently based on direct microscopy using silver, giemsa and immu-
noflorescent staining and real-time PCR performed on broncho-alveolar lavage samples [58]. 
Several issues complicate these techniques. Microscopical methods have limited sensitivity, 
require well trained and experienced personnel and involve time demanding procedures. On 
the other hand, real time PCR methods yield high sensitivity and can be implemented as a 
rapid routine diagnostic test, but might lack the required specificity since it may also detect 
P. jirovecii in patients who are colonized with P. jirovecii but do not suffer from PCP [30, 59-62]. 
A P. jirovecii antibody test was developed but failed to yield sufficient diagnostic power [63]. 
This is probably caused by the pre-existing antibody response to P. jirovecii [28, 64].
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When sampling of the lower airways cannot be performed for clinical reasons, the diag-
nosis of PCP relies solely on clinical signs and chest imaging. In such situations the need for 
a sensitive and specific, non-invasive test for PCP becomes particularly urgent. A number 
of serum markers were recently studied for their ability to discriminate between PCP and 
other pulmonary conditions in patients infected with HIV [65-67]. It remains questionable 
whether advances made in prevention strategies and diagnostic markers for PCP in HIV-
positive patients can be extrapolated to the HIV-negative population at risk. HIV-related PCP 
and non-HIV related PCP are known to be different in terms of clinical characteristics [68, 69]. 
Autopsy studies demonstrate that higher loads of P. jirovecii are present in the lungs of pa-
tients with HIV as compared to patients with PCP due to other underlying disorders [70, 71]. 
Interestingly, the inflammatory reaction evoked by Pneumocystis is relatively more severe in 
HIV-negative immunocompromised individuals with PCP [69, 72]. This probably reflects a less 
impaired immunity as compared to end stage HIV patients. Prospective studies that address 
the clinical utility of serum markers for diagnosing PCP in solid organ transplant recipients 
and in patients with other causes of immunodeficiency are needed [73].
Invasive Aspergillosis
Aspergillus and Invasive aspergillosis
The term ‘invasive aspergillosis’ refers to tissue invasion by the filamentous fungus Aspergillus, 
of which A. fumigatus, A. flavus, A. niger or. A. terreus are most commonly found responsible 
for human disease. Aspergillus spp. are widely present in soil, food and moist environments 
and are known to have a worldwide distribution [74]. Spores (called conidia) are abundantly 
distributed in the air and can cause various respiratory diseases following inhalation. Ex-
posure from the environment is difficult to preclude, with the exception of hospital rooms 
equipped with HEPA-filters [75]. Invasive pulmonary aspergillosis is a disease associated 
with high mortality but only occurs in immunocompromised patients. In contrast, the more 
chronic forms of pulmonary aspergillosis, e.g., aspergilloma and allergic broncho-pulmonary 
aspergillosis (ABPA), are found in patients without severe immune deficiency [76, 77]. The 
lungs or the rhino-sinusal cavities are the primary location of invasive infection in 90-95% of 
cases. Via the blood circulation Aspergillus can metastasize to other organs, dissemination to 
the central nervous system being one of the complications most feared [78, 79].
Recognition as one of the most important infectious complications following hematopoi-
etic stem cell transplantation is the driving force of the clinical and experimental research 
related to Aspergillus in general and the pathogenesis of invasive aspergillosis in particular. 
Although sufficient clinical and biochemical markers are now seemingly available to prevent 
or identify invasive aspergillosis, the current incidence of disease has stabilized at approxi-




Neutropenia has been designated as the most important risk factor for invasive pulmonary as-
pergillosis [80]. Clinical characteristics defining risk for development of invasive aspergillosis 
in patients with haematological diseases were subsequently identified in several studies [81-
83]. Overall, older age, presence of graft versus host disease (GVHD), Cytomegalovirus virus 
infection, use of steroids, recurrence of the underlying disease, and prolonged neutropenia 
are most strongly associated with acquisition of invasive aspergillosis [84, 85]. With altered 
transplantation practices, the impact of each of these risk variables for invasive aspergillosis 
modulate over time [86]. Based on these risk factors, national and international guidelines 
now assist in the selection of patients with hematological disorders for whom chemoprophy-
laxis for invasive aspergillosis is indicated [87]. Nevertheless, it has remained incompletely 
understood why some patients with haematological diseases develop invasive aspergillosis 
while others remain unaffected. Hence, the risks imposed by exposure, underlying disease, 
other infectious complications and treatment are not to be considered absolute. In patients 
with non-haematological underlying disorders (e.g., solid organ transplant recipients), which 
represent a minority of patients at risk, it is largely unknown which variables predict the 
development of invasive pulmonary aspergillosis [88, 89].
Innate immunity and defense against Aspergillus
Next to the acknowledged importance of the cellular immunity in the form of neutrophilic 
granulocytes and - to a lesser extent - specific T-cells, an increasing number of in-vitro and 
animal studies pointed to the relevance of the innate immune response [90]. Antigen sensing 
and activation of appropriate host defences by dendritic cells and alveolar macrophages is 
a pivotal step in the host defence against Aspergillus [90]. Transmembrane receptors, includ-
ing Toll-like receptors and C-type lectin receptors, initiate this process by recognition of the 
fungus and activates signalling pathways that lead to an inflammatory response (figure 2).
The Toll receptor was originally discovered in Drosophila sp. and appeared to play a major 
role in this organism’s defence against fungi [91]. Multiple Toll-like receptors (TLRs) were 
subsequently identified in humans. TLRs are expressed on the surface of dendritic cells 
and alveolar macrophages and contain an extracellular domain with leucine-rich repeats 
and a cytoplasmatic Toll/interleukin-1 receptor domain [92]. This latter domain activates 
common signalling pathways and modulates the expression of genes encoding cytokines 
and inflammatory molecules. Research in murine models and experimental in-vitro studies 
pointed to the relevance of TLR2 and TLR4 mediated anti-fungal responses in humans [93, 
94]. Furthermore, the overall response of the innate immune system to Aspergillus depends 
on a complex network of activated components encompassing pathogen recognition recep-
tors as well as molecules of the intracellular pathways like MyD88, NFκB and subsequently 
secreted cytokines [95]. A small number of studies showed that depletion of IL-12, IL-18, TNF 
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(tumor necrosis factor) and IFN-γ delayed pulmonary clearance of Aspergillus fumigatus in 
mice [96]. In addition, high production of IL-12 and IFN-γ acted protective [97]. In vivo - i.e., 
in the transplant recipient developing invasive aspergillosis - knowledge about the exact 
role of these TLRs and cytokines in the context of macrophage-related innate anti-fungal 
defense mechanisms is limited. The components of innate immunity may become trivial in 
the absence of neutrophilic granulocytes. In this setting, reduced functioning of a TLR or 
other pattern recognition receptor and impairment in the downstream chain of signalling 
molecules and cytokines may constitute an important additional risk factor for the acquisi-
tion of invasive aspergillosis.
Diagnosis of invasive aspergillosis
The European Organization for Research and Treatment of Cancer and Invasive Fungal In-
fections Cooperative Group’s revised defi nitions of invasive fungal disease, categorizes the 
diagnosis of invasive aspergillosis (and other invasive mycosis) in 3 levels of certainty [98]. 
The defi nitions ‘proven’, ‘probable’ and ‘possible’ established a formal context that allowed the 
identifi cation of more or less homogeneous groups of patients for clinical and epidemiologic 
research. Expanding knowledge of the molecular biology and immunology has led to the 
development of diagnostic tests that detect cell wall components of Aspergillus in serum or 
TLR2    TLR4 Other PRRs





























Figure 2. Recognition of fungi and fungal pathogen-associated molecular patterns (PAMPs) by Toll-like receptors (TLRs) 2 and 4 and other 
pathogen recognition receptors (PRRs) lead to the activation of protective antifungal macrophage responses. The common signaling pathway 
for mammalian Toll-like receptors (TLRs) and other PRRs involves interaction with the adaptor molecule MYD88 (myeloid diff erentiation primary 
response gene 88) located in the cytoplasm. The activation of the MYD88 adaptor eventually results in the activation and nuclear translocation 
of nuclear factor-κB (NF-κB) and subsequent gene transcription of modulating cytokine genes. Depending on the stimulus, enhanced 
phagocytosis and proliferation of macrophages as well as further activation or deprivation of the cellular immunity will occur.
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BAL fluid [99, 100]. The commercial galactomannan and β-D-glucan assays are now widely 
used for both screening and diagnosis of invasive aspergillosis during neutropenia. Although 
concerns with regard to sensitivity and specificity do exist, these tests attribute to earlier 
diagnosis and subsequently improved survival [101]. Noteworthy, new tests that rely on 
quantification of circulating Aspergillus specific T-cells or PCR methods are being developed 
and assessed in clinical practice for usefulness and reliability with regard to the diagnosis of 
invasive aspergillosis [102].
Pneumocystis pneumonia and Invasive aspergillosis following 
transplantion: Indicators of transmission, risk and disease.
In general, no curative therapy matches the effects of prevention. Of the four major preven-
tive medical strategies: immunization (I), behavioral counseling (II), screening for early stages 
of disease or screening for risk factors for disease (III) and chemoprevention (IV), the latter 
two in particular apply to the prevention (or early diagnosis) of invasive fungal infection of 
the lungs. In both infections with Pneumocystis and Aspergillus the prognosis depends on the 
timing of diagnosis. Therefore, reliable indicators of disease, or even better: well described 
clinical and biochemical markers that flag the need for selective interventional chemopro-
phylactic strategies or pre-emptive treatment, are required.
For Pneumocystis pneumonia, the elucidation of the clinical epidemiology and mode(s) of 
transmission together with more accurate definition of the clinical risk factors in the non-
HIV infected hosts would enable more efficient, selective prescription of chemoprophylaxis 
and other measures of prevention. Furthermore, there is an urgent need for improving the 
diagnostic tools by development and implementation of non-invasive tests to establish or to 
rule out a diagnosis of PCP.
In the advanced research field of invasive pulmonary aspergillosis unraveling of the role of 
innate immunity precedes the next question (investigated in many other areas of medicine) 
on how certain genetic mutations, or the individual genetic signature as a whole, influences 
the likelihood for developing disease in the context of other risk factors. Answers to this 
question may potentially lead to more sophisticated and effective selection of patients at 
risk and subsequent prevention by chemoprophylaxis or optimized screening strategies that 
enable the start pre-emptive treatment.
The research described in this thesis focuses on:
• Analysis of the potential mode(s) of transmission of P. jirovecii during an outbreak of PCP
• Identification of risk factors for fungal infection in transplant recipients by case control 
studies:
 a)  Clinical risk factors in kidney transplant recipients for development of PCP
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 b)  Genetic risk factors in allogeneic stem cell transplant recipients for development of 
invasive aspergillosis
• Exploration of potential selective (i.e. individualized) chemoprophylactic strategies for 
prevention of PCP in transplant recipients
• The prospective assessment of the diagnostic utility of new serum markers for the diag-
nosis of PCP in the HIV-negative immunocompromised host.
• Evaluation of currently available radiolabeled tracers for future use as specific markers for 
fungal infection.
Outline of the thesis
Part I
Pneumocystis in kidney transplant recipients: transmission, risk factors , new diagnostic and 
chemo-prophylactic strategies.
Chapter 2 describes the characteristics of a large outbreak of Pneumocystis pneumonia 
among kidney transplant recipients. By performing a classical outbreak investigation and 
by application of new molecular genotyping techniques, the potential of the ‘interhuman 
transmission hypothesis’ is addressed and discussed.
In Chapter 3 all currently available data on reported outbreaks of Pneumocystis pneumonia 
is systematically reviewed with the emphasis on mortality data, clinical risk factors and trans-
mission analyses.
In the case-control study described in Chapter 4, we performed a detailed risk factor analysis 
for development of PCP in kidney transplant recipients and used the multivariate output data 
to estimate the effects of several chemoprophylactic strategies by modeling the expected 
incidence and number-needed-to-treat to provide efficient PCP chemoprophylaxis over a 
2-year period post transplantation.
Chapter 5 reports the data of a prospective study on the serum markers S-adenosylmethi-
onine and (1-->3)-β-D-glucan serum levels and correlation with clinical parameters in HIV-
negative immunocompromised patients – the majority kidney transplant recipients - with 
Pneumocystis pneumonia. Potential applicability for treatment monitoring and assessment 




Genetic predisposition for development of invasive aspergillosis in stem cell transplant recipients
Chapter 6 describes a multicenter study on the impact of the Y238X stop mutation in the 
human Dectin-1 receptor (which senses and attaches to glucan moieties of the fungal cell 
wall) on the risk of development of invasive aspergillosis in stem cell transplant recipients.
In Chapter 7 a retrospective study of the influence of genetic variation in the macrophage 
activation route with respect to the relative additional risk for development of invasive 
aspergillosis is presented.
Part III
Experimental markers for detection of fungal infection: scintigraphic imaging.
In Chapter 8 the clinical applicability of radiolabeled antimicrobial peptides and antifungal 
drugs for the diagnosis of invasive fungal infections is reviewed, together with a concise 
discussion about how promising agents should be further developed.
The results of the thesis are summarized and discussed in Chapter 9.
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Background: An outbreak of Pneumocystis pneumonia (PCP) in renal transplant recipients 
attending the outpatient department occurred in the Leiden University Medical Centre 
between the first of March 2005 and the first of February 2006; clinical, epidemiological and 
molecular characteristics were analysed to trace its origin.
methods: Renal transplant recipients with a clinical suspected diagnosis of PCP were 
included. The diagnosis had to be confirmed by direct microscopy or real time PCR of the 
dihydropteroate synthase (DHPS) gene in broncho-alveolar fluid. To detect contacts between 
patients a transmission map was constructed. A case-control analysis was performed to asses 
whether infection was associated with certain wardrooms. Genotyping of Pneumocystis was 
performed by sequence analysis of the internal transcribed spacer number 1 (ITS1) and ITS2 
gene regions.
results: 22 confirmed PCP cases were identified; about 0 to 1 would have been expected 
over the same time period. No risk factor was predominantly present and standard immune-
suppressive regimens had not changed. Liver transplant recipients using the same outpa-
tient facilities had not acquired PCP. The transmission map was compatible with interhuman 
transmission on multiple occasions. The case-control study did not point to wardrooms as a 
common source. Genotyping by sequencing of the ITS1 and ITS2 gene regions showed type 
‘Ne’ in 12 out of 16 successfully typed samples. Genotype ‘Ne’ was found in only 2 out of 12 
reference samples.
Conclusions: The clinical data and genotyping are compatible with either interhuman trans-






An outbreak of Pneumocystis jirovecii pneumonia
Introduction
Pneumocystis pneumonia (PCP), caused by Pneumocystis jirovecii, remains a substantial cause 
of morbidity and mortality in immuno-compromised individuals [1]. The development of 
animal models and genotyping methods has contributed to an increased understanding of 
the complex behaviour of this opportunistic pathogen [2, 3]. However, the exact mode of 
transmission and acquisition of this saprophytic infection are still unclear. Different sources of 
infection have been proposed, e.g. the environment or asymptomatic carriers [4, 5]. Recently, 
the possible role of interhuman transmission between immuno-compromised patients was 
described [6-8]. In this article we report an outbreak of PCP in a population of renal trans-
plant recipients attending the outpatient post-transplantation department of the the Leiden 
University Medical Center (LUMC) between the first of March 2005 and the first of Febru-
ary 2006. PCP was diagnosed in 22 renal transplant recipients (figure 1). In our transplant 
program ±100 patients receive a kidney or kidney-pancreas transplant each year; specialized 
care is provided for about one thousand renal transplant recipients. In this population the 
expected incidence of PCP is 0 to 1 case per year as estimated from registration data from 
the departments of microbiology and infectious diseases from 1995 onwards. Because of the 
sudden rise in incidence and possible contact between patients when visiting the nephrol-
Figure 1. Number of renal transplant recipients with confirmed PCP in 2005-2006 per month; * marks the last case, reported after February 1st 
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ogy outpatient department, either interhuman transmission or a local environmental source 
was suspected. The clinical, epidemiological and molecular characteristics of this outbreak 
were analysed by conducting five separate investigations (descriptive epidemiology, statis-
tical analysis of outpatient contacts, a case-control study, air sampling and genotyping of 
Pneumocystis strains) to elucidate its origins. We discuss the results along with two currently 
proposed models of transmission of P. jirovecii.
methods
Patient data
All renal transplant recipients presenting with dyspnoea and interstitial pneumonia in which 
the diagnosis of PCP was considered, were included. The time window of the study ranged 
between the first of March 2005 and the first of February 2006. After the beginning of the 
outbreak, nephrologists and microbiologists in hospitals participating in our transplant pro-
gram were requested to report patients with a renal transplant and interstitial pneumonia. 
The diagnosis of PCP was regarded confirmed if P. jirovecii was detected by direct microscopy 
(Silver- and Giemsa staining) or real time PCR of the dihydropteroate synthase (DHPS) gene in 
bronchoalveolar lavage (BAL) fluid [9]. Data about underlying disease, immune suppressive 
medication, use of PCP prophylaxis, dates of hospital visits and demographical data were 
obtained from the files. The clinical presentation of PCP was briefly described. A transmission 
map was constructed to detect contacts between patients during admittances to the ne-
phrology unit and visits to the nephrology outpatient department. Two nephrologists (A.G. 
and S.P.B.) verified that there had been no changes in immune-suppressive regimens. PCP 
prophylaxis was not prescribed routinely.
Statistical analysis of outpatient department contacts
A separate analysis was performed on the transmission map data to assess whether a patient 
who had received the diagnosis of PCP on a particular day had more often visited the out-
patient department in the four months preceding the diagnosis in comparison with patients 
who would become diseased later. Also it was assessed whether a patient that was diagnosed 
with PCP on a particular day, had more frequently encountered other future patients (i.e., 
potentially contagious patients) in the outpatient department in comparison to patients who 
would only become diseased later. These analyses were performed with a Cox model wherein 
the time varying exposure were the number of visits and the number of potentially infected 
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Case-control study for inpatient rooms (Nephrology Unit)
Because the majority of the patients had been hospitalised before the PCP outbreak, we in-
vestigated the possibility of transmission via a common source located in – or nearby – rooms 
of the nephrology unit by means of a case-control analysis. Cases were defined as renal trans-
plant recipients with confirmed PCP in 2005 who had stayed in the nephrology unit earlier 
in 2005, i.e. before the diagnosis of PCP. The control group consisted out of renal transplant 
recipients admitted to the unit in the same time window but who were not diagnosed with 
PCP later. Data were obtained from the hospital’s administrative department. Odds ratios and 
95%-confidence intervals were calculated for all rooms.
Air sampling
Air sampling was performed to detect Pneumocystis in rooms of the nephrology unit and in 
the waiting room of the outpatient department. Because this expertise was not available in 
our institution, the collection of air samples and the procedure of extracting DNA from the 
filters were carried out by a company specialised in measuring microbiological air quality (In-
tersave Groeneveld B.V., Dordrecht, The Netherlands). The following locations were sampled: 
a wardroom of the nephrology unit, the nurse post of the nephrology unit and the outpatient 
department waiting room (twice). Also a room in the hospital that was never used for patient 
care, and a room that was used by a patient with PCP (a supposed negative and positive 
control room) were sampled. The outpatient department was sampled overnight when no 
patients were present. Air sampling was performed by use of Gilair air sampler pumps (Sen-
sidyne Inc., Florida, USA.), creating an airflow over a glass fiber filter with a velocity of 2 liters 
per minute for ±8 hours on each location. After filtration of approximately 1000 litres of air, 
the filters were removed and DNA was extracted (Chemagic DNA extraction kit, Chemagen, 
Baesweiler, Germany). Specimens were transported to the laboratory of the microbiology 
department of the LUMC for analysis by real time PCR (DHPS gene). Further investigations 
included the analysis of multi-layered filters of the ventilation system of the outpatient de-
partment. Two filters passed by inflowing air and one outflow filter were sampled by cutting 
a 10 cm2 piece of each filter, which was washed with 500 ml of MilliQ and centrifuged. Both 
supernatant and residue were subjected to real time PCR (DHPS gene).
Genotyping of Pneumocystis strains
Genotyping of P. jirovecii was performed by sequence analysis of the internal transcribed 
spacer number 1 (ITS1) and ITS2 of the nuclear rRNA operon. Reference data reflecting the 
distribution of P. jirovecii genotypes in this region was obtained by genotyping 11 samples 
obtained from patients with PCP admitted to the LUMC between January 2003 and January 
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2005 and 3 samples containing P. jirovecii from other Dutch hospitals (all not related to this 
outbreak).
The forward primer (ITS1F) was described previously by Lu et al.[10, 11]. The reverse primer 
(ITS2R1) from Lu et al. was shortened and used with the sequence 5’-GCGGGTGATCCTGCCT-3’ 
to lower the melting temperature. The formed PCR product consists of the ITS1, 5.8S gene and 
the ITS2 gene region and has a total length of approximately 540 bp. DNA was extracted from 
BAL samples using the total nucleic acid protocol with the MagNA pure LC nucleic acid isola-
tion system (Roche Diagnostics, Almere, The Netherlands). Each sample was eluted in 100 μl 
of buffer and stored at –80°C until processing. 5 μl of DNA-extract was added to 45 μl reaction 
mix containing 25 μl of 2x Hotstar mastermix (Qiagen, Venlo, The Netherlands) and 25 pmol of 
each primer. Cycling conditions: 15 min at 95°C, 50 cycles of 30 s at 92°C, 30 s at 62°C, and 30 
s at 72°C respectively, followed by a 5 min. hold at 72°C. The PCR product was analysed with 
agarose gel electrophoresis. In case of aspecific amplification, the correct product was cut out 
and purified using the Qia-quick gel-extraction kit (Qiagen). Sequencing was performed on 
an ABI3100 automatic sequencer (Applied Biosystems) using a sequencing ready reaction kit 
(ABI). Sequence types were designated according to the method of Lee et al. [12].
results
Patient characteristics and outcome
Twenty-six patients presenting with symptoms and radiological signs compatible with PCP 
were identified. The diagnosis of PCP was confirmed in 22 cases; 16 with positive microscopy 
and PCR, 1 with microscopy and 6 with PCR only. Twelve (55%) were male; age ranged from 
36 to 72 years (median 57). No geographic clustering according to postal code was noted. 
All patients (including the 6 patients reported from other hospitals) except one had visited 
the nephrology outpatient department of the LUMC. The cause of original renal disease was 
heterogeneous; 3 out of 22 cases had received a kidney-pancreas transplant and 11 cases had 
received their graft within 1 year prior to the diagnosis of PCP. Immune-suppressive regimens 
contained mofetyl mycofenolate and prednisone (7.5 to 20 mg once daily) in all but one 
patient. Ten patients also used cyclosporine. No changes in routine immune-suppressive 
regimens had been implemented in the past 5 years. Although aware of the recommenda-
tion of the European guidelines [13], it was the nephrology department’s policy - prior to this 
outbreak - not to prescribe trimethoprim-sulfamethoxazole prophylaxis. Because the very 
low incidence of PCP so far, the benefits were not considered to outweigh the side effects.
Cytomegalovirus (CMV) replication was present in 10 of 19 patients with known CMV 
status; only one received anti-viral medication at the time of diagnosis. Five patients had 
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One patient became critically ill and died due to pulmonary and cardiac failure; none of the 
other patients was transferred to an intensive care unit.
Transmission map
The transmission map (figure 2) showed that interhuman transmission of Pneumocystis might 
have been possible on multiple occasions during outpatient department visits. The map does 
not allow to define a moment that all patients were in contact. However, if time windows are 
taken in to account, multiple possibilities of transmission exist. When each case is regarded 
as a possible index case, a combination of patient No.3 and No.9 suffices to trace potential 
contacts with all but one case with type ‘Ne’ (the predominant genotype). Both patients had 
received multiple treatments for rejection and had a higher load of Pneumocystis in BAL fluid 
(microscopy 3+, Ct values 34.4 and 27.5 respectively) in comparison to other patients.
Figure 2. Transmission map.
 
Legend: Genotyping of Pneumocystis showed ITS type ‘Ne’ in cases 2,3,6,7,9-13,16-18. Only ITS2 could be determined for case 14: ‘e’. 
Determination of ITS genotypes failed in case 1,4,5 and 20-22. Genotype ‘Bi’ was found in case 8. PCP was diagnosed in this case after a long 
stay on the hematology ward due to treatment for malignant lymphoma.
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Statistical analysis of outpatient department contacts
An analysis of the frequency of visits to the outpatient department, and the encounter of 
other future patients over the four months preceding the PCP diagnosis was performed on 
the transmission chart data (i.e. on cases only). The frequency of visit was more strongly as-
sociated with disease development than encounter of other patients who developed PCP at 
a later time (i.e., potentially contagious patients).
Case-control analysis
There were several time windows in which 2 or more patients of this cluster had been admit-
ted to the nephrology unit at the same time before they had developed PCP. In the case-
control study on inpatient rooms, a total of 24 and 257 hospitalisations of 10 case patients 
and 139 control patients were analysed (data not shown). The odds ratios for individuals 
rooms and for combinations of rooms varied from 0.75 to 1.89 with 95% confidence intervals 
including 1.00.
Air sampling
This part of the study was conducted in January and February 2006. The mean total amount 
of filtered air on each location was 1000 liters (range 861-1216 liters). In none of the 6 samples 
derived from the pump filters Pneumocystis was detected by real time PCR. The supposedly 
positive control room was found to be negative. The negative results were not due to in-
hibition of the samples since the internal controls (phocine herpes virus) were positive. A 
specimen derived from one of the inlet-filters of a ventilation shaft tested positive for PCP. 
Subsequent ITS genotyping failed probably due to sequence homology with ITS eukaryotic 
plant material. The outlet filters tested negative.
Genotyping of Pneumocystis strains
Identification of Pneumocystis strains by genotyping of the ITS1 and ITS2 gene regions was 
accomplished in 16 of the 22 available BAL samples from 22 different patients. Sequence 
analysis showed type ‘Ne’ in 12 out of 16 successfully analysed samples, type ‘Bi’ was present 
in 1 sample. In 3 samples only the ITS2 genotypes could be determined: type ‘e’ once and 
‘g’ twice. Genotyping failed in 6 samples due to a weak signal or the presence of >2 strains. 
Interestingly, of the 12 successfully genotyped reference samples (i.e. unrelated to the pres-
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discussion
Unique aspects of this outbreak of PCP are the relatively large number of cases, the high 
probability of contact between cases and the observation of one predominant P. jirovecii 
genotype. From the first of December 2005 - the 10th month of the outbreak - trimethoprim-
sulfamethoxazole or an alternative form of prophylaxis was prescribed for patients within 
their first year post transplantation as well as for patients treated for graft rejection. Despite 
increased alertness among physicians, only one new case was reported since February 
2006. We found no indication that the incidence of PCP had increased due to changes in 
immune-suppressive medication. The risk of PCP is associated with the treatment for rejec-
tion and CMV reactivation [14, 15], but none of these risk factors was predominantly present 
or changed over time and thus unlikely to have played a major role. We discuss the results of 
this outbreak investigation along with two hypothetical models of transmission of P. jirovecii.
The environmental source hypothesis
This thesis is based on the assumption that inhaled forms of P. jirovecii that cause PCP do 
directly originate from a niche in the environment. No environmental source has been dis-
covered to harbour P. jirovecii in previous outbreaks. Air sampling studies indicated that the 
route of transmission is by air [16, 17]. However, the source from which P. jirovecii becomes 
airborne remains to be specified: either environmental or human. Attempts to isolate Pneu-
mocystis by air sampling were unsuccessful in this study; the sensitivity and specificity of the 
methods used are unknown. The positive PCR analysis of one of the inlet filters is compatible 
with more than one hypothesis about transmission, but suggests an environmental source.
The epidemiological data neither exclude nor suggest the presence of an environmental 
source. The communal presence of patients in the outpatient department can equally indi-
cate that they acquired PCP through interhuman transmission as that they were infected by a 
local environmental source. No geographic clustering by postal code was noted, making one 
or multiple regional environmental source(s) outside the hospital less likely.
The statistical approach - the analysis of outpatient visit frequency and frequency of en-
counter of other future patients in the outpatient department – showed the strongest asso-
ciation with the number of times a patient visited the outpatient department. This points to 
an environmental source. However, the almost constant presence of several future patients 
and the unknown incubation time makes it uncertain whether these calculations can reliably 
discriminate between interhuman transmission and an environmental source.
Genotyping showed that 12(75%) of genotyped strains were P. jirovecii type ‘Ne’. Analysis 
of the reference strains indicates that type ‘Ne’ is less frequent in this region. However, in 
Denmark type ‘Ne’ was the second most prevalent strain in a study of randomly selected P. 
jirovecii positive BAL samples, but was not found in a cluster reported from that country [12, 
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18]. Data from Thailand and England confirm a regional dependent distribution of P. jirovecii 
ITS types [19, 20]. Since the frequency of different ITS types of P. jirovecii in the Leiden region 
is unknown, definite interpretation of the genotyping results is not possible. Genotype ‘Ne’ 
has not been reported as a more virulent type in human disease [21].
The interhuman transmission hypothesis
In this model PCP is considered a transmittable disease; i.e. the source is another infected (or 
colonized) individual [22]. Accumulating evidence from animal models, the host specificity 
of P. jirovecii and the phenomenon of carriage of P. jirovecii in the respiratory tract of healthy 
and immuno-compromised individuals all support the idea that humans may constitute the 
reservoir themselves [3, 23-26]. Transmission would then occur by spreading and subsequent 
inhalation of air or aerosols containing infectious forms of P. jirovecii. Four previous studies 
attempted to elucidate the possible role of interhuman transmission in small clinical clusters 
of PCP by genotyping (summarized in table 1). The methods used and the clinical evidence 
of contact between patients differs between these studies. In the two more recent investiga-
tions, genotyping and clinical data suggest the possibility of interhuman transmission [8, 28].
The transmission map from our study shows that contact between cases was possible 
on multiple occasions in this outbreak. Although details of interactions between patients 
Table 1. Studies of recent clinical clusters of Pneumocystis pneumonia in which genotyping was performed.
authors (ref.) year of 
publication
No. of patients 
(clustered)
Clinical background Genotyping 
method
authors’ conclusions




8 Clustered cases of patients 
with an haematological 
malignancy and PCP plus 2 





transmission may occur 
but may not constitute 
the major route of 
transmission.
Ollson et al. [27] 2001 17
(3+7+7)
3 Clusters, 2 in renal 
transplant recipients, 







Rabodorina M. et 
al. [8]
2004 10 A cluster of PCP in renal 
transplant recipients who 









Hocker B. et al. [26] 2005 6
(3+3)
Sudden rise in incidence of 
PCP in a paediatric transplant 
unit; 3 cases on a clinical and 









SSCP denotes single strand confirmation polymorphism, ITS1: internal transcribed spacer 1, 26S intron of the Nuclear 26S rRNA gene, mt26: 
variable region of the Mitochondrial 26S rRNA gene, beta tubulin: region surrounding intron 6 of the beta-tubulin gene, mtLSU-rRNA: 
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could not be reconstructed, it accurately describes the presence of one or more cases 
within a limited waiting area (16m2) within a limited time period. In view of the fact that 
the actual mechanism of transmission of P. jirovecii is unknown, the thesis that one or two 
‘hyper-spreaders’ (case No.3 and No.9) caused this outbreak remains speculative.
Interestingly, the outbreak was restricted to renal transplant recipients. No case of PCP was 
found in the population of 200 liver transplant recipients in our hospital, despite the fact that 
these patients wait in the same waiting room as the renal transplant recipients. The number 
of hospital visits in both populations is proportional but visiting hours overlap just one morn-
ing per week. Because the liver transplant recipients use comparable immune-suppressive 
drugs and do not receive PCP prophylaxis, a proportional incidence of up to 4 cases of PCP 
would be expected in case of an environmental source in the outpatient department [29]. 
The interpretation of the genotyping results - potentially supportive for both hypotheses - is 
discussed in the previous paragraph.
Interpretation and conclusions
In this outbreak the evidence for clinical clustering as well as the presence of one predominant 
genotype are compatible with either an environmental source or interhuman transmission. 
From published data one can not assess whether clustering of PCP usually starts with index 
patients, comes from a temporary increased reservoir of carriers in the general population 
or from an environmental source. Hence, the need for further elucidation of the general 
mode of transmission of P. jirovecii seems evident. This requires sophisticated methods to 
investigate possible environmental sources and clinical research aimed at understanding the 
role of carriers of P. jirovecii. More complex transmission models may account for clusters of 
PCP. Progress in understanding the source of PCP may permit to undertake effective action to 
prevent and control future outbreaks.
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From 1980 onwards, an increasing number of outbreaks of Pneumocystis pneumonia (PCP) 
among kidney transplant recipients have been reported. The cause of these outbreaks is 
unclear and different explanations have been provided. We performed a systematic review to 
provide a comprehensive overview of the epidemiologic characteristics as well as the involved 
clinical risk factors. A total of 15 peer reviewed English language articles published from 1980 
onward were included. Outbreak settings were all marked by absence of chemoprophylaxis, 
frequent inter-patient contacts and lack of isolation measures taken during hospitalization of 
PCP cases. PCP associated mortality rates significantly decreased from a weighted mean of 
38% before 1990 to 19% and 13% in the following two decades. Clinical risk factors for PCP in 
outbreaks settings were largely similar to non-outbreak settings. Genotyping by multilocus 
sequence typing (MLST) or comparison of the internal transcribed spacer (ITS) regions 1 
and 2 showed that the outbreaks are most frequently caused by a predominant or a single 
Pneumocystis strain. Pooled epidemiological data and genotyping results strongly attest to 
the emerging insight that acquisition of Pneumocystis occurs through interhuman transmis-
sion. No seasonal trend was noted. The results emphasize the need for chemoprophylaxis 
in kidney transplant recipients despite a low baseline incidence of PCP in this population 
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Introduction
Pneumocystis pneumonia (PCP), caused by Pneumocystis jirovecii, has been recognized 
as an important potential cause of morbidity and mortality in patients susceptible due to 
immunosuppressive medication needed after kidney or other (solid organ) transplantation 
[1]. Interestingly, and apart from the expected observation of solitary cases, an increasing 
number of sudden outbreaks or clusters* of PCP among kidney transplant recipients was 
reported from several continents. The pathogenesis of these outbreaks has not been clarified 
and different explanations e.g. changes in the standard immunosuppressive regimen, an 
environmental source or patient-to-patient transmission have been proposed [2-4]. Recent 
outbreaks occurred in the absence of chemoprophylaxis, while in general the prescription 
of Trimethoprim-Sulfamethoxazole (TMP-SMX) to prevent PCP for at least a duration of 3-6 
months after kidney transplantation now is a widely accepted practice and incorporated in 
several kidney transplantation guidelines [5, 6].
During the first observations of clusters of PCP in kidney transplant units in the 1980s, 
where transplant recipients were hospitalized together with AIDS patients, the possibility 
of patient-to-patient transmission and a relation with the developing HIV epidemic in the 
northern hemisphere in general was proposed [7]. Outbreaks among kidney transplant 
recipients and other immunocompromised hosts were thereafter repeatedly observed but 
analysis was restricted to assessment of the epidemiological data and investigation of poten-
tial clinical risk factors [8-11]. The application of molecular genotyping methods from 1990 
onwards pointed to the likelihood of a either a common environmental source or interhuman 
transmission of PCP during an outbreak [12-16]. Untill now an environmental source has not 
been identified and evidence from several studies demonstrated colonization of the human 
respiratory tract in asymptomatic healthy and immunocompromised individuals in up to 
50% of the studied cases [17-20].
Combining these and other recent findings with the historical data of PCP outbreaks 
involving kidney transplant recipients, may lead to improved understanding of the factors 
contributing to Pneumocystis transmission and development of outbreaks of PCP among 
kidney transplant recipients (26). Main objective of this systematic review is to provide 
a comprehensive overview of the involved clinical risk factors as well as epidemiological 
characteristics of PCP outbreaks among kidney transplant recipients. Based on the results, 
we update current opinions with regard to the involved risk factors and mechanism(s) of 
transmission. This should lead to improved implementation – and maybe new - strategies for 
prevention of PCP in solid organ transplant recipients.





A systematic literature review was performed to identify all English language papers 
describing PCP outbreaks in renal transplant recipients from 1980 onwards. An outbreak 
was defined as a reported unexpected sudden rise in incidence of PCP comprising at least 
5 kidney transplant recipients. A comprehensive literature search using the PubMed and 
Medline databases was performed. The following exact search commands were used in both 
databases: (I) ‘transplantation AND Pneumocystis AND outbreak’, (II) ‘transplantation AND 
Pneumocystis AND cluster’, (III) ‘kidney transplantation AND Pneumocystis’. Results were limited 
to English language articles, adult human subjects and time period from 1980 onward. The 
search procedure was repeated several times untill the 1st of August 2010. A total of 145 peer 
reviewed articles were identified. All available abstracts were reviewed by the first author. Of 
the 32 articles of potential interest 14 fulfilled the inclusion definition. In case of doubt the 
last author was consulted. The PubMed option ´related articles´, reference lists of included 
articles and consultation of expert sources were used to find additional articles missed by the 
initial search. One additional article was included by this secondary search (figure 1).
The following data was obtained from all 15 included articles: the total number of patients, 
year of publication, year of index case diagnosis, geographical region, PCP incidence prior 
to the outbreak, overall mortality, outcome of nested risk factor analysis, outcome of ge-
notyping analysis performed on Pneumocystis organisms (if available) and environmental 
investigations. In table 1 (page 75) the major characteristics of the included outbreaks are 
described. A meta-analysis was not attempted due to the heterogeneity of transmission 
analyses. In the sections below the results and observations are discussed in the context of 
the current knowledge about P. jirovecii.
Figure 1. Summary of systematic literature search results.
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results and discussion
Descriptive epidemiology
A total of 16 outbreaks, described in 15 articles, were identified and comprised a median 
number of 12 cases, with a range up to 28 cases. In the first reports of clusters of PCP in kidney 
transplant units in the 1980s, the rise of PCP incidence was linked to the rapidly expanding 
solid organ transplanted population and the introduction of Cyclosporine as a maintenance 
drug to prevent graft rejection [3, 21]. Overlapping hospitalization of PCP cases was already 
noted but absence of molecular methods only allowed speculation about the possibility of 
interhuman transmission [3, 4, 22]. In one study a case-control investigation strongly indicat-
ed transmission of PCP from HIV-infected patients to kidney transplant recipients [7]. At the 
time, this observation was seen as support for the hypothesis that the overall rising incidence 
of PCP due to the HIV epidemic influenced the risk for PCP in other immunocompromised 
populations [23]. More extended mapping of potential interhuman transmission occasions 
was performed in later outbreak studies. These detailed descriptions all demonstrated the 
high probability of frequent contact between kidney transplant recipients who developed 
Table 1. Included Pneumocystis outbreaks in kidney transplant recipients 1980-2010.



























San Juan, Peurto 
Rico
1985 11 NA No No 45.5
3- Talseth [4] 1988 Oslo, Norway 1985 14 100 No No 50.0
4- Bensousan [8] 1990 Brest, France 1990 6 NA No No NA
5- Chave [7] 1991
Lausanne 
Switzerland
1988 5 40 No No NA
6- Branten [9] 1995
Nijmegen, 
Netherlands
1991 28 NA Yes No 21.4
7- Hennequin [10] 1995 Paris, France 1995 7 86 No No 42.9
8- Lufft [11] 1996 Hannover, Germany 1993 7 NA No No 0
9- Olsson [50] 2001 Solna, Sweden 1987/1988 5+7† NA No Yes NA
10- Rabodorina [13] 2004 Lyon, France 1994 10 50 No Yes 10.0
11- de Boer [2] 2007 Leiden, Netherlands 2005 22 50 No Yes 4.5
12- Schmoldt [15] 2008 Munchen, Germany 2006 16 94 No Yes 25.0
13- Yazaki [14] 2009 Nagoya, Japan 2004 27 41 No Yes 3.7
14- Arichi [16] 2009 Hyogo, Japan 2007 9 44 Yes No 33.3
15- Gianelli [12] 2009 Zurich, Switzerland 2006 20 55 No Yes 15.0
Legend: NA denotes that information was not available; † 2 separate clusters were described.
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PCP. However, this observation may be inherent also to the post transplant state in which 
patients have to submit to frequent hospital visits. Interestingly, none of the studies report a 
coincidental increase in PCP incidence in other immunocompromised populations e.g. liver 
or lung transplant recipients at the same institution. The epidemiological data of the larger 
outbreaks (n>15, all occurring after 1990) show bell shaped incidence curves, suggesting a 
common origin resulting from either interhuman transmission or an environmental source.
A period of preceding years with very low prevalence (<2%) of PCP in the kidney transplant 
population was reported in 75% of the outbreaks. As discussed by many of the authors, this 
low incidence of PCP had prompted local transplant committees to weigh Trimethoprim-Sul-
famethoxazole side effects against overall morbidity and mortality of PCP. In the respective 
institutions this resulted in a policy endorsing the absence of PCP chemoprophylaxis post 
kidney transplantation. Furthermore, avoidance of placement of a patient with PCP next to 
other immunocompromised patients - as currently recommended by the Centers for Disease 
Control and Prevention (CDC) - was not routinely practiced at the time in any of the outbreak 
settings [24].
Mortality
Over time, mortality rates in kidney transplant recipients during outbreaks declined from a 
weighted average of 38% in the 1980s (n=3 studies) to 19% in the 1990s (n=4 studies) and 
13% in the first decade of this century (n=5 studies). For 3 studies no mortality data were 
available. The trend in declining mortality was significant between the first and the last two 
decades (figure 2). The mortality in HIV-negative immunocompromised patients with PCP has 
been reported to be relatively high as compared to HIV-positive patients with PCP. In autopsy 
studies of patients with PCP, the number of Pneumocysts was found to be relatively lower in 
immunocompromised patients without HIV [25]. In contrast, inflammation was found to be 
more extensive ref. These observations indicate that not P. jirovecii burden but the intensity 
of the evoked inflammatory reaction determines the severity of disease and the risk of fatal 
outcome. A number of trials published in the early 1990s demonstrated the beneficial effects 
of steroids in the treatment of PCP [26-28]. The implementation of conjunct steroid treat-
ment probably accounts for the observed decrease in PCP associated mortality after 1990. In 
addition, early diagnosis and the availability of high quality intensive care facilities are other 
important factors that probably attribute to a declining mortality [29].
Clinical risk factors
Only 3 out of the 15 outbreaks explored the potential risk factors by a retrospective case-
control investigation. Up to date, only two other retrospective case-control studies that 






Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients
not receiving any prophylaxis, were published [30, 31]. Since the included patients in these 
studies were isolated cases, they were not primarily included for the purpose of this review. 
Table 2 shows the major findings of the risk factor analyses in two non-outbreak and three 
outbreak investigations. Patients were most at risk in the first year post transplantation. The 
weighted average percentage of cases diagnosed within the first year post transplantation 
was 63% (range: 40% to 100% of cases).
Rejection treatment
A higher frequency of treatment for rejection prior to development of PCP was reported 
from both non-outbreak studies. In the complete series of outbreak studies any previous 
treatment for rejection, i.e. high dose steroids or ATG (anti-thymocyte globulin) was present 
in 22% to 100% of cases (median 50%). Data from 4 outbreak studies specifically reported 
the use of ATG or OKT3 globulins as rejection treatment in 20 to 39% of cases as compared 
to 41% and 73% in the two non-outbreak studies. Insufficient data was available to assess 
Figure 2. Histogram showing average Pneumocystis pneumonia associated mortality per decade; N represents the total number of cases from 

















1980-1989 1990-1999 2000-2010  
                       Time period 
Mortality (%) 
N=39  N=52  N=94 
p=0.04 
p=0.001 
Legend: N represents the total number of cases from pooled studies per time period. P-values were calculated by Pearson-chi-square test.
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the role of basiliximab or other immunotherapy’s administered at time of transplantation to 
prevent rejection.
CMV infection
Concurrent CMV infection was associated with development of PCP in both non-outbreak 
studies as well as in 2 of the 3 case-control investigations within outbreak studies. A high 
incidence of CMV infection - either reactivation or primary infection - coinciding with PCP 
was reported in 7 out of the total of 15 outbreak studies. The weighted average percentage of 
cases with concurrent CMV replication was 63% (range 18% to 100%). Comparisons of these 
percentages are flawed by changes in the diagnostic methods as well as definition of CMV 
infection in kidney and other solid organ transplant populations. In addition, new screening 
and prevention strategies for CMV disease have been implemented over time [32]. It remained 
unclear whether the association of CMV infection with PCP is due to the underlying gap in 
T-cell function, putting patients at risk for both infections, or due to the suppressive effect 
of CMV replication on T-cell function itself. Several clinical studies and in-vitro experiments 
indicate that CMV has a negative effect on the cellular immune response [33].
Table 2. Potential individual risk factors for Pneumocystis pneumonia in outbreak and non-outbreak settings.
Non-outbreak studies Outbreak studies











No. included cases/controls 15/95 17/34 14/26 28/27 10/431
Mean age: (years)
 cases 48.8 39.7 40.7 50* 46.9*
 controls 43.3 35.4 NAβ 38 34.0
Treatment for rejection (any): n (%)
 cases 13 (87)* 17 (100)* 10 (71) 13 (46) NA
 controls 57 (60) 26 (76) NA 11 (41) NA
ATG/OKT3 as rejection treatment: n (%)
 cases 11 (73)* 7 (41)* NA 11 (39) 2 (20)
 controls 30 (32) 3 (9) NA 6 (22) 29 (7)
CMV infection: n (%)
 cases  8 (53)* 9 (53)* 14 (100)* 5 (18) NA
 controls 15 (19†) 8 (24) 13 (65∫) 4 (15) NA
Legend: NA denotes that information was not available; †: of 80 controls for whom data about CMV was available; ∫: of 20 cases for whom 
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Immune suppressive regimen
The occurrence of PCP in renal transplant recipients was directly linked to the immunosup-
pressive regimen in 4 out of the 15 studies [3, 11, 16, 22]. In two studies the PCP outbreak 
coincided with the introduction of Cyclosporine A as part of the immunosuppressive therapy 
[3, 22]. The influence of Cyclosporine A on the risk for PCP was additionally suggested in 
the publication of case series from several large transplantation centers in the 1980s [21, 
34]. However, contradicting observations were reported from case series as well as in one of 
the outbreak studies [11, 35]. In the case control investigations (of both outbreak and non-
outbreak studies) Cyclosporine A based immune suppression was found not to be associ-
ated with increased risk for PCP. Experimental studies in rats had previously demonstrated a 
protective effect of the purine antagonist Mofetyl Mycofenolate against PCP [36]. However, 
the clinical relevance of this finding was never confirmed through comparative research in 
humans (16;37;38). In the multivariate analysis performed in the outbreak study performed 
by Arichi et al., the use of Mofetyl Mycofenolate was even associated with increased risk for 
PCP [16] .
Molecular epidemiology
In 6 of the 15 included outbreak studies a molecular analysis of the P. jirovecii organisms 
was undertaken to investigate the possibility of interhuman transmission. Table 3 shows the 
genotyping results of the six PCP outbreak studies among kidney transplant recipients. In 5 
of the outbreaks one predominant or a single strain was identified.
Over 14 unique gene loci have been evaluated for the purpose of genotyping applications 
[37]. The original approach by sequencing of the mitochondrial large subunit (mt LSU) RNA 
in conjunction with single stranded confirmation polymorphism (SSCP), was used in only 1 
of the included studies. After this time newer methods were preferred. Multilocus sequence 




No. of cases included in 




included in the 
analysis
-9- Mt LSU RNA +SSCP
3 / 5 Different strains No
7 / 7 2 pairs of cases with identical strains No
-10- MLST 9 / 10 6 out of 9 strains identical Yes
-11- ITS1+ITS2 16 / 22 12 out of 16 strains identical Yes
-12- MLST 16 / 16 all strains identical Yes
-13- ITS1+ITS2 8 / 27 all strains identical Yes
-15- MLST 7 / 7 all strains identical Yes
Legend: Mt-LSU denotes mitochondrial large subunit ribonucleic acid; MLST: multilocus sequence typing; ITS: internal transcribed spacer 
region; SSCP: single strand confirmation polymorphism.
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typing (MLST) described by Hauser et al. [38], probably has become the most frequently used 
method and was applied in 3 of the outbreak studies. ITS genotyping, described by Lee et al. 
[39], was used in 2 of the 6 outbreak studies that applied genotyping methods as well as in 
several cross sectional epidemiological studies investigating the geographic distribution of 
P. jirovecii genotypes [40, 41]. Interpretation of P. jirovecii genotyping results in any outbreak 
of Pneumocystis needs to be performed with care. Several lines of evidence now strongly sug-
gest that infection with P. jirovecii occurs through airborne transmission from either patients 
with overt PCP or individuals – either healthy or immunocompromised – colonized with P. 
jirovecii. This model implicates that genotyping results obtained from an outbreak must not 
only be linked within the outbreak itself, but should be held also against the background of 
the circulating genotypes in the population. Background information on circulating strains is 
necessary to determine whether the outbreak is more likely due to patient-to-patient trans-
mission or increased random transmission from colonized individuals. Secondly, colonization 
and infection with more than one P. jirovecii genotype has been described. The validity of the 
genotyping methods to detect these double or triple configuration of Pneumocystis strains 
involved is yet unknown and may further complicate interpretation of the genotyping results.
An interpretation of the genotyping results of the outbreak against the background of 
circulating strains was performed in 5 out of the 6 studies in which genotyping methods 
were applied. Although reference groups were relatively small (n<50), the genotypes of 
strains from the control groups were found to be different from those detected in the re-
spective outbreaks. Difficulties in interpretation of the genotyping results due to presence 
of multiple strains were not reported as a major problem. Variation in virulence between 
individual Pneumocystis strains may have contributed to the genesis of PCP outbreaks. Thus 
far, investigations failed to indicate such a possible relationship [42].
Environmental investigations
In 2 out of the 15 outbreak studies a local environmental investigation was performed in the 
hospital. Yazaki et al. [14] performed two sets of environmental surveys using 30-40 swabs in 
areas visited by affected patients. P. jirovecii DNA was found in outpatients consulting rooms. 
However, the finding could be interpreted as a consequence of the observed outbreak as well 
as a link to the (environmental) cause. In a study by our group, air samplers were used to collect 
air specimens during the aftermath of the observed outbreak [2]. From the air filters no Pneu-
mocystis jirovecii DNA could be extracted. Though limited by the lack of validated sampling 
methods, the search for a specific environmental source, during outbreaks and in separate 
investigations, practically remained without meaningful results [43, 44]. Recently, Choukri et 
al. published the first report of detection of dispersion of P. jirovecii in the air surrounding PCP 
patients [45]. In this study it was demonstrated that a significant relation existed between the 
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finding further supports the hypothesis that airborne transmission occurs during contact 
between patients with Pneumocystis pneumonia and individuals at risk [45].
Climatic influence
A total of 10 out of the 15 studies contained data about the timing of the cases throughout 
the year. The timing of peak incidence occurred during winter in 4, during spring in 1 and in 
summer or early fall in 5 out of 10 studies. The time of diagnosis of the index case was not 
associated with any month or season. The majority of studies were reported from geographic 
locations with moderate climate in coastal areas. In epidemiological studies investigating the 
possible association between overall PCP incidence and climatologic factors from the UK and 
Spain, a positive correlation was found between PCP incidence and colder months [46-48]. 
In contrast to these findings, a recent study form Germany, found that higher incidences of 
PCP were associated with the summer period by using four different climatic factors and the 
season as variables in a multivariate statistical model [49]. A possible explanation for these 
different observations may be that other more important factors linked to climate, e.g. hu-
man behavior, outweigh the influence of single climatic factors with regard to Pneumocystis 
transmission. As suggested by the study reported by Santiago-Delpin [3], the occurrence of 
Pneumocystis is not restricted to temperate climates only.
summary and Conclusions
Over time, the descriptive epidemiological and genotyping data of the 15 PCP outbreak 
studies increasingly pointed to a common source, either environmental or human. This is in 
contrast to the previous concept of reactivation of Pneumocystis in the immunocompromised 
host, but concurs with the current hypothesis of acquisition of Pneumocystis via individuals 
that are carriers of P. jirovecii or that suffer from PCP. Though limited by available methods, 
the search for a specific environmental source during outbreaks and in separate investiga-
tions remained without result. PCP associated mortality rates significantly decreased from a 
weighted average of 38% before 1990 to less than 20% in the past two decades. Clinical risk 
factors for PCP during outbreaks were largely similar to non-outbreak settings. Alterations in 
immune suppressive regimens were at first highly suspected, but never proven to be a major 
factor in the cause of an outbreak. Treatment for rejection, CMV infection and (potentially) 
older age were the most important individual risk factors. During the past decades changes 
occurred with regard to most of these factors. The age limit for solid organ transplantation 
gradually shifted upwards and more advanced T-cell specific compounds for maintenance 
immune suppression and treatment as well as prevention of rejection became available. 
This could have shifted the ratio of kidney transplant recipients at risk versus not at risk for 
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development of PCP within the kidney transplant population. As a consequence, this would 
at least facilitate the initiation and propagation of an outbreak. Furthermore, two other im-
portant factors permitted the development of the PCP outbreaks. First, the lack of application 
of droplet isolation measures during hospitalization of kidney transplant recipients with PCP 
probably increased the exposure of the rest of the population at risk. More importantly, the 
risk for development of PCP was not negated by the use of chemoprophylaxis for PCP in any 
of the reported outbreaks settings.
The studies of PCP outbreaks in kidney transplant recipients provide important data that 
have contributed to the understanding of the mode of transmission and epidemiology of 
Pneumocystis. The discovery of the linkage of each species of Pneumocystis to a specific mam-
malian host and the phenomenon of common asymptomatic carriage in the airways of both 
healthy and immunocompromised hosts further supports the hypothesis that the human 
population forms the primary – if not the only - source.
With regard to the data presented in this review, it must be concluded that although 
PCP incidence in kidney transplant recipients may be low for a prolonged period of time, 
a chemoprophylactic strategy needs to be implied to prevent both incidental cases and 
PCP outbreaks. Furthermore, isolation measures must be installed during hospitalization of 






Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients
references
 1. Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, et al. Infectious complications 
after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 
2006; 20(4): 401-9.
 2. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, Berger SP, Gelinck LB, et al. An outbreak 
of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant 
recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007; 
44(9): 1143-9.
 3. Santiago-Delpin EA, Mora E, Gonzalez ZA, Morales-Otero LA, Bermudez R. Factors in an outbreak 
of Pneumocystis carinii in a transplant unit. Transplant Proc 1988; 20(1 Suppl 1): 462-5.
 4. Talseth T, Holdaas H, Albrechtsen D, Berg KJ, Fauchald P, et al. Increasing incidence of Pneumocys-
tis carinii pneumonia in renal transplant patients. Transplant Proc 1988; 20(3): 400-1.
 5. European best practice guidelines for renal transplantation. Section IV: Long-term management 
of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial 
Transplant 2002; 17 Suppl 4: 36-9.
 6. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, et al. KDIGO clinical practice guideline for 
the care of kidney transplant recipients: a summary. Kidney Int. 2010; 77(4):299-311.
 7. Chave JP, David S, Wauters JP, van Melle G, Francioli P. Transmission of Pneumocystis carinii from 
AIDS patients to other immunosuppressed patients: a cluster of Pneumocystis carinii pneumonia 
in renal transplant recipients. AIDS 1991; 5(8): 927-32.
 8. Bensousan T, Garo B, Islam S, Bourbigot B, Cledes J, Garre M. Possible transfer of Pneumocystis 
carinii between kidney transplant recipients. Lancet 1990; 336(8722): 1066-7.
 9. Branten AJ, Beckers PJ, Tiggeler RG, Hoitsma AJ. Pneumocystis carinii pneumonia in renal trans-
plant recipients. Nephrol Dial Transplant 1995; 10(7): 1194-7.
 10. Hennequin C, Page B, Roux P, Legendre C, Kreis H. Outbreak of Pneumocystis carinii pneumonia 
in a renal transplant unit. Eur J Clin Microbiol Infect Dis 1995; 14(2): 122-6.
 11. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R. Incidence of Pneumocystis carinii 
pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 1996; 
62(3): 421-3.
 12. Gianella S, Haeberli L, Joos B, Ledergerber B, Wuthrich RP, et al. Molecular evidence of interhu-
man transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant 
recipients. Transplant Infectious Dis 2010; 12(1) 1-10.
 13. Rabodonirina M, Vanhems P, Couray-Targe S, Gillibert RP, Ganne C, et al. Molecular evidence of 
interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospi-
talized with HIV-infected patients. Emerg Infect Dis 2004; 10(10): 1766-73.
 14. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci 
pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Trans-
plantation 2009; 88(3): 380-5.
 15. Schmoldt S, Schuhegger R, Wendler T, Huber I, Sollner H, et al. Molecular evidence of nosocomial 
Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Micro-
biol 2008; 46(3): 966-71.
Chapter 3
54
 16. Arichi N, Kishikawa H, Mitsui Y, Kato T, Nishimura K, et al. Cluster outbreak of Pneumocystis 
pneumonia among kidney transplant patients within a single center. Transplant Proc 2009; 41(1): 
170-2.
 17. Beck JM. Pneumocystis carinii and geographic clustering: evidence for transmission of infection. 
Am J Respir Crit Care Med 2000; 162(5): 1605-6.
 18. Hauser PM, Blanc DS, Bille J, Nahimana A, Francioli P. Carriage of Pneumocystis carinii by im-
munosuppressed patients and molecular typing of the organisms. AIDS 2000; 14(4): 461-3.
 19. Huang L, Crothers K, Morris A, Groner G, Fox M, et al. Pneumocystis colonization in HIV-infected 
patients. J Eukaryot Microbiol 2003; 50 Suppl: 616-7.
 20. Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the 
autopsied lungs of the general population. Clin Infect Dis 2010; 50(3): 347-53.
 21. Franson TR, Kauffman HM, Jr., Adams MB, Lemann J, Jr., Cabrera E, Hanacik L. Cyclosporine therapy 
and refractory Pneumocystis carinii pneumonia. A potential association. Arch Surg 1987; 122(9): 
1034-5.
 22. Hardy AM, Wajszczuk CP, Suffredini AF, Hakala TR, Ho M. Pneumocystis carinii pneumonia in renal-
transplant recipients treated with cyclosporine and steroids. J Infect Dis 1984; 149(2): 143-7.
 23. Haron E, Bodey GP, Luna MA, Dekmezian R, Elting L. Has the incidence of Pneumocystis carinii 
pneumonia in cancer patients increased with the AIDS epidemic? Lancet 1988; 2(8616): 904-5.
 24. Jane D.Siegel M, Emily Rhinehart RMC, Marguerite Jackson P, Linda Chiarello RM, the Healthcare 
Infection Control Practices Advisory Committee (CDC). Guideline for Isolation Precautions: Pre-
venting Transmission of Infectious Agents in Healthcare Settings. 2007.
 25. Limper AH, Offord KP, Smith TF, Martin WJ. Pneumocystis carinii pneumonia. Differences in lung 
parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 
140(5): 1204-9.
 26. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, et al. A controlled trial of early adjunctive 
treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodefi-
ciency syndrome. California Collaborative Treatment Group. N Engl J Med 1990; 323(21): 1451-7.
 27. Montaner JS, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent 
early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the 
acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 113(1): 14-20.
 28. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La VL. Corticosteroids as adjunctive therapy 
for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A 
double-blind, placebo-controlled trial. N Engl J Med 1990; 323(21): 1444-50.
 29. Sugimoto H, Uchida H, Akiyama N, Nagao T, Tomikawa S, et al. Improved survival of renal allograft 
recipients with Pneumocystis carinii pneumonia by early diagnosis and treatment. Transplant 
Proc 1992; 24(4): 1556-8.
 30. Arend SM, Westendorp RG, Kroon FP, van’t Wout JW, Vandenbroucke JP, et al. Rejection treat-
ment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal 
transplant recipients. Clin Infect Dis 1996; 22(6): 920-5.
 31. Radisic M, Lattes R, Chapman JF, del Carmen RM, Guardia O, et al. Risk factors for Pneumocystis 







Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients
 32. van der Beek MT, Berger SP, Vossen AC, van der Blij-de Brouwer CS, Press RR, et al. Preemptive 
versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal 
transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010; 
89(3): 320-6.
 33. Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, et al. Cytomegalovirus infection: a driving 
force in human T cell immunosenescence. Ann N Y Acad Sci 2007; 1114: 23-35.: 23-35.
 34. Kahan BD, Kerman RH, Wideman CA, Flechner SM, Jarowenko M, Van Buren CT. Impact of cyclo-
sporine on renal transplant practice at the University of Texas Medical School at Houston. Am J 
Kidney Dis 1985; 5(6): 288-95.
 35. Kee T, Lu YM, Vathsala A. Spectrum of severe infections in an Asian renal transplant population. 
Transplant Proc 2004; 36(7): 2001-3.
 36. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophe-
nolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J 
Infect Dis 1997; 175(4): 901-4.
 37. Beard CB. Molecular typing and Epidemiological insights. In: Walzer PD, Cushion MT, eds. Pneu-
mocystis pneumonia. 2004: 479-95.
 38. Hauser PM. The development of a typing method for an uncultivable microorganism: the ex-
ample of Pneumocystis jirovecii. Infect Genet Evol 2004; 4(3): 199-203.
 39. Lee CH, Helweg-Larsen J, Tang X, Jin S, Li B, et al. Update on Pneumocystis carinii f. sp. hominis 
typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA 
genes. J Clin Microbiol 1998; 36(3): 734-41.
 40. Nimri LF, Moura IN, Huang L, del RC, Rimland D, et al. Genetic diversity of Pneumocystis carinii f. 
sp. hominis based on variations in nucleotide sequences of internal transcribed spacers of rRNA 
genes. J Clin Microbiol 2002; 40(4): 1146-51.
 41. Tsolaki AG, Miller RF, Underwood AP, Banerji S, Wakefield AE. Genetic diversity at the internal 
transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS 
patients with recurrent pneumonia. J Infect Dis 1996; 174(1): 141-56.
 42. Miller RF, Lindley AR, Copas A, Ambrose HE, Davies RJ, Wakefield AE. Genotypic variation in Pneu-
mocystis jirovecii isolates in Britain. Thorax 2005; 60(8): 679-82.
 43. Bartlett MS, Vermund SH, Jacobs R, Durant PJ, Shaw MM, et al. Detection of Pneumocystis carinii 
DNA in air samples: likely environmental risk to susceptible persons. J Clin Microbiol 1997; 35(10): 
2511-3.
 44. Casanova-Cardiel L, Leibowitz MJ. Presence of Pneumocystis carinii DNA in pond water. J Eukaryot 
Microbiol 1997; 44(6): 28S.
 45. Choukri F, Menotti J, Sarfati C, Lucet JC, Nevez G, et al. Quantification and spread of Pneumocystis 
jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010; 
51(3): 259-65.
 46. Lubis N, Baylis D, Short A, Stebbing J, Teague A, et al. Prospective cohort study showing changes 
in the monthly incidence of Pneumocystis carinii pneumonia. Postgrad Med J 2003; 79(929): 
164-6.
 47. Miller RF, Grant AD, Foley NM. Seasonal variation in presentation of Pneumocystis carinii pneu-
monia. Lancet 1992; 339(8795): 747-8.
Chapter 3
56
 48. Varela JM, Regordan C, Medrano FJ, Respaldiza N, de La HC, et al. Climatic factors and Pneumocys-
tis jiroveci infection in southern Spain. Clin Microbiol Infect 2004; 10(8): 770-2.
 49. Sing A, Schmoldt S, Laubender RP, Heesemann J, Sing D, Wildner M. Seasonal variation of Pneu-
mocystis jirovecii infection: analysis of underlying climatic factors. Clin Microbiol Infect 2009; 
15(10): 957-60.
 50. Olsson M, Eriksson BM, Elvin K, Strandberg M, Wahlgren M. Genotypes of clustered cases of 




rIsK faCtOrs fOr Pneumocystis jirovecii PNeumONIa IN KIdNey 
traNsPLaNt reCIPIeNts aNd aPPraIsaL Of strateGIes fOr seLeCtIVe 
use Of ChemOPrOPhyLaxIs
Mark G.J. de Boer1
Frank P. Kroon1
Saskia le Cessie3
Johan W. de Fijter2
Jaap T. van Dissel1
1. Department of Infectious Diseases, Leiden University Medical Center, The Netherlands.
2. Department of Nephrology, Leiden University Medical Center, The Netherlands.
3.  Department of Clinical Epidemiology and Department of Medical Statistics and Bio-Informatics, 
Leiden University Medical Center, The Netherlands




Differentiated use of Trimethoprim-Sulfamethoxazole (TMP-SMX) chemoprophylaxis to 
prevent Pneumocystis pneumonia (PCP) in kidney transplant recipients based on risk factor 
analysis is not a universally adapted strategy and supporting evidence based sources are 
limited. We performed a large retrospective study to identify risk factors for PCP in kidney 
transplant recipients and to define parameters for use in clinical prophylaxis guidelines. 
Fifty consecutive patients with confirmed PCP and two time-matched controls per case were 
enrolled. Potential risk factors were compared between groups by uni- and multivariate 
matched analyses. At transplantation, age >55 years and not receiving basiliximab induction 
therapy predicted development of PCP. In addition, CMV infection (OR 3.0 95%CI 1.2-7.9) and 
rejection treatment (OR 5.8 95%CI 1.9-18) were independently associated with PCP. Using the 
variables identified by the multivariate analyses, effects of different hypothetical chemopro-
phylaxis strategies were systematically evaluated. Exploring different scenarios showed that 
chemoprophylaxis in the first 6 months for all- and during the first year post-transplantation 
for patients >55 years or those treated for rejection would result in very low PCP incidence 
and optimal avoidance of TMP-SMX toxicity. The clinical approach towards application of PCP 
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Introduction
Pneumocystis pneumonia (PCP), caused by Pneumocystis jirovecii is a recognized cause of 
morbidity and mortality in kidney- and other solid organ transplant recipients [1, 2]. Recently 
issued kidney transplantation guidelines recommend the prescription of chemoprophylaxis 
for at least 3-6 months after transplantation, whereas other sources or expert opinions may 
advice other time based schedules [3-5]. Trimethoprim-Sulfamethoxazole (TMP-SMX) is the 
drug of choice and has been proven highly effective in preventing PCP in solid organ trans-
plant recipients [6, 7]. However, although in general the use of PCP chemoprophylaxis after 
kidney transplantation is a widely accepted practice, a definitive more individualized ap-
proach towards the prescription of chemoprophylaxis has not been established [8]. Incentives 
to abstain from a prophylactic strategy using TMP-SMX include adverse effects e.g. increase 
in serum creatinine, severe hyperkalemia, gastro-intestinal complaints, Stephen-Johnson’s 
syndrome, interstitial nephritis and interactions with other medication [9-12]. Weighing the 
incidence and impact of these side effects against the overall morbidity and mortality of PCP 
among kidney transplant recipients, local renal transplantation program committees or indi-
vidual physicians may decide when to – or not to – prescribe PCP chemoprophylaxis [13, 14]. 
Nonetheless, individual cases and ‘outbreaks’ of PCP that occur in the absence of adequate 
chemoprophylaxis are reported with some regularity [15-18]. Hence, the need for selective 
prescription of chemoprophylaxis for patients with an increased risk profile is an important 
issue to be considered, but few evidence-based sources exist [19]. Two small case-controlled 
studies with less than 20 cases each, indicated that treatment for graft rejection and Cyto-
megalovirus virus (CMV) infection are important risk factors [20, 21]. From case series other 
risk factors were suggested including smoking behavior, use of specific immunosuppressive 
compounds e.g. Cyclosporine A (CsA) or Tacrolimus (TCR), concurrent Hepatitis C infection, 
or active tuberculosis [22-26]. In this larger retrospective case-control study the potential 
risk factors for PCP in kidney transplant recipients are evaluated with the emphasis on the 
appraisal of previously attributed risks and on the definition of the parameters that could 
enable future guidelines to contain a differentiated, more individualized approach towards 
the prescription of PCP chemoprophylaxis in this population.
methods
Study population
Case patients were identified from the database of the Department of Infectious Diseases 
of the Leiden University Medical Center, a tertiary care and teaching hospital in the Neth-
erlands with an extensive transplantation program. All consecutive kidney- and combined 
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kidney-pancreas transplant recipients with clinical signs and symptoms compatible with 
PCP and with confirmed presence of P. jirovecii by direct microscopy (giemsa- and/or silver 
staining) and/or PCR between January 1983 and July 2008 were included. A standard PCP 
prophylaxis policy (comprising the first year post transplantation for all patients) was only 
properly implemented after the end of this period. Control patients were recruited from the 
transplantation database of the Department of Nephrology. To prevent time period related 
bias in the analysis, the patients receiving their graft directly before- and after the patient 
that finally developed PCP were selected as controls. Control patients had to have an at least 
equal time of immunosuppression as their matched case. Also, they had to be negative for 
suspicion of PCP throughout their complete follow-up. The use of TMP-SMX (e.g. if prescribed 
for other indications) or other antibiotics effective as PCP chemoprophylaxis and infection 
with HIV-1/2 were exclusion criteria for both case- and control patients. If a control patient 
was excluded, he or she was replaced by the patient transplanted directly before or after 
this individual. When this method failed, a patient transplanted within a 5 year period was 
randomly selected as control.
Patient data
Clinical data about mortality, demographic characteristics and the following potential risk 
factors for development of PCP was collected from the hospital’s electronic- and paper patient 
records and the Nephrology Department’s transplantation database: underlying renal and in-
fectious diseases, type of transplant (kidney vs. combined kidney-pancreas), graft origin, im-
munosuppressive regimen, treatment for graft rejection, smoking behavior and CMV-status. 
Routine pre-transplantation evaluation included serologic screening for CMV, HIV (from 1985 
onward), Hepatitis B and C, and a Mantoux test for the detection of latent or active tubercu-
losis. Observed time in case patients ranged from transplantation to the day of diagnosis, 
defined as the day that microbiological evidence of PCP was obtained by broncho-alveolar 
lavage. For control patients the observed time window ranged from transplantation to the 
corresponding day of diagnosis in their matched case. Data about the immunosuppressive 
regimen was obtained at 3 months post-transplantation and at the time of diagnosis (and 
at corresponding times for control patients). Pre-emptive treatment with the monoclonal 
antibody basiliximab at the time of transplantation as well as specifics concerning rejection 
treatment(s) (number, timing and type of medication) within the observed time window was 
recorded. To investigate the association between CMV infection and PCP, the 3 month period 
prior to diagnosis of PCP was evaluated. Imperative due to the time period spanned by this 
study, prove of CMV infection was defined by presence of either a positive pp65 antigen test, 
CMV seroconversion, rising (4-fold) CMV titers or a positive PCR test for CMV. Surveillance 
and a low threshold for performing diagnostics in case of suspected CMV infection was the 
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ods is referred to as CMV infection throughout the article without discriminating between 
reactivation and primo infections of CMV. If no test to detect CMV was performed in the time 
window of interest, this was processed in the analysis as missing data.
Statistical Analysis
Uni- and multivariate (conditional logistic regression for matched data) analyses were per-
formed to assess the association of each of the variables with respect to the risk for develop-
ment of PCP. Binary variables were incorporated in the multivariate model if the univariate 
p-value was <0.10 or when incorporation was deemed necessary for logical reasons. Relative 
risks were approximated by odds ratio’s (OR) with 95% confidence intervals (95%CI). A p-
value of <0.05 was considered statistically significant. Continuous variables are expressed as 
medians with interquartile ranges, for binary variables numbers and percentages are given. 
Using risk factors, identified by the multivariate analysis, the effect of different strategies for 
prescribing chemoprophylaxis were evaluated (see supplement 1 for details). STATA version 
10.0 and SPSS version 17.0 were used to perform all analyses.
results
Study population characteristics
Fifty-two kidney transplant recipients with PCP were identified and the overall incidence 
of PCP was 27 per 1000 transplantation procedures (i.e. 2.7%) in the period of study. None 
had used SMX-TMP chemoprophylaxis. Two cases were excluded from the analysis due to 
incomplete data and absence of suitable controls as defined previously. ICU admission and 
need for mechanical ventilation developed in 4/50 cases and overall 30-day mortality was 
6%. Two out of the three patients that died suffered from severe co-morbidity (necrotizing 
pancreatitis, heart failure). PCP did not occur in the first 60 days post-transplantation despite 
the absence of prophylaxis; 85% of cases were diagnosed within 24 months after transplan-
tation (figure 1). Some clustering of cases occurred in 2005, but this had no influence on 
the study outcomes. Uni- and multivariate comparisons of baseline characteristics between 
case- and control patients are showed in tables 1, 2 and 4A. Due to very low incidences of 
Hepatitis C infection and active tuberculosis, possible associations could not be established.
Immunosuppressive regimen
At 3 months post transplantation the immunosuppressive regimen generally constituted out 
of low dose prednisone (5-10 mg/day) in combination with one or two additional compounds. 
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CsA and Mofetyl mycophenolate (MMF) were predominantly used. PCP occurred more fre-
quent when three in stead of two drugs, including prednisone, were used at 3 months post 
transplantation, but this difference was not statistically significant (OR 1.5 95%CI 0.4-4.9). 
Use of CsA within the regimen at 3 months showed a trend towards an association with the 
development of PCP; but these findings were not confirmed at the time of diagnosis nor in 
the multivariate analysis at baseline (tables 2 and 4A). In case patients, median daily doses of 
medication at time of diagnosis were 1500 mg (range 1000-2000 mg) for MMF, 75 mg (range 
50-100 mg) for Azathioprine (AZA), 3.1 mg/kg (range 1.1-8.4 mg/kg) for CsA and 3 mg (range 
2-4 mg) for TCR. Everolimus or Sirolimus were prescribed to less than 5 cases per group. A 
difference with regard to dosage was found for CsA only, with higher dosages in the group of 
control patients (median 4.3, range 1.7-12.2 mg/kg; p=0.03).
Treatment for graft rejection and CMV infection
Table 3 summarizes the frequency, number and type of rejection treatments for patients and 
controls with the corresponding OR’s and 95%CI. The standard first treatment was Solume-
drol 1000 mg for 3 days. If rejection was steroid resistant, subsequent treatments consisted 
of anti-thymocyte globulin (ATG) or, if contraindicated, a repeated course of Solumedrol. The 

























PCP in RTx recipients over time (N=50) 
0% : 60 days 
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median duration from transplantation to the first and last rejection treatment given were 16 
and 48 days respectively, with 95% of treatments administered within 6 months post trans-
plantation for patients with PCP. These numbers were 15, 36 days and 7 months in the group 
of control patients. The median interval between the first rejection treatment and PCP was 67 
days (IQR 53-81 days). The time to development of PCP inversely correlated with the number 
of rejection treatments given. If no rejection treatment (either Solumedrol, ATG or both) was 
prescribed, the median time from transplantation to PCP was 114 days (IQR 90-242 days) and 
decreased to 104 days (IQR 68-216 days) after one rejection treatment, 98 days (IQR 79-199 
days) after two and 87 days (IQR 67-117 days) after ≥3 rejection treatments.







total No. 50 99














sex (male) 19 (38) 54 (55) 0.5 (0.2-1.0) 0.05
BmI, median (IQR),



































































 Smoking 7/48 (15) 24/97 (25) 1.1 (0.5-2.6) 0.83
Pre-emptive use of basiliximab at 
transplantation
15 (30) 39 (39) 0.3 (0.1-1.1) 0.08
PCP denotes Pneumocystis pneumonia; OR: odds ratio; 95%CI: 95% confidence interval; IQR: inter-quartile range; BMI: body mass index; ADPKD: 
autosomal dominant polycystic kidney disease; DM: diabetes mellitus; ATG: anti-thymocyte globulin. fl: systemic vasculitis e.g. Wegener’s 
granulomatosis, Systemic Lupus Erytematodes etc.; ‡: p-value’s determined by univariate matched analysis (binary variables) or Student-t test 




The CMV donor/acceptor serostatus at transplantation was not significantly associated 
with PCP, even if the donor was CMV positive and the acceptor CMV negative (OR 1.2 95%CI 
0.5-2.7). In case patients, CMV infection was more frequently present prior to PCP diagnosis 
(unadjusted OR 2.7 95%CI 1.2-6.2). In the multivariate analysis both CMV infection (OR 3.0 
95%CI 1.2-7.9) and rejection treatment (OR 5.8 95%CI 1.9-18) were independently associated 
with development of PCP (table 4B).








At 3 months post Tx:






At time of PCP diagnosis:














































†: data available for 50 cases and 96 control patients, all used oral prednisolon (median daily dose of 10 mg). PCP denotes Pneumocystis 
pneumonia; OR: odds ratio; 95%CI: 95% confidence interval; MMF: Mofetyl mycophenolate; CsA: cyclosporine A; AZA: Azathioprine; TCR: 
tacrolimus; CNI: calcineurin inhibitor (i.e. CsA or TCR); PUR: purine synthese inhibitor (i.e MMF or AZA); p-values determined by univariate 
matched analysis (see methods section). Sirolimus and Everolimus were used only incidentally.







No. of patients in the analysis∑





 -Solumedrol only :























∑: the analysis was restricted to all patients with PcP < 2years post transplantation. PCP: Pneumocystis pneumonia; OR: odds ratio; 95%CI: 95% 
confidence interval; ATG: anti-thymocyte globulin; OR: odds ratio; 95%CI: 95% confidence interval; OR, 95%CI and p-value as determined by 
matched approach of the data; µ: corrected for the number of treatments given by use of binary conditional logistic regression with matched 
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Exploring the need for chemoprophylaxis: calculated estimations
The relevant variables from the multivariate analyses were used to describe several strategies 
for selective use of PCP chemoprophylaxis. The effect of each of the different strategies is 
described in table 5. Some strategies - depending on the expected incidence - resulted in in-
cidences <1% and a substantially reduced use of chemoprophylaxis. Assuming a 100% effect 
of TMP-SMX chemoprophylaxis, prescribing PCP chemoprophylaxis between the 2nd and 6th 
month prevents approximately 80% of cases occurring within 2 years post transplantation 
and reduces the use of TMP-SMX more than 5-fold as compared to its use for the whole 2-year 
period. Continuing chemoprophylaxis between the 2nd and 12th month is more effective 
(prevention of 91% of cases) but results in a higher number of patients (11-50) needed to 
treat to prevent one case (NNTP). Effective use of TMP-SMX was also predicted if all patients 
used chemoprophylaxis between the 2nd and 6th month post transplantation and if patients 
older than 55 years of age and/or patients treated for graft rejection continued this prophy-
laxis until 1 year post transplantation (prevention of 83-88% of cases, NNTP at incidences 
1-5%: 37-7). Adding CMV infection into the strategy rules did not improve the results.
Table 4. Multivariate analysis of baseline and contemporary risk factors for development of Pneumocystis pneumonia in kidney transplant 
recipients
a) risk factors for development of PCP at baseline
Variable adjusted Odds ratio∫ 95% Confidence Interval p-value
Sex (male) 0.4 0.2-1.0 0.06
Age 55+ 2.7 1.3-5.9 0.01
CsA containing regimen first 3 months post-
transplantation
2.1 0.5-8.5 0.30
TCR containing regimen first 3 months post-
transplantation‡
0.2 0.2-2.3 0.22
Basiliximab induction therapy 0.2 0.1-0.9 0.04
B) Baseline and contemporary risk factors for development of PCP
Variable adjusted Odds ratio∫ 95% Confidence Interval p-value
Sex (male) 0.5 0.2-1.3 0.17
Age 55+ at transplantation 1.9 0.8-4.7 0.18
Treatment for rejection (≥1 vs none) † 5.8 1.9-17.5 0.002
CMV infection 3.0 1.2-7.9 0.02
Basiliximab induction therapy 0.4 0.1-1.3 0.10
∫ OR’s are adjusted for all other variables in the same section of the table. ‡: use of TCR at 3 months post transplantation was added to the 
analysis to correct for an alternate choice of calcineurine inhibitors with respect to CsA. †: If treatment for rejection was replaced by ‘use of ATG’ 




The main findings of this study are that age older than 55 years at the time of transplantation, 
CMV infection and treatment for rejection were independent risk factors for development of 
PCP in kidney transplant recipients. No specific immune-suppressive compound was associ-
ated with PCP. The vast majority (85%) of PCP cases developed within two years post transplan-
tation. Furthermore, within the first 60 days post transplantation no PCP case was observed. 
This may be explained by the incubation period as well as by the cumulative suppressive effect 
on T-cell related immunity. The fact that no cases occurred within these first 2 months post 
transplantation strongly suggests that the probability that PCP develops in this time window 
is very low. The observed attributable mortality in this cohort due to PCP was estimated less 
than 6%. Although higher fatality rates, up to 50%, were previously reported, in more recent 
publications similar low rates were observed [16, 27]. This may indicate that, due to a multitude 
of factors e.g. improved post transplantation care and increased awareness among physicians 
mortality due to PCP in this solid organ transplant population can be diminished.
Table 5. Estimated effects of implementation of different selective prophylactic strategies on PCP rate and prescription of TMP-SMX prophylaxis 











residual frequency | NNtP
frequency ∫
1.0% 2.5% 5.0%
#0 No prophylaxis 0.00 0 1.00 0 2.50 0 5.00 0
#1 All patients 2-24 mo. 1 1 0.00 100 0.00 40 0.00 20
#2 All patients 2-12 mo. 0.91 0.45 0.09 50 0.23 21 0.45 11
#3 All patients 2-6 mo. 0.79 0.18 0.21 24 0.53 10 1.05 6
#4 Age 55+ 0.64 0.32 0.36 51 0.90 21 1.80 11
#5 Treatment for rejection 0.62 0.31 0.38 51 0.95 21 1.90 11
#6 Age 55+ OR Treatment for rejection 0.88 0.52 0.12 60 0.30 25 0.60 13
#7 Age 55+ OR Treatment for rejection OR CMV 
infection
0.93 0.71 0.07 77 0.18 31 0.35 16
#8 All patients 2-6 mo. & 55+ → 1yr post Tx 0.83 0.27 0.17 33 0.43 14 0.85 7
#9 All patients 2-6 mo. & 55+ → 2yrs post Tx 0.86 0.44 0.14 52 0.35 21 0.70 11
#10 All patients 2-6 mo. & RejRx → 1yr post Tx 0.83 0.26 0.17 32 0.43 13 0.85 7
#11 All patients 2-6 mo. & RejRx → 2yrs post Tx 0.88 0.43 0.12 50 0.30 20 0.60 11
#12 All patients 2-6 mo. & RejRx or 55+ → 1yr post Tx 0.88 0.32 0.12 37 0.30 16 0.60 8
#13 All patients 2-6 mo. & RejRx or 55+ → 2yrs post Tx 0.95 0.61 0.05 65 0.13 27 0.25 14
∫:frequency of PCP as percentage of the total No. of transplantation procedures; Tx denotes transplantation; mo.: months; RejRx: treatment 
for rejection; yr(s): year(s); 55+: above 55 years of age; NNTP: number needed to treat to prevent one case; → 1 yr post Tx: when TMP-SMX 
is prescribed until 1 year post transplantation. Grey bars highlight prophylactic strategies that result in a relatively high proportion of cases 
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Analysis of Risk factors for PCP
The study has some limitations due to the retrospective design and the size of the study 
cohort, although it is to our knowledge the largest study published on this topic up to date. 
Robust aspects of our study include the time matched approach of both the selection of 
control patients and the statistical analysis, which prevented skewed results due to changes 
in e.g. the first choice of immunosuppressive regimen and alterations of diagnostic strategies 
to diagnose CMV infection over time. Also, next to microbiological ascertainment, the case 
definition required clinical signs and symptoms compatible with PCP, thereby preventing 
inclusion of asymptomatic carriers of Pneumocystis jirovecii [28].
The occurrence of PCP in renal transplant recipients has previously been linked to the type 
of immunosuppressive regimen. It was suggested by case series and experimantal studies 
that CsA in particular increased the risk for PCP in contrast to Azathioprine or MMF [22, 
29, 30]. In our study more cases than controles used CsA, but this difference did not reach 
significance. Noteworthy, CsA was used in a lower dosage in cases as compared to controls, 
conferring a protective mode of action. This finding remains unexplained by the current 
knowledge of its effects on either the immune system or P. jirovecii.
In concordance with prior observations, we found treatment for graft rejection to be the 
most important risk factor [20, 21]. A ‘dose-dependent’ effect was noted, with an OR of more 
than 10 in patients who received more than 3 rejection treatments compared to patients 
without rejection. Basiliximab induction therapy at transplantation appeared to be protective 
which was associated with a decreased need for the use of ATG (data not shown). In the mul-
tivariate model to correct for this confounding, basiliximab use as factor that prevented PCP 
was no longer significant. Presence of CMV infection was independently associated with PCP 
in uni- and multivariate analyses, suggesting that it is not only an epiphenomenon caused 
by increased levels of immune suppression. Other clinical studies and in-vitro experiments 
indicated that CMV may have a direct effect on the cellular immune response [31]. The asso-
ciation we found may be partly ascribed to a decreased immune status due to treatment for 
rejection, and at least in part to a direct effect of CMV infection on cellular immune responses.
Appraisal of prophylactic strategies for PCP
In modeling the risk for development of PCP, knowledge of exposure rates or risk per patient 
could increase our understanding of managing the issue of chemoprophylaxis. However, 
exposure rates for kidney transplant recipients or other patient groups at risk are, for obvi-
ous reasons, not available. Although the mode of transmission of Pneumocystis jirovecii is 
heavily debated, increasing consensus exist about asymptomatic carriership in humans as 
the primary source (in healthy- and immunocompromised individuals) and about interhu-
man transmission [32-35]. Since it is known from serologic and microbiologic evidence that 
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more than 80% of infants is exposed within 2 years after birth, it is unlikely that exposure 
can be avoided long term by kidney transplant recipients [36]. From a clinical practice 
point of view, the impact of 13 simple selective chemoprophylactic strategies - based on 
the outcome of this study - was explored at different PCP incidence rates (table 5). Without 
chemoprophylaxis, the estimated burden of hospital admissions, need for treatment at an 
ICU and mortality at an incidence <1% is less than 10, 0.8 and 0.5 cases per 1000 transplanta-
tion procedures respectively. To maintain these desirable low rates at higher PCP incidences 
and at the same time avoiding unnecessary use and side effects, several chemoprophylactic 
strategies seemed feasible. In addition to solely time-based schedules, combining timing 
with risk factors from the multivariate analysis predicted a more effective use of TMP-SMX 
and avoidance of unneeded use (60-70%) and subsequent adverse events. Of note, a selec-
tive chemoprophylactic strategy may be rolled out only when regular follow-up visits, easy 
access to high standards of care and awareness of attending physicians is warranted. Next 
to chemoprophylaxis, other preventive measures, e.g. avoiding contact of patients with PCP 
with kidney transplant recipients when hospitalized must be considered.
summary and conclusions
The results of this study provide substantial support for a risk factor based, differentiated 
approach towards PCP chemoprophylaxis, comprising the first 6 months for all- and for a 
prolonged period (e.g. during the first year) post transplantation for patients over 55 years 
of age and those treated for graft rejection. This is partly in line with the recently updated 
KDIGO guidelines but adds considerably to European guidelines issued in 2002 [5]. As for 
PCP, chemoprophylaxis may be delayed 4-6 weeks post transplantation. However, depending 
on local circumstances, other indications (e.g. the risk for Toxoplasmosis) may necessitate 
the prophylactic use of TMP-SMX in this period [37]. Physicians should also be aware that 
prolonged prescription of prophylaxis, even more than 2 years post transplantation, some-
times is necessary for those patients at increased risk due to accompanying, conditions (e.g. 
treatment for lymphoma). Since PCP in kidney transplant recipients remains relatively rare, 
the safety and effectiveness of the above mentioned strategic approach for managing PCP 
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Chapter 4 | Supplement I
CaLCuLatION Of the dIffereNt Parameters fOr the effeCtIVeNess Of 
seLeCtIVe PrOPhyLaxIs fOr PNeumOCystIs PNeumONIa (suPPLemeNt 
tO taBLe 5)
Proportion of prevented PCP cases
The effect of a strategy to prevent PCP can be described by the proportion of prevented 
PCP cases by this strategy (Pprev) within a certain time period post transplantation (in this 
study between the 2nd month and the first 2 years post-transplantation). The (estimated) 
proportion of prevented cases Pprev is calculated by dividing the number of cases that would 
have prevented (Nprev) by a strategy (e.g. strategy X) by the number of cases that would have 
occurred without this strategy (Nnorm):
If no strategy is applied Pprev = 0 / Nnorm = 0
If a strategy is applied that prevents all cases:
Nprev = Nnorm and thus Pprev = Nnorm / Nnorm = 1
Pprev = Nprev / Nnorm
In the current described model, the data from the cases (PCP patients) were used to calculate 
Pprev. For example: suppose strategy X was to prescribe prophylaxis from the 2
nd month to the 
first 2 years post-transplantation to all patients older than 55 years. There were 42 patients 
who experienced a PCP in this period, of whom 27 were older than 55 years at the time of 
diagnosis. Assuming that the prophylaxis is 100% succesful, this means that Nprev = 27 and 
Nnorm =42 and filling in the formula: Pprev = Nprev / Nnorm = 0.64. This implies that 64% of cases , 
could be prevented by strategy X.
residual frequency
Assume that I is the incidence (the frequency of occurrence) of PCP in the general population 
before applying any stragegy. The incidence (residual frequency) after applying stragey X (Ires) 
can be calculated as:
Ires = (1 - Pprev) x I
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Proportion of patients treated unnecessary
From the data of control patients, the proportion who would have received unneeded pro-
phylaxis can be calculated (Proportion of persons treated, Ppt) under a strategy X :
Ppt = Number of controls receiving prophylaxis under strategy X
 total Number of controls
In this model the control group serves as a representative of the total population of kidney 
transplant recipients. At low incidences of the disease, the need for correction due to the 
number of ‘would be case’ patients receiving prophylaxis in this model can be neglected.
the number needed to treat to prevent one case (NNtP)
To assess the efficacy of a strategy X, we calculated the number needed to treat to prevent 
one case (NNTP). The NNTP for strategy X is equal to the total number of patients that would 
receive prophylaxis (i.e. the number of cases that would have been prevented (Pprev x I) plus 
the number of controls that would receive prophylaxis ( (1-I) x Ppt), divided by the number of 
cases that would have been prevented (Pprev x I):
NNTP =
I × Pprev + (1 − I)Pp
I × Pprev
Note:
To work with a both useful and practical model, only the most relevant variables from the 
multivariate analyses (in this study: age >55 years and treatment for rejection, as well as the 
time windows of interest ) should be incorporated in the set of simple prediction rules to 
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Objective: To prospectively assess the diagnostic utility of S-adenosylmethionine (AdoMet) 
and (1→3)-β-D-glucan (β-D-glucan) serum markers for Pneumocystis pneumonia (PCP) in 
HIV-negative patients.
methods: HIV-negative, immunocompromised patients suspected of PCP based on clinical 
presentation and chest imaging were included. PCP was confirmed or rejected by results of 
direct microscopy and/or real time PCR on broncho-alveolar lavage (BAL) fluid. Measurement 
of serum β-D-glucan and AdoMet was performed on serum samples collected at enrollment 
and during follow-up. Both serum β-D-glucan and AdoMet were assessed for diagnostic ac-
curacy and correlation with clinical and laboratory parameters.
results: In 31 patients enrolled (21 PCP-positive, 10 PCP-negative), AdoMet levels did not 
discriminate between patients with and without PCP. Elevated serum β-D-glucan was a reli-
able indicator for PCP with a sensitivity of 0.90 and specificity of 0.89 at the 60 pg/ml cut-off. 
In PCP-positive patients β-D-glucan serum levels decreased during treatment and inversely 
correlated with Pneumocystis PCR cycle threshold values in BAL fluid.
Conclusions: The level of serum β-D-glucan – but not AdoMet – was diagnostic for PCP 







β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia
Introduction
Pneumocystis pneumonia (PCP), caused by Pneumocystis jirovecii is an important cause 
of morbidity and mortality in patients with human immunodeficiency virus (HIV) infection 
and other conditions associated with immunosuppression [1]. The diagnosis of PCP is based 
on microscopy methods (silver, giemsa and immunoflorescent staining) and real-time PCR 
performed on broncho-alveolar lavage (BAL) samples obtained from patients with a com-
patible clinical picture [2]. Microscopy techniques are limited by their sensitivity and time 
demanding procedures. Currently used real time PCR methods to detect P. jirovecii yield high 
sensitivity but might lack the required specificity by detecting P. jirovecii also in patients who 
are colonized but do not suffer from PCP [3-6]. Furthermore, the need for both sensitive and 
specific serum tests for PCP becomes particularly evident when invasive diagnostic proce-
dures cannot be performed due to a patient’s clinical condition. Hence, a number of serum 
markers, including (1→3)-β-D-glucan (β-D-glucan) and S-adenosylmethionine (AdoMet) lev-
els were recently studied for their ability to discriminate between PCP and other pulmonary 
conditions [7-10].
The polysaccharide β-D-glucan is one of the major components of the cyst wall of P. jirove-
cii, but is present also in the cell wall of other fungal pathogens e.g. Aspergillus fumigatus 
and Candida spp. [11, 12]. Its potential as a discriminative marker in serum was first proposed 
after studies in PCP infected rats as well as in human case series [10, 13]. Watanabe et al. 
recently demonstrated the high potential of β-D-glucan as a discriminative marker for PCP 
in a study with HIV infected patients [14]. Yet, prospective data about its use for diagnosing 
PCP in solid organ transplant recipients and patients with other causes of immunodeficiency 
is limited. Alternatively, being proposed as a useful biochemical marker in 2003, the measure-
ment of AdoMet levels in serum was recently re-introduced as a promising diagnostic test for 
PCP in patients infected with HIV, yielding a sensitivity and specificity of >90% [7, 15]. In the 
cell’s metabolism, AdoMet serves as an essential intermediate substance e.g. for methylation 
reactions and polyamine synthesis. In contrast to almost all other micro-organisms capable 
of causing disease in humans, Pneumocystis spp. seem to depend on exogenous AdoMet 
although conflicting data were published [16, 17]. Contrary to high intracellular concentra-
tions, extracellular concentrations are low and may be depleted during PCP [17].
The question has remained whether the observations in HIV-infected individuals with 
regard to the accuracy of these new serum markers for PCP can be extrapolated to the HIV-
negative population. HIV-related PCP and non-HIV related PCP are known to be different in 
terms of clinical characteristics [18, 19]. Several studies demonstrated that a higher load of P. 
jirovecii is present in the lungs of patients with HIV as compared to patients with PCP due to 
other underlying disorders [20, 21]. Despite the lower amount of antigen, the inflammatory 
response of the immune system appeared to be more severe in HIV-negative immunocom-
promised individuals with PCP, which is thought to account for the more severe clinical 
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picture and higher mortality reported in this group [19, 22]. In this study we prospectively as-
sessed whether serum AdoMet, its most direct metabolite adenosylhomocysteine (AdoHcy), 
the AdoMet/AdoHcy ratio and β-D-glucan, would be reliable indicators for the diagnosis of 
PCP in HIV-negative immunocompromised individuals. In addition, the correlation of serum 
AdoMet and β-D-glucan levels with real-time PCR results as well as with other biochemical 
and clinical parameters were evaluated.
methods
Patients
In this prospective observational study, consecutive HIV-negative, adult immunocompro-
mised patients suspected of having PCP based on presentation and chest imaging were 
enrolled during admission in the Leiden University Medical Center, a tertiary care and teach-
ing hospital in The Netherlands. Videobronchoscopy was performed and a segment of an 
involved lung zone was lavaged using 20 ml aliquots. The diagnosis of PCP was confirmed or 
rejected by results of direct microscopy methods and/or real-time PCR of the dihydroptero-
ate synthetase (DHPS) gene of P. jirovecii on the BAL fluid [23]. Patients who were thereafter 
considered PCP negative served as a control group. None of the case- or control patients 
had other proven invasive fungal infections. Demographical characteristics and data about 
medical history, symptoms at clinical presentation, treatment and disease outcome were 
extracted from the medical files. Levels of Lactate dehydrogenase (LDH) and leukocyte count 
in BAL fluid were acquired from the hospitals’ electronic database. PCR cycle threshold values 
(ct-values) were obtained from the database of the Department of Medical Microbiology. The 
time of diagnosis was defined as the date when microbiological evidence was first obtained, 
i.e. the date of the BAL procedure. Data were anonymously noted on case record forms (CRFs) 
and a database was constructed. The study was approved by the institutional review board of 
the Leiden University Medical Center and all patients provided written informed consent for 
participation in the study. Because in our hospital performing a bronchoscopy is part of the 
standard work-up protocol for immunocompromised patients presenting with pneumonia in 
which atypical or fungal micro-organisms are suspected to be the cause, informed consent 
for bronchoscopy was obtained seperately by the lung physician as part of clinical routine.
Sample collection and measurement of S-adenosylmethionine and (1→3)-β-D-glucan
Serum samples were prospectively collected around the time of diagnosis and during one or 
more time points during the first week of follow-up. Per protocol, blood was drawn for study 
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were measured by a method adapted from Gellekink et al. [24, 25]. In short, after withdrawal 
and rapid centrifugation of EDTA-blood for determination of AdoMet and AdoHcy, plasma 
aliquots were stored at -80C until the time of analysis. AdoMet, AdoHcy and their ratio were 
determined using liquid chromatography mass spectrometry (LC-MS/MS). After thawing of 
the non-acidified plasma samples, portions of 10 ul were injected on a 50 x 2.1 mm Atlantis 
C-18 column (Waters) and eluted in a gradient of methanol in aqueous acetic acid (0.1%). 
The retention times were 0.6 min (AdoMet) and 1.4 min (AdoHcy). Standards were dissolved 
in 1 mmol/L HCl; pool sera were AdoMet/AdoHcy depleted by solid phase extraction (SPE) 
and spiked with the calibrator. Calibration curves for AdoMet and AdoHcy were linear to 500 
nmol/l. For the measurement of β-D-glucan, a commercial β-D-glucan assay (Fungitell®, As-
sociates of Cape Cod, Massachusetts, USA) was used. After thawing of samples, the test was 
performed according to the manufacturers’ instructions. All serum tests were performed in 
batches at the end of the study in a blinded fashion, i.e. the laboratory staff performing the 
serum tests was unaware of the clinical condition of the patients and outcome of the BAL 
examinations (which were performed in an other laboratory and by different personnel).
Statistical analysis
Comparisons between groups were performed by use of the Mann-Whitney U test for 
continuous variables and chi-square and Fishers exact tests for categorical variables. Data 
were expressed as medians with ranges or interquartile ranges (IQR). Potential correlations 
between variables were analyzed by use of Kendall’s tau-b and Spearman’s rho rank correla-
tion tests. Receiver operating characteristic curves were constructed to assess diagnostic 
accuracy. A p-value of p<0.05 was considered significant. All calculations were performed 
using the SPSS statistical software package for Windows version 17.0.
results
Study population
Thirty-one consecutive immunocompromised patients suspected of having PCP were 
enrolled over a 12 month period from March 2005 to March 2006. The majority of patients 
(65%) were at risk due to receiving a solid organ transplantation (liver transplant: 1, kidney 
transplant: 19). The baseline characteristics of case and control patients are presented in table 
1. None used PCP chemoprophylaxis at presentation. The diagnosis of PCP was ascertained 
in 21 and rejected in 10 patients. Patients with a solid organ transplantation were overrep-
resented in the group with PCP (81% versus 30%). No other differences were found between 
groups. Four out of the 21 patients with PCP were admitted to the ICU and two patients 
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died within the first 30 days following PCP diagnosis. All ascertained PCP cases received 
Trimethoprim-Sulfamethoxazole (TMP-SM) 2400 mg b.i.d. and steroid treatment according 
to local guidelines. Among the patients without PCP, 3 had community acquired pneumonia, 
5 were diagnosed with lung fibrosis and interstitial pneumonitis related to their underlying 
disease, 1 patient had a pulmonary infection with Mycobacterium malmoense and 2 patients 
recovered spontaneously while no definite diagnosis was made. Empirical treatment for PCP 
was given for a short time (i.e. usually <48 hours) to 6 of these patients while awaiting the 
results of the BAL examination. None of the control patients developed PCP at a later time 
point.
Comparisons of serum markers at time of diagnosis
AdoMet
The baseline serum AdoMet concentrations as well as the AdoHcy levels and AdoMet/AdoHcy 
ratios are shown in figure 1A-C. At initiation of empirical treatment for PCP (which coincided 
with the timing of the BAL) the median AdoMet level in patients with confirmed PCP was 
93.6 nM (IQR 61.1-188.4 nM; range 12.0-385.8 nM) as compared to 80.3 nM (IQR 58.2–125.3 






Male/female ratio 11/10 8/2
Age (years), median (IQR) 57 (50-62) 59 (55-70) 0.19
Diagnostic methods (BAL fluid), n (%)
 Microscopy positive 13 (62) 0
 PCR positive 20 (100†) 0
Underlying condition, n (%)
 Solid organ transplantation 17 (81) 3 (30)
 Hematological malignancy 3 (14) 5 (50)
 Other‡ 1 (5) 2 (20)
Laboratory findings, median (IQR)
 LDH (U/L) 794 (526-1078) 525 (418-599) 0.05
 CRP (mg/L) 114 (48-218) 154 (60-217) 0.62
 PaO2 (kPa) 8.3 (7.0-9.2) 8.3 (7.1-9.4) 0.72
Outcome of PCP
 Length of hospitalisation (days), median (IQR) 11 (7-20) -
 ICU admission, n (%) 4 (19) -
 30-day mortality, n (%) 2 (10) -
Note: PCP: Pneumocystis pneumonia; IQR: inter quartile range; LDH: lactate dehydrogenase; CRP: c-reactive protein. ‡:The patient with PCP and 
2 patients without PCP were at risk due to Cushing’s syndrome or received medication to treat autoimmune disease respectively. †: PCR was not 
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nM; range 1.0-346.6 nM) in the control group (p>0.05; figure 1A). AdoHcy serum levels and 
AdoMet/AdoHcy ratio were also not significantly different when compared between patients 
with and without PCP. Follow-up measurement of serum AdoMet levels after a median of 3 
days (IQR 2-4 days) of treatment did not show a significant change in patients with PCP as 
compared to patients without PCP (figure 2A).
β-D-glucan
Serum levels of β-D-glucan were significantly higher in patients with PCP as compared to 
patients without PCP as depicted in figure 1D. The median serum β-D-glucan level in patients 
with confirmed PCP was 956.9 pg/ml (IQR 281.6-1171.5 pg/ml; range 0-1279 pg/ml) and 
25.3 pg/ml (IQR 14.9-48.4 pg/ml; range 4.5-228.3 pg/ml) in the control group (p<0.001). A 
second β-D-glucan serum level measured at a median of 3 days (IQR 2-4 days) showed an 
Figure 1. Whisker box-plots of serum levels of AdoMet, AdoHcy, AdoMet/AdoHcy ratio and β-D-glucan in patients with and without 
Pneumocystis pneumonia at time of suspected diagnosis.
Figure 1.   
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patients with and without PCP at time of suspected diagnosis. 
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average decrease of 92.9 pg/ml during treatment in patients with PCP compared to a 13.1 
pg/ml increase in patients without PCP (figure 2B). At the standard cut-off point of 80 pg/ml, 
β-D-glucan yielded a sensitivity of 0.86 and specificity of 0.89. When the cut-off point was 
attenuated to 60 pg/ml, receiver operating characteristic curves showed that the β-D-glucan 
test performed optimally as an indicator for PCP (AUC 0.89 95%CI 0.75-1.0, p=0.001), with a 
sensitivity and specificity of 0.90 and 0.89 respectively.
Correlation of β-D-glucan and AdoMet with clinical and laboratory parameters
The median PCR ct-value in of patients with PCP was 34.7 (range 26.1 to 46.8). In this group 
the β-D-glucan serum levels tended to correlate with the PCR cycle threshold value in BAL 
fluid (Kendall’s tau-b correlation coefficient r=-0.30, p=0.07; Spearman’s rho =-0.47, p=0.04). 
This correlation was more profound when the analysis was repeated for the group with a 
solid organ transplant only (Kendall’s tau-b correlation coefficient r=-0.40, p=0.03; Spear-
man’s rho=-0.61, p=0.01; figure 3). Neither serum β-D-glucan levels nor ct-values of the Pneu-
mocystis PCR (regarded as both dependent on detection of constituents of P. jirovecii) were 
linked with LDH or CRP in serum at time of BAL. For AdoMet no significant correlations were 
found between the serum levels and the above variables. Death, ICU admission or length of 
hospital stay (i.e. time from start of TMP-SM to discharge) was not predicted by β-D-glucan 
or AdoMet serum levels.
Figure 2. Absolute changes in serum AdoMet and β-D-glucan levels between time of diagnosis and follow-up at day 3 in patients without PCP 
and in patients with PCP on treatment.
Figure 2.  
Absolute changes in serum AdoMet and β-D-glucan levels between time of diagnosis and follow-up 
at day 3 in patients without PCP and in patients with PCP on treatment.  
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discussion
In this prospective clinical study of immunocompromised patients not infected with HIV, we 
found that serum β-D-glucan - but not AdoMet - was a reliable indicator for PCP. In addi-
tion, we detected a significant correlation between the quantity of P. jirovecii DNA detected 
in BAL fluid and the serum β-D-glucan level. Furthermore, follow-up levels of β-D-glucan 
significantly decreased over a relatively short time during treatment. However, the median 
absolute value measured after a median of 3 days of treatment still remained far above the 
upper limit of normal, indicating that a clinical response observed at the bedside is of at least 
equal importance. At present, the kinetics of serum β-D-glucan during PCP are incompletely 
understood. Previously reported data indicate that, in patients with PCP, the elevated serum 
β-D-glucan levels only slowly return to normal over a period of several weeks after the start of 
adequate treatment [26]. Nevertheless, limited data from two small studies investigating the 
kinetics of serum β-D-glucan suggest that a decreasing β-D-glucan level correlates with the 
clinical recovery of the patient [27]. Clearly, this aspect of the clinical use of the β-D-glucan 
assay needs further prospective evaluation.
In HIV infected individuals the clinical relevance of serum β-D-glucan was convincingly 
addressed recently [14]. However, studies have demonstrated that relatively lower loads of 
P. jirovecii exist during PCP in the lungs of immunocompromised patients without HIV [20, 
21]. In a study performed by Nakamura et al., serum β-D-glucan levels were also significantly 
Figure 3. Scatter plot of β-D-glucan levels in serum by Pneumocystis real-time PCR cycle threshold value in solid organ transplant 
recipients with PCP.
Figure 3.  
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lower in patients with PCP due to other underlying causes than HIV [28]. These observations 
question whether serum β-D-glucan levels can be used to reliably aid in the diagnosis of 
PCP in HIV negative immunocompromised patients. Due to limited clinical data yet available, 
this issue has not been completely clarified. Table 2 shows an overview of recent English 
language medical literature on β-D-glucan as a serum marker for PCP in patients without 
HIV. Although numbers of included patients are small and most of the reported data were 
obtained retrospectively, these earlier observations concur with the findings of our study. In 
contrast to the study of Tasaka et al. (n=44), the population of our study is dominated by solid 
organ transplant recipients [9].
Despite previous investigations claiming AdoMet to be a both highly sensitive and specific 
marker for PCP in HIV positive patients, this could not be confirmed in our study of a HIV-
negative population with PCP. Knowledge about AdoMet as a marker for PCP in the clinical 
setting is currently driven by one research group only and the method in general is laborious, 
requires costly, advanced technical equipment and would be hard to sustain in its present 
form as a test performed in daily hospital routine. High performance liquid chromatography 
(HPLC) was used in preceding studies investigating the association between serum AdoMet 
and PCP [7, 29]. In this study we applied the method of stable-isotope dilution liquid chro-
Table 2. Recent studies of β-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV-negative immunocompromised patients.
1st Author (ref ) Year Journal
N HIV-
(N HIV+)‡





Retrospective, case control study: Hematological and HIV-
infected patients; serum β-D-glucan yielded a sensitivity of  
94% and specificity of 100% at a 100 pg/ml cut-off level.




Prospective, case control study: β-D-glucan is a reliable 
marker for diagnosing PCP. No difference between HIV and 
non-HIV PCP.
Nakamura (28) 2008 Intern Med 16 (19) G
Retrospective study: β-D-glucan was a reliable diagnostic 
marker for PCP. The detection rate of β-D-glucan in non-HIV 





Part of larger retrospective  study, investigating the use 






Case series:  β-D-glucan testing may be useful as a 
noninvasive diagnostic tool for PCP.
Tasaka (9) 2007 Chest 44 (13) G
Case-control study: HIV-negative patients mainly had 
collagen-, or hematological diseases. Serum β-D-glucan  was 





Case series: all patients had connective tissue disease,
β-D-glucan testing may be useful as a noninvasive 
diagnostic tool for PCP.
Note: HIV: human immunodeficiency virus; G: G-test (Seikagaku Corporation, Tokyo, Japan); F: Fungitell test (Associates of Cape Cod, 
Massachusetts, USA); PCP: Pneumocystis pneumonia; ‡: Due to the mixed population in most β-D-glucan clinical studies, the number of 
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matography–electrospray injection tandem mass spectrometry, a more advanced and now 
commonly used method for measuring AdoMet and AdoHcy [24, 30, 31]. The mechanism by 
which AdoMet would be useful as a marker for PCP is its depletion from the serum during 
infection with P. jirovecii. Since lower pulmonary fungal loads are present in HIV-negative 
patients with PCP, this may influence the serum AdoMet level in a way that its reliability as 
a diagnostic test for PCP becomes severely compromised. Moreover, because AdoMet is the 
product of the human body’s own metabolism, other factors e.g. malnourishment, general 
clinical condition and other variables may easily affect the level of serum AdoMet. For ex-
ample, it was recently reported that serum folate correlated with AdoMet and that body mass 
index was the strongest determinant of AdoMet and AdoHcy in multivariable analyses [25].
summary and Conclusions
Although AdoMet at first appeared a most promising candidate marker, it failed to discrimi-
nate between HIV-negative immunocompromised patients with and without PCP. In contrast, 
serum β-D-glucan levels >60 pg/ml showed high diagnostic accuracy for PCP in HIV-negative 
immunocompromised patients without other fungal infections. Given the correlation with 
the PCR cycle threshold value (i.e. a quantative surrogate for presence of P. jirovecii DNA) and 
significant decrease of the serum β-D-glucan level after treatment initiation, its additional 
purpose in both research and clinical settings may be that of an indicator of pulmonary load 
of P. jirovecii. Due to the relatively slow decrease of serum β-D-glucan over time, clinical 
judgment probably should prevail in estimating the response to treatment. Though, whether 
in special circumstances (e.g. in case of suspected TMP-SM resistance) the trend of the 
serum β-D-glucan level may be of additional value, remains to be researched. Due to the 
‘panfungal’ nature of β-D-glucan, its use for the purpose of diagnosing PCP is clearly limited 
during concurrent infection with other fungal pathogens [12]. The serum β-D-glucan test 
must therefore not be used as a single test for PCP but interpreted within the clinical context. 
Thus, a primary suspicion of PCP above other fungal infections (supported by clinical signs 
and symptoms as well as chest imaging) seems warranted. Under this condition the serum 
β-D-glucan level may be used as a test with both high sensitivity and specificity for PCP in 
HIV-negative immunocompromised patients.
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Background: Dectin-1 is the major receptor for fungal beta-glucans on myeloid cells. We 
investigated whether defective Dectin-1 receptor function, due to the early stop codon 
polymorphism Y238X enhances susceptibility to invasive aspergillosis (IA) in at-risk patients.
methods: Association of the Dectin-1 Y238X polymorphism with occurrence of IA was evalu-
ated in a cohort of 71 patients who developed IA post hematopoietic stem cell transplantation 
(HSCT), and in a separate cohort of 21 non-HSCT patients who had IA post-chemotherapy. 
The control group consisted of 108 patients who had undergone HSCT. Presence of the Y238X 
polymorphism was linked with the occurrence and clinical course of IA. Functional studies 
were performed to investigate the consequences of the Y238X Dectin-1 polymorphism.
results: In HSCT recipients, heterozygosity for the Y238X polymorphism showed a trend 
towards IA susceptibility (odds ratio 1.79, 95% confidence interval 0.77-4.19, p=0.17). Pos-
session of Y238X polymorphism did not influence the clinical course of IA. The Y238X allele 
frequency was higher in non-HSCT patients with IA (19.0%) as compared to HSCT patient/do-
nor cohort and the healthy population (range 6.9%-7.7%, p<0.05). Functional assays revealed 
that human peripheral blood mononuclear cells with complete defect in Dectin-1 function 
due to Y238X responded less efficiently to Aspergillus. However, macrophages showed an 
adequate response to Aspergillus despite deficient Dectin-1 function.
Conclusions: Dectin-1 Y238X heterozygosity has a moderate influence on susceptibility 
to IA. This is partly attributable to redundancy inherent in the innate immune system. The 
Y238X polymorphism may be important in susceptible non-HSCT patients. Larger studies are 
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Introduction
Invasive fungal infections (IFI) remain a major cause of morbidity and mortality in immunocom-
promised patients, of which invasive aspergillosis (IA) is emerging as the most common IFI [1, 
2]. Susceptibility and host response to fungal infection is largely determined by the immune 
status of the host, its ability to recognize the pathogen and to respond appropriately [3]. The 
mechanism responsible for this recognition is represented by pattern recognition receptors 
(PRRs) which include the family of Toll-like receptors (TLR) and C-type lectin receptors (CLR) 
[4]. Dectin-1 is a C-type lectin receptor present on human immune cells e.g. macrophages 
and monocytes. It recognizes the β-1,3-glucan motif present on the cell walls of Candida and 
Aspergillus species, and mediates host immune response to these fungal pathogens [5].
Recently, we described a functional single nucleotide polymorphism (SNP) in Dectin-1 
(Y238X, rs16910526) leading to an early stop codon which resulted in loss of the last ten 
amino acids of the carbohydrate-recognition domain of the Dectin-1 receptor. Subsequently, 
this resulted in diminished expression of the Dectin-1 receptor on immune cells and its in-
ability to bind β-glucan, leading to defective production of proinflammatory cytokines [6]. 
Clinically, this polymorphism was found to be associated with colonization with Candida 
spp. in hematopoietic stem cell transplantation (HSCT) recipients [7], as well as recurrent 
mucocutaneous fungal infection in a Dutch family [6].
Results from in-vitro and murine models have shown that Dectin-1 is pivotal in host 
defense against Aspergillus infection [8-10]. However, no data is available from human stud-
ies to validate these findings. Hence, we aimed to investigate the clinical relevance of the 
Dectin-1 early stop codon polymorphism for the susceptibility and outcome of IA in a cohort 
of patients with underlying hematological disorders.
Patients and methods
Patient population
Ninety-two patients of Dutch-Flemish ancestry with underlying hematological diseases in 
which IA was diagnosed were enrolled from 3 academic hospitals: Leiden University Medical 
Center, Radboud University Nijmegen Medical Center, both in the Netherlands, and Uni-
versity Hospitals Leuven, Belgium between May 1996 to July 2009. Of these 92 patients, 71 
developed IA following allogenic HSCT while 21 other patients had IA after receiving chemo-
therapy but without undergoing HSCT. Invasive aspergillosis had been diagnosed as either 
proven or probable IA as per current European Organization for Research and Treatment of 
Cancer/Mycology Study Group (EORTC/MSG) criteria [11]. One hundred and eight patients 
with comparable underlying disorders who underwent HSCT but did not develop IA were 
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enrolled as controls for the HSCT patients. All HSCT IA patients and the control patients had 
undergone T cell-depleted allogenic HSCT. The clinical characteristics of the HSCT patients 
and controls are summarized in Table 1.
Of the 21 non-HSCT patients who developed IA following chemotherapy, 18 patients had 
acute myeloid leukemia, except for one case each of acute lymphocytic leukemia, multiple 
myeloma and aplastic anaemia. The median age was 50 years, (interquartile range [IQR] 40-
61), and 13 of the 21 subjects (62%) were males. Seventeen of the 21 cases (81%) had prob-
able IA, while proven IA was diagnosed in the remaining 4 patients. Prolonged neutropenia 
(defined as absolute neutrophil count < 500 cells/mm3 for more than 14 days prior diagnosis 
of IA) was present in 9/21 cases (43%).
None of the patients or controls in this study received prior mould-active anti-fungal pro-
phylaxis [12, 13]. DNA was obtained from patients following informed consent as required by 
the ethical committee of each respective institution. For all HSCT cases, DNA was obtained 
from both recipients and their respective donors prior to transplantation.




Patients without Ia p-value
total No. 71 108
sex ratio m/f 47/24 71/31 0.95
age (median, IQr) 47 (40-57) 48 (40-56) 0.84
































Prolonged neutropenia 31/71 40/108 0.46
site of Ia n (%)
 Pulmonary 68 (96) -
 Extra-pulmonary 3 (4) -
GVhd 34/71 58/104† 0.36
The median period of follow-up was 8.4 months (range 0.1-170.7) for patients with invasive aspergillosis and 59.9 months (range 0.4-163.9) for 
control patients. IA denotes invasive aspergillosis; IQR : interquartile range, HSCT: hematopoietic stem cell transplantation, AML : acute myeloid 
leukemia, CML : chronic myeloid leukemia, ALL: acute lymphocytic leukemia, NHL : non-Hodgekin’s lymphoma, CLL : chronic lymphocytic 
leukemia, MDS :myelodysplastic syndrome, Prolonged neutropenia was defined as absolute neutrophil count < 500 cells/mm3 for a period of 
more than 14 days prior diagnosis of IA, GVHD : graft-versus-host disease. †GVHD data was not available for 4 control patients. P-values were 






The Y238X Stop Codon polymorphism in the human beta-glucan receptor Dectin-1
Genotyping for Dectin-1 Y238X Polymorphism
The Y238X SNP (rs16910526) in exon 6 is the only known exonic polymorphism in the Dectin-1 
gene in Caucasian populations [7]. Genotyping for the presence of the Y238X polymorphism 
was performed using the TaqMan SNP assay C_33748481_10 on the 7300 ABI Real-Time 
polymerase chain reaction system (Applied Biosystems).
Cytokine stimulation assays
Cytokine profiling was performed to ascertain the functional consequence of the Dectin-1 
Y238X polymorphism. The isolation of peripheral blood mononuclear cells (PBMC) and dif-
ferentiation of monocyte-derived macrophages (MDM) from study subjects were performed 
as previously described [14]. The cells were stimulated with live and heat-killed conidia, as 
well as with heat-killed hyphae of a well-characterized Aspergillus fumigatus clinical strain, 
V05-27 [15]. Where indicated, Candida albicans blastoconidia belonging to strain ATCC 
MYA-3573 (UC820) [16] and particulate β-glucan (courtesy of Dr David Williams, University 
of Tennessee) were used as control stimuli. The supernatants were collected after 24 h of 
incubation at 37oC and stored at -20oC until cytokine assay. Interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF-α) concentrations were measured by commercial sandwich ELISA 
kits (Pelikine Compact, CLB, Amsterdam, Netherlands and R&D Systems respectively) accord-
ing to manufacturers’ instructions.
Flow cytometry
Freshly isolated human PBMC were incubated with 5 µg/ml murine anti-Dectin-1 mAb 
259931 (R&D Systems, Minneapolis, MN) or mouse IgG2b isotype control in RPMI 1640 
(supplemented with 2% human serum) followed by allophycocyanin-conjugated goat 
anti-mouse Ab (BD Pharmingen, San Diego, CA). Monocytes were labeled with anti-CD14-
PE (Pelicluster, Sanquin, Amsterdam, The Netherlands) and Dectin-1 expression on CD14+ 
cells was determined by flow cytometry (FACScalibur, BD Biosciences). Detection of Dectin-1 
receptor surface expression on MDM was performed as described above. Surface mannose 
receptor (MR), TLR2 and TLR4 expression was determined using anti-MR-FITC (R&D Systems), 
anti-TLR2-FITC and anti-TLR4-PE (both from eBioscience, San Diego, CA) in addition to their 
respective isotype controls.
Statistical Analysis
Genotype frequencies were compared between groups by Fisher’s exact- and Pearson-chi-
square tests. Odds ratio (OR) and 95% confidence interval (95%CI) were calculated for the 
Chapter 6
100
presence (homozygous or heterozygous) or absence (homozygous wild type allele) of the 
Dectin-1 Y238X polymorphism. Multivariate adjustments for neutropenia and development 
of graft-versus-host disease (GVHD) were made where appropriate. The influence of the vari-
ant Dectin-1 SNP on the clinical course of disease i.e. day from HSCT or start of chemotherapy 
to the day of diagnosis was assessed by Kaplan-Meier analysis (logrank test). Likewise, as-
sociations with presence of the polymorphism and time from IA diagnosis to death were 
assessed. The cytokine data was presented as mean + standard error of the mean (SEM). 
Differences in cytokine production were assessed by using Student’s t test. A p-value of <0.05 
was considered significant. The SPSS version 17.0 statistical software package for Windows 
was used to perform the calculations.
results
Dectin-1 Y238X Polymorphism in IA Patients and Controls
Following HSCT, the primary immune cells of the recipient will eventually assume genotype 
of the donor after successful engraftment. Hence presence of the Dectin-1 Y238X SNP was 
determined in all patients and HSCT donors. The genotype frequencies of the study cohort 
were in Hardy Weinberg equilibrium. Thirteen of the 71 patients who developed IA post 
HSCT (18.3%) and 12 of 108 control patients (11.1%) had the Dectin-1 Y238X SNP. All these 
individuals were heterozygous for the SNP. Possession of the Y238X polymorphism was only 
associated with a limited trend towards IA susceptibility and this did not reach statistical 
significance (odds ratio [OR] 1.79, 95% confidence interval [CI] 0.77-4.19, p=0.17), see Table 
2a. Following multivariate adjustment for neutropenia and GVHD, the adjusted OR was 1.70, 
95% CI 0.72-4.00, p=0.22. Donor genotype did not influence risk of IA in the recipient. Like-
wise, simultaneous possession of Y238X in both HSCT donor-recipient pair did not increase 
susceptibility to IA.
In addition, the Dectin-1 Y238X SNP was found in 7 of the 21 non-HSCT patients (33.3%) 
who developed IA following immunosuppressive chemotherapy, of which one individual was 
homozygous for the Y238X polymorphism. Given the limited case patients in this non-HSCT 
cohort, we opted to compare the allelic frequencies of Dectin-1 Y238X variant against the 
following patient cohorts/healthy populations: (1) the HSCT patients with and without IA in 
this study who had similar underlying hematological diseases (2) the healthy HSCT donors (in 
this study) and (3) healthy population of comparable Dutch ancestry [6] (Table 2b). The allele 
frequency of the Y238X SNP was significantly elevated in the non-HSCT IA patients (19.0%) 







The Y238X Stop Codon polymorphism in the human beta-glucan receptor Dectin-1
Influence of Dectin-1 Polymorphism on Clinical Course of IA
In addition to its effect on the susceptibility to IA, we assessed whether the presence of the 
Dectin-1 variant gene might influence clinical course during IA. Kaplan-Meier analysis did 
not reveal a difference in time-to-development of IA from HSCT between recipients or their 
donors bearing either the wild-type (WT) or variant allele (Figures 1a &b, p=0.94 and p=0.88 
respectively). There was no difference in survival (time to death following diagnosis of IA) 
consequent to having the WT or variant Dectin-1 allele in both patients and donors (Figures 
2 a & b, p-logrank 0.83 and 0.99 respectively).













hsCt Ia recipients vs control recipients 13/71 12/108 1.79 (0.77-4.19) 0.17
hsCt donors to Ia patients vs control donors† 10/68 17/107 0.91 (0.39-2.13) 0.83
Presence of y238x in both hsCt recipient & 
donor† 5/68 8/107 0.98 (0.27-2.80) 0.98
† DNA belonging to HSCT donors of 3 IA cases and 1 control case were unavailable for genotyping. IA denotes invasive aspergillosis; HSCT: 
hematopoietic stem cell transplantation; OR: odds ratio; 95%CI: 95% confidence interval. P-values were obtained by Pearson-chi-square test.










dectin-1 y238x variant‡ 7/21 25/179 27/175 19/138
allele frequency 19.0%π 7.0% 7.7% 6.9%
IA: invasive aspergillosis. ‡: All individuals were heterozygous for the Y238X Dectin-1 polymorphism except for one individual in the Non-HSCT 
group who was homozygous. #: Dutch healthy population [6]. π : Frequency of the allele frequency was significantly higher as compared to the 
all three other populations (Fishers exact test: p<0.05), see text for details.











































Functional Consequences of the Dectin-1 Y238X Polymorphism
Functional assays were performed to attempt to find a mechanistic explanation on the lim-
ited influence of Dectin-1 on susceptibility to IA. To fully elucidate the phenotypic effects of 
the Dectin-1 Y238X polymorphism, we had used Dectin-1- deficient PBMC and differentiated 
MDM from two siblings whom we have characterized as being homozygous for the variant 
Dectin-1 allele [6], and from healthy control subjects who were WT for the Dectin-1 gene.
Cytokine stimulation
We assessed the capacity of the immune cells to respond to the various stimuli. In PBMC, 
homozygosity for Dectin-1 Y238X resulted in marked reduction of proinflammatory TNF-α 
and IL-6 production in response to heat-killed A. fumigatus hyphae, C. albicans blastoconidia 
and live A. fumigatus conidia as would have been anticipated given the key role that the Dec-
tin-1 receptor is known to play in recognition of fungal cell wall β-glucan (Figure 3a & b) [7, 
9]. In the MDM, however, there were no significant differences in proinflammatory cytokine 
responses between subjects who were homozygous or WT for Dectin-1. This was apparent 
for both live A. fumigatus conidia, as well as heat-killed hyphae (Figures 3c & d). As control, 
stimulation using β-glucan still failed to generate TNF-α response in the Dectin-1-deficient 
MDM in contrast to MDM containing the wild-type Dectin-1. Despite the intrinsic inability 
to signal via the Dectin-1 pathway in the Dectin-1-deficient MDM, the demonstrated ability 
of these cells to still respond to Aspergillus indicated the presence of alternative signaling 
pathways.
Flow Cytometry
We demonstrated earlier that monocytes from individuals homozygous for Y238X polymor-
phism had diminished Dectin-1 receptor cell surface expression [7]. We further demonstrate 
Figure 2. Patient survival following diagnosis of invasive aspergillosis
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here that MDM from these individuals also had deficient expression of the Dectin-1 receptor 
(Figures 4a & c) which is corroborated by the inability to respond to β-glucan as shown above. 
Besides Dectin-1, other PRRs such as the mannose receptor (MR), TLR2 and TLR4 participate 
in recognition of fungal ligands [5]. Of note, the MR is a distinct CLR commonly found 
mainly on macrophages, while TLR2 and TLR4 are ubiquitous on most immune cells includ-
ing monocytes and macrophages. It is plausible that the host tissue macrophages recognize 
Aspergillus through these alternative PRRs, especially the MR pathway. This may circumvent 
deficiency in the Dectin-1 signaling pathway, and account for the normal cytokine produc-
tion in Dectin-1 deficient MDM. To substantiate this, we showed that Dectin-1 deficient MDM 
had similar levels of expression of MR as normal cells (Figures 4b & d), and that TLR2 and TLR4 
expression was normal (data not shown).






















































































(c) MDM (d) MDM
Legend: Functional assays to assess consequence of the Dectin-1 Y238X polymorphism in response to live Aspergillus fumigatus conidia 1x107/
ml (Asp Conidia), heat-killed A. fumigatus hyphae 1x107/ml (Asp hyphae), Candida albicans blastoconidia 1x106/ml (Candida) and beta-glucan 
20µg/ml. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) responses of peripheral blood mononuclear cells (PBMC, Fig 3a &b) and 
monocyte-derived macrophages (MDM, Fig 3c & d) from 2 sibling homozygous for the Y238X polymorphism (Dectin -/-) [6] and 5 Dectin-1 
wild-type controls (Dectin +/+) were assessed. Data was from 3 sets of experiments and presented as mean ± standard error of the mean 
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discussion
Though much has been reported on the central role that Dectin-1 plays in host recognition 
of Aspergillus, this is based largely on findings from experimental murine models. In this 
study, however, we found that a defective function of Dectin-1 due to a premature stop 
codon polymorphism may potentially enhance susceptibility to IA in susceptible non-HSCT 
patients although the effect was moderate in the HSCT cohort and did not significantly alter 
the clinical course of the disease. In contrast to the observations on Dectin-1 obtained from 
in-vitro and mice models, the above clinical findings remain significant as they also highlight 
the system of redundancy inherent in the human innate immune system against invading 
pathogens like Aspergillus.
Recently, Dectin-1 has been recognized as being a pivotal PRR for the control of fungal 
infections [17] and specifically for anti-Aspergillus host defense [10]. In-vitro studies demon-
strated the involvement of Dectin-1 in both TLR-dependent and TLR-independent anti-fungal 
responses [14, 18]. The clinical significance of Dectin-1 in mucosal candidiasis was highlighted 
recently in a study that described how defective Dectin-1 expression and function resulted 
in recurrent vulvovaginal candidiasis in a family of siblings who were homozygous for the 
Y238X polymorphism [6], while another study reported an increased incidence of oral and 
gastrointestinal Candida colonization in HSCT recipients heterozygous for the same variant 
gene [7].
Despite the in-vitro studies pointing out the importance of Dectin-1 as receptor for fungal 
β-glucans, the perceived importance of Dectin-1 for invasive mycosis in mice models had 
been debated. Contrary to findings of Taylor et al that Dectin-1 deficient mice showed in-
creased susceptibility to disseminated candidiasis, another study by Saijo et al did not yield 
similar corresponding results using an independently developed Dectin-1 -/- mice strain [19, 
20]. A later study showed that Dectin-1 had an important role in a murine model of invasive 
aspergillosis [10]. Nevertheless, it was also interesting to note that a family with siblings 
who had a complete deficiency of the Dectin-1 function did not report susceptibility to 
systemic fungal infections [6]. This suggests that although Dectin-1 has an unchallenged role 
as β-glucan receptor, in the in-vivo situation, alternative recognition pathways can initiate 
effective anti-fungal responses.
Patient studies remain crucial for the validation of the host defense mechanisms identified 
in in-vitro and experimental studies. To be at-risk for development of IA, a profoundly immu-
nocompromised status consequent to immune-ablative chemotherapy, HSCT conditioning 
regimens or chronic corticosteroid treatment is obligate. In this study we found a markedly 
increased Y238X allele frequency of 19.0% in non-HSCT patients who developed IA post-
chemotherapy as compared to other reference populations (range 6.9-7.7%). In concordance 
to earlier findings from a previous study which reported the Y238X allele frequency to be 6.9% 
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in the general Dutch population, our analysis of healthy donors to HSCT patients also yielded 
a comparable allele frequency of 7.7% (p=0.76). One consideration would have been whether 
the possession of the Y238X polymorphism could remotely be related to acquisition and pro-
gression of the underlying hematological disease state resulting in an over-represented allele 
frequency in the above non-HSCT IA cases. However, this was not the case as we had also 
determined that in the HSCT patients with similar predisposing hematological disorders, the 
allele frequency of Y238X was 7.0%; this was comparable to the above healthy populations.
The occurrence of IA in HSCT presents a challenge in studying genetic susceptibility as both 
donor and recipient genotype will invariably exert their influence on function of the immune 
cells post transplantation. Even after documented engraftment, it remains unresolved when 
chimerism is actually achieved at the level of the pulmonary macrophages which form the 
frontline against the invading Aspergillus. We found that Y238X status in the HSCT recipient 
was associated with a modest trend towards susceptibility to IA (OR 1.79, 95% CI 0.77-4.19, 
p=0.17). This was not accentuated following multivariate adjustment (adjusted OR 1.70, 95% 
CI 0.72-4.00, p=0.22). Also, donor Y238X status was found not to be an attributable factor. 
Simultaneous presence of the Dectin-1 Y238X variant in both donor-recipient pair did not 
further confer a dose-dependent effect on susceptibility to IA (Table 2a). Immune recognition 
and activation at the epithelial level is a key mechanism in host defense against invasive 
pathogens [21]. Post-HSCT, Dectin-1 expression on epithelial cells and pneumocytes remains 
as determined by recipient genotype in contrast to immune cells of myeloid origin. Hence 
this reasonably accounts for our finding that it was the recipient Dectin-1 Y238X status, rather 
than the donor, which had an influence on susceptibility to IA.
The stronger association observed in the non-HSCT cohort despite the smaller patient 
numbers may be because patient and treatment profiles are relatively more homogenous. 
Comparisons incorporating both cohorts, though, may be confounded as there remain inher-
ent differences in treatment regimens (and possibly IA susceptibility) between non-HSCT and 
HSCT patients [22]. Nevertheless, the increased incidence of the Dectin-1 Y238X variant in 
non-HSCT IA patients, as well as its association towards IA susceptibility in HSCT recipients, 
suggest that heterozygosity for the Y238X SNP has a moderate association with acquisition 
of IA in at-risk patients. Recognizing the potential limitation of our finding - pertaining spe-
cifically to the smaller non-HSCT study cohort as well as the methodology employed for the 
sub-group analysis - further validation of this observation in a larger cohort of non-HSCT IA 
patients and controls is needed.
Our functional assays using cells isolated from individuals homozygous for the Dectin-1 
Y238X polymorphism also shed light on why susceptibility to Aspergillus infection may be 
limited and clinical course of disease relatively unaltered despite reduced Dectin-1 receptor 
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with normal production of proinflammatory cytokines upon challenge with A. fumigatus. As 
pulmonary macrophages form the first line of defense against inhaled Aspergillus conidia, 
our findings highlight the capacity of macrophages to retain their response even with defi-
cient Dectin-1 function probably lies in their capacity to engage alternative PRRs: MR, TLR2 
and TLR4. These receptors are known to be involved in immune recognition of Aspergillus 
and antifungal host defense [23-26]. This ability to retain the capacity to respond to the 
pathogen in the absence of Dectin-1 underscores the redundancy that is inherent to the 
human antifungal host defense. On the other hand, the modest susceptibility to aspergillosis 
in patients bearing the Y238X polymorphism, coupled to the defective monocyte function, 
suggest an adjuvant yet essential role of infiltrating monocytes for host defense. In contrast 
to monocytes and macrophages, the main β-glucan receptor on neutrophils is complement 
receptor 3 [27]. Although neutrophils are important in anti-Aspergillus host defense [28], the 
Dectin-1 Y238X polymorphism does not affect these cells as neutrophil function was normal 
in individuals with homozygous Dectin-1 Y238X mutation [6].
Other polymorphisms in genes coding for components of the innate immunity have been 
recently reported to increase susceptibility to Aspergillus infections: TLR1, TLR4, TLR6 and 
IL-10 promoter [29-34]. In all of the above studies, like ours, the polymorphism of interest 
was studied in isolation and not in association with each other. It is tempting to consider that 
the concomitant presence of two or more of these polymorphisms in a patient may further 
enhance the risk profile to IA.
In conclusion, in the present study we report that the Dectin-1 Y238X polymorphism was 
associated with a moderate increase in susceptibility to IA, particularly in non-HSCT immu-
nocompromised patients. Additional studies are needed to validate these findings, yet these 
data provide novel insight in human host defense during invasive aspergillosis.
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The innate immune system plays a pivotal role in the primary defence against invasive fungal 
infection. Genetic variation in genes that regulate this response, initiated by pulmonary 
macrophages, may influence susceptibility to invasive aspergillosis (IA) in patients at risk. 
We investigated whether common polymorphisms in Toll-like receptor- (TLR) and cytokine 
genes involved in macrophage regulation contribute to susceptibility to IA. Forty-four al-
logeneic stem cell transplantation (ASCT) recipients diagnosed with probable- or proven IA 
according to 2008 EORTC/MSG criteria, were enrolled. The control group consisted of 64 ASCT 
recipients without IA. The TLR4 1063A>G single nucleotide polymorphism (SNP) was associ-
ated with IA when present in donors of ASCT recipients (OR 4.50 95%CI 1.14-17.8, p=0.02). 
In a multivariate analysis adjusted for occurrence of graft-versus-host-disease and duration 
of neutropenia, paired presence of the TLR4 1063A>G and IFNG 874T>A or TLR6 745C>T 
and IFNG 874T>A SNPs showed a trend towards increased susceptibility to IA (p=0.038 and 
0.081 respectively). These findings point to the relevant immunological pathway involved in 
resistance to IA and warrant further study of the effects of TLR and cytokine polymorphisms 
and their interaction, which may occur on different levels of the complex biological interplay 
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Introduction
It is incompletely understood why some hematologic transplant patients develop invasive 
aspergillosis (IA), a cause of considerable morbidity and mortality, while others remain unaf-
fected [1]. Clinical risk factors for development of invasive fungal infections (IFI), have been 
identified, but such risks are not absolute [2, 3]. Likely, the host’s or, in case of allogeneic 
stem cell transplantation (ASCT), the donor’s genetic signature may influence susceptibility 
to acquiring manifest IA or at least affect its clinical course. In-vitro- and animal studies indi-
cated that the innate immune system plays a pivotal role in defence against IFI, by pathogen 
recognition and activation of appropriate host defence mechanisms in pulmonary macro-
phages [4, 5]. A family of pathogen recognition receptors (PRRs), the Toll-like receptors (TLRs), 
mediate this process through detection of fungal components and initiation of intracellular 
signalling pathways that lead to a pro-inflammatory cytokine response [6-10]. Only recently, 
certain single nucleotide polymorphisms (SNPs) in TLR4 as well as in TLR1 and TLR6 genes 
were associated with occurrence of IA in ASCT recipients [11-13]. However, the response of 
the innate immune system relies on a complex network of components which encompasses 
TLRs as well as molecules of signaling pathways (e.g. MyD88 and NFκB) and subsequently 
secreted cytokines [14] In this respect, animal studies showed that depletion of IL-12 and 
IFN-γ delayed pulmonary clearance of A. fumigatus in mice [15]; moreover, a high production 
of IL-12 and IFN-γ had a protective effect [16]. In humans, little is known about the role of 
these or other cytokines in the context of innate or acquired anti-fungal defense mechanisms 
and only scarce data is available to validate the clinical and experimental findings so far. 
Hence, we aimed to investigate relevance of common genetic polymorphisms, focusing on 
the TLR-mediated-IL-12-IFN-γ loop to macrophage activation, with regard to susceptibility to 
development of IA in ASCT recipients.
methods
Study population
The study cohort consisted of 44 patients with hematological disorders and diagnosed 
with either proven or probable IA following ASCT according to the revised 2008 European 
Organization for Research and Treatment of Cancer and Mycosis Study Group (EORTC/MSG) 
criteria[17]. All patients were treated at the Leiden University Medical Center, a tertiary 
care and teaching hospital in the Netherlands. Patients were recruited from the database 
of the Department of Infectious Diseases. Sixty-four patients with comparable hemato-
logical disorders but who did not develop IA, were enrolled in the control group. The ethnic 
background was Caucasian in both groups and all patients had undergone T-cell depleted 
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ASCT. Demographic and clinical characteristics as well as outcome data were collected from 
the hospital’s electronic database. The duration of neutropenia to the diagnosis of IA was 
defined as the number of consecutive days from the first day of a granulocyte count <0.5 
x106 cells/L (determined ±3 times weekly) to the day that microbiological evidence of IA was 
first obtained. The study was endorsed by the local medical ethics committee. No standard 
prophylaxis active against Aspergillus sp. was used. Clinical characteristics per group are as 
summarized in table 1.
Polymorphisms and genotyping
Polymorphisms were considered eligible for study if the SNP was previously reported to be 
associated with the occurrence of IA and had an expected allele frequency of ≥5% in the 
population. With regard to the focus of interest as pointed out in the introduction, two SNPs 
Table 1. Clinical characteristics of patients with underlying hematological disease with (cases) or without (controls) invasive aspergillosis 
developing after allogeneic stem cell transplantation.
Variable





total No. 44 64
sex ratio male/female 18/26 71/31 0.70
age (median, IQr) 47 (41-57) 51 (46-58) 0.26



































site of Ia n (%)
 Pulmonary 42 (95) -
 Extra-pulmonary 2 (5) -
Complications n (%)
 Prolonged neutropenia† 15 (34) 29 (45) 0.32
 GVHD 25 (57) 21 (32) 0.02
Legenda: IA: invasive aspergillosis; IQR: interquartile range, ASCT: allogeneic stem cell transplantation, AML : acute myeloid leukemia, CML: 
chronic myeloid leukemia, NHL: non-Hodgekin’s lymphoma, ALL: acute lymphocytic leukemia, CLL: chronic lymphocytic leukemia, MDS: 
myelodysplastic syndrome, †: Prolonged neutropenia defined as absolute neutrophil count <500 cells/mm3 for a period of more than 14 days. 
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reported to influence IL-12p40 and IFN-γ production were additionally included (table 2). 
Blood- or bone marrow samples were used to isolate DNA. Genotyping of polymorphisms 
was performed by use of a Mass Array platform according to the manufacturer’s protocols 
(Sequenom, San Diego, USA). Multiplex assays were designed using Assay designer software 
(Sequenom). In brief, after PCR on 2.5 ng of DNA a primer extension reaction was performed 
to introduce mass-differences between alleles and, after removing salts by adding a resin, 
~15 nl of the product was spotted onto a target chip with 384 patches containing matrix. 
Mass differences were detected using a Bruker Autoflex MALDI-TOF mass spectrometer 
and genotypes were assigned real-time using Typer 3.1 software (Sequenom). As quality 
control, 10% of samples were genotyped in duplo; no inconsistencies were observed. Primer 
sequences are available upon request.
Statistical analysis
Genotype- and allele frequencies were calculated and compared between groups by Pear-
son-chi-square and Fisher’s exact tests. Odds ratio (OR) and 95% confidence interval (95%CI) 
were calculated for the presence (homozygous or heterozygous) or absence (homozygous 
wild type allele) of the selected SNPs. All polymorphisms were tested for the Hardy-Weinberg 










Negatively Influences IL-1β levels. A higher frequency of the IL1B -511TT 
genotype was found in patients with IA as compared to patients without IA.
Wilkinson et al. 23
Sainz et al. 24
IL10 rs1800872 -592A>C
Promotor SNP, protective effect in conjunction with the -1082 and -819 IL10 
promotor polymorphisms
Seo et al. 25
IL10 rs1800896 -1082G>A
Promotor SNP, conferring a diminished expression of the IL10 gene and a 
subsequent protective effect with respect to IA
Sainz et al. 18
IL12B rs41292470 GC>CTCTAA





Confers dimished production of IFN-γ, resulting in decreased activation 
of macrophages. Reported to influence cellular response to tuberculosis. 
Association with IA unknown.
Pravica et al. 27
Rossouw et al. 28
TLR1 rs5743611 239G>C Associated with IA in ASCT recipients Kesh et al. 13
TLR1 rs4833095 743A>G
Associated with IA in ASCT recipients when present in combination with 
the TLR6 745C>T polymorphism
Kesh et al. 13
TLR4 rs4986791 1363C>T Associated with IA when present in donor DNA of ASCT recipients Bochud et al. 11
TLR4 rs4986790 1063A>G
Associated with IA in ASCT when present in recipient DNA
Associated with IA when present in donor DNA of ASCT recipients
Carvalho et al. 12
Bochud et al. 11
TLR6 rs5743810 745C>T
Associated with IA in ASCT recipients when present in combination with 
the TLR1 743A>G polymorphism
Kesh et al. 13
Legenda: IL denotes interleukin; TLR: toll-like receptor; IFN: interferon; ASCT: allogeneic stem cell transplantation; IA: invasive aspergillosis; 
SNPdb id: Single Nucleotide Polymorphism database identification number.
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equilibrium. Due to the possibility that development of IA was influenced by SNPs in the 
donor DNA, genotype and allele frequencies were also compared between donors of the pa-
tients with IA and donors of control patients. Because of expected redundancy and complex-
ity in the pathway to granulocyte and macrophage activation, the relevance of the combined 
presence of the selected polymorphisms was assessed in a contingency table. The influence 
of a selected SNP on the course of disease (i.e., duration of neutropenia to day of diagnosis 
or time from IA diagnosis to death) was assessed by Kaplan-Meier analysis (log rank-test). 
The SPSS version 17.0 statistical software package for Windows was used for all calculations.
results
A total of 10 candidate polymorphisms, all acting within the type-1 cytokine loop to macro-
phage activation, were selected for analysis: five SNPs in three different TLR genes (-1,-4 and 
-6) and five SNPs in the IL10, IL12B and IFNG genes (table 2). Distribution of genotypes was 
consistent with the Hardy-Weinberg equilibrium except for the IL12B SNP. The TLR4 1063A>G 
and TLR4 1363C>T SNPs were in strong linkage disequilibrium, i.e. when the 1063A>G SNP 
was found, the 1363C>T was almost always also present. No significant difference in geno-
type or allele frequencies was found between patients with IA and control patients (data 
not shown). When comparing donor genotype and allele frequencies, the TLR4 1363C>T and 
TLR4 1063A>G SNPs were more frequently present in donors of patients with IA (table 3).
The donor DNA contained the TLR4 1063A>G SNP in 9 of the 43 case patients (21%) and in 3 
(6%) of the 54 control patients successfully genotyped for this polymorphism (OR 4.50 95%CI 
1.14-17.8, p=0.02). Following multivariate correction for GVHD and duration of neutropenia 
the adjusted OR was 3.76 (95% CI 0.90-15.8, p=0.07). In addition, the allele frequency of the 
IFNG 874T>A polymorphism showed a trend towards association with IA when present in 
donors of patients with IA (OR 1.60 95%CI 0.91-2.79, p=0.10).
Since our hypothesis was that susceptibility to IA by genetic mutations could be influenced 
by the interplay of both TLR and cytokine gene mutations, relevance of the combined pres-
ence of the selected polymorphisms was assessed in a contingency table (i.e. association of 
occurrence of IA with the presence of at least one minor allele in both genes in the interaction 
term). With respect to this analysis no significant associations with IA were found in the com-
parison of patients with IA versus control patients. However, a similar analysis performed for 
the genotypes of the donor samples revealed that paired combinations of the TLR4 1063A>G, 
TLR6 745C>T, or IFNG 874T>A SNPs correlated with occurrence of IA in the recipient (table 
4). After multivariate adjustment for GVHD and neutropenia only the association between 
the TLR4 1063A>G and IFNG 874T>A combination and IA remained statistically significant 
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strength of the association of individual or paired polymorphisms with IA, incorporating 
both the single presence of the minor SNP in the TLR4, TLR6 and IFNG genes as well as their 
paired combinations, showed that the TLR4 1063A>G / IFNG 874T>A combination was most 
strongly linked with IA (p=0.033).
Kaplan-Meier analysis did not reveal significant differences in time to development of IA 
between recipients or their donors bearing either only the wild-type or variant allele. There 
was no difference in survival (time to death following diagnosis of IA) consequent to having 
one or two minor alleles of the selected SNPs in either recipients or their donors.
Table 3. Genotype frequencies of SNPs in TLR, IL10, IL12 and IFNG genes in the donor DNA of patients who developed invasive aspergillosis after 
allogeneic stem cell transplantation.
gene  sNP
distribution of Genotypes (mm/mm/
mm) in donors of asCt recipients*
allele frequency of the
minor allele
X2 p-value Or (95%CI)
cases controls cases controls
iL1B -511C>T 2/19/19 5/18/28 0.29 0.28 0.04 0.85 1.07 (0.56-2.04)
iL10 -592A>C 2/15/26 3/19/31 0.22 0.24 0.06 0.81 0.92 (0.47-1.81) 
iL10 -1082G>A 5/24/14 13/26/15 0.40 0.48 1.44 0.23 0.70 (0.40-1.25)
iL12B∑ GC>CTCTAA 11/21/9 10/39/10 0.52 0.50 0.12 0.73 1.10 (0.63-1.94)
iFnG 874T>A 11/21/11 8/31/22 0.50 0.39 2.71 0.10 1.60 (0.91-2.79)
tLr1 239G>C 1/5/36 0/9/50 0.08 0.08 0.03 0.86 1.10 (0.39-3.08)
tLr1 743A>G 2/16/25 4/20/37 0.23 0.23 0.003 0.96 1.02 (0.53-1.96)
tLr4 1363C>T 1/7/34 0/4/55 0.11 0.03 4.37 0.04 3.42 (1.02-11.5)
tLr4 1063A>G 2/7/34 0/3/51 0.13 0.03 7.17 0.01 5.13 (1.38-19.0)
tLr6 745C>T 7/25/10 11/29/19 0.46 0.43 0.20 0.67 1.14 (0.65-2.00)
Legenda: IL denotes interleukin; TLR: toll-like receptor; IFN: interferon; ASCT: allogeneic stem cell transplantation; IA: invasive aspergillosis; 
X2: chi-square test value; OR: odds ratio; 95%CI: 95% confidence interval. ∑: distribution of this genotype was not in Hardy-Weinberg 
equilibrium (p=0.045). *:Due to incidental failing of genotyping the No. of cases and controls are not equal for each SNP; m: minor allele; 
M:major allele.
Table 4. Final results of the contingency table analysis for the association between the paired presence of TLR and cytokine polymorphisms in 
donors of ASCT recipients and development of invasive aspergillosis using all 10 polymorphisms.







TLR4 1063A>G and IFNG 874T>A 10.9 1.29-92.2 0.02 10.2 1.14-91.7 0.038
TLR6 745C>T and IFNG 874T>A 2.21 0.99-4.93 0.07 2.02 0.86-4.73 0.105
TLR4 1063A>G and TLR6 745C>T 4.11 1.02-15.7 0.05 3.65 0.85-15.7 0.081
∫: p-value calculated with Fisher’s exact test. IL: interleukin; TLR: toll-like receptor; IFN: interferon. *: Adjusted for presence of GVHD and 




We found that in this study cohort the TLR4 1063A>G polymorphism was associated with 
increased susceptibility to IA, when present in the donors DNA of ASCT recipients (alone or in 
combination with TLR6 745C>T or IFNG 874T>A SNPs). None of the cytokine polymorphisms 
alone was linked with occurrence of IA. The results of our investigations concur with the 
study by Bochud et al in which the 1363C>T and 1063A>G polymorphisms in the TLR4 gene 
were demonstrated to be associated with IA when present in donors of ASCT recipients.[11] 
In contrast, an increased risk for IA was previously reported for the 1063A>G SNP if present in 
the recipients DNA but not in the donor DNA [12]. The association between IA and the TLR1 
239G>C SNP or between IA and the combination of the TLR1 743A>G and TLR6 745C>T SNPs 
as reported in a smaller study by Kesh et al. [13], was not confirmed by our data.
The IFNG 874T>A SNP was found to potentially add up to the risk conferred by two of the 
TLR polymorphisms. Although carriers of this genetic variation produce suboptimal levels of 
IFN-γ, putting them at increased risk for perhaps manifest tuberculosis, the isolated presence 
in either donor or recipient did not increase the risk for IA. Remarkably, SNPs that affect the 
production of IL-10, one of the most important broad-acting negative modulators of the TLR 
to IL-12 and IFN-γ macrophage-activating pathway, did not influence susceptibility to IA. 
Absence of IL-10 was demonstrated to cause increased survival of susceptible mice when 
exposed to Aspergillus fumigatus and in a prospective clinical study a tendency towards 
protection against IA was detected when the -1082 A/A-genotype was present [18].
As compared to other risk factors, the absolute risk conferred by relevant SNPs in PRR- and 
cytokine genes is likely to be limited, given the fact that individuals carrying these SNPs do 
not develop IA unless another immune deficiency is present. Moreover, our data indicate 
that even in hosts most at risk, the ability to maintain a response to IA is largely unaffected 
by the studied SNPs, underscoring the already expected redundancy inherent to the human 
antifungal defense [19]. Likely, specific patterns of genetic polymorphisms rather than a 
single genetic variation in TLRs or subsequent cytokine pathways that activate macrophages 
may be associated with IA in patients at risk. The observation of the association between the 
TLR4 1063A>G plus IFNG 874T>A SNP combination and IA fits such a hypothesis. However, 
probable associations of IA with conditional combinations of mutations may also attest to 
the complex immuno-pathogenesis of invasive aspergillosis. As a consequence of neutrope-
nia, the role of key components within the innate immune response (e.g. lung macrophages 
phagocytosing and eliminating Aspergillus conidia) could be more prominent in the remain-
ing defense against invasive fungal infection and thus facilitate linkage to TLR- in combina-
tion with cytokine SNPs. Assuming that the studied SNPs have an effect on the functioning 
of the innate immune system, different SNPs may also be working at different time points to 
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The study has limitations, e.g. due to a retrospective design and size of the study cohort. 
However, two studies that explored the role of TLR SNPs and risk for IA included a comparable 
or even smaller number of patients [12, 13]. Of note, rather than performing a genome-wide 
analysis, or testing a random collection of immune genes, we chose to investigate the as-
sociation of IA with pre-set polymorphisms in candidate genes involved in type-1 cytokine 
loop to macrophage activation. This ameliorates implications with regard to the concept 
of multiple testing, but by some a significance level of 0.05 may be regarded too liberal. 
Currently an ongoing discussion about the necessity of p-value adjustment in exploratory 
epidemiological studies still evolves and with all relevant data reported, final judgment is 
left to the reader [20, 21]. Furthermore, due to the rapidly evolving research field, produc-
ing newly found candidate SNPs like the Dectin-1 Y238X polymorphism, investigations can 
hardly ever be complete [22].
The overall impact of the reported TLR4 1063A>G and IFNG 874T>A SNPs on the risk of IA 
should be interpreted with care. Relative risk associations of genetic variations in the case 
of IA do not stand alone but likely are influenced again by other components in the host’s 
defense. As discussed above, the observations of this study may be accounted for by both 
a system of redundancy in the innate immune system as well as by the complex biological 
interaction between the immunocompromised host and the invading fungus. At present, 
the findings do not extent to the bedside yet, e.g., by providing guidance for individualized 
prophylaxis or early intervention. However, by further unravelling the interplay between the 
innate host defence and Aspergillus sp. through experimental and clinical investigations, 
increased comprehension of the underlying immuno-pathogenetic processes may, in time, 
translate into insights directly relevant to clinical practice.
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Invasive fungal infections are recognized as an important cause of morbidity and mortal-
ity in the immunocompromised host. Rapid initiation of adequate antifungal treatment is 
often hampered by the limitations of current diagnostic methods. This review encompasses 
the promises and limitations of newer tracers (believed to target the infectious agents), i.e. 
radiolabeled antimicrobial peptides, antifungals and chitin-specific agents, for fungal infec-
tion imaging by scintigraphy. In mice 99mTc-labeled peptides derived from human ubiquicidin 
(UBI29-41) and lactoferrin (hLF1-11) distinguished local Candida albicans and Aspergillus 
fumigatus infections from sterile inflammatory processes, but not from bacterial infections. 
Clinical trials showed that 99mTc-UBI29-41 can distinguish infectious from inflammatory le-
sions with 80% specificity and 100% sensitivity. 99mTc-hLF1-11 was able to monitor the anti-
fungal effects of fluconazole on C. albicans infections. Moreover, 99mTc-fluconazole proved to 
be an excellent tracer for C. albicans infections as it did not accumulate in bacterial infections 
and inflammatory processes. However this tracer poorly detected A. fumigatus infections. 
Furthermore, 123I-chitinase and 99mTc-HYNIC-CBP21 accumulated in both C. albicans and A. 
fumigatus infections in mice at later time points. In conclusion, despite the recent advances in 
radiolabeled imaging techniques for invasive fungal infections, the search for better tracers 
for fungal infection imaging should be continued.
Abbreviations: hLF1-11: human lactoferrin peptide corresponding to residues 1-11, UBI29-41: 
ubiquicidin peptide corresponding to residues 29-41, LPS: lipopolysaccharide, CBP21: chitin-
binding protein (21 kDa), HYNIC: hydrazino nicotinamide
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Positive blood cultures have remained the gold standard for the diagnosis of invasive 
candidiasis, a condition still associated with high morbidity and mortality [1]. Whether at-
tempted treatment is successful depends on the choice of the antifungal agent and duration 
of therapy as well as on the elimination of the primary focus [2]. However, patients may 
have no evident clinical signs or symptoms pointing to the origin of the candidemia or new 
foci that developed through hematogenous spread. In general, intravascular catheters are 
most frequently involved as a primary or maintaining focus of candidemia and should then 
promptly be removed [3, 4]. In surgical patients, infection with Candida spp. and subsequent 
candidemia can be related to the type and site of operation, e.g. intra-abdominal abscesses, 
mediastinitis, vascular grafts or joint prosthesis. In patients with hematological disorders 
requiring treatment with bone-marrow transplantation or intensive chemotherapy fungal 
infections may originate from the gastro-intestinal tract, where the growth of yeasts like C. 
albicans is restricted by the microbial flora, the actions of host’s immune defenses, and other 
local environmental conditions. Disturbance of this balance in severely immunocompromised 
patients, e.g. loss of the gastro-intestinal mucosal integrity and neutrophil depletion [5], can 
result in uncontrolled growth of C. albicans and lead to invasion of deeper mucosal tissue or 
dissemination to other organs [6]. Due to an increase in the numbers of these patients it can 
be anticipated that the absolute number of patients with invasive candidiasis is increasing.
It is often a major challenge for clinicians to determine the primary focus of the infection, 
the extent of dissemination or whether the surgical site is involved. Important clinical con-
sequences may include extended antifungal treatment, abscess drainage or even removal of 
the graft or prosthesis [2, 7, 8]. Currently available techniques such as ultrasonography, com-
puted tomography (CT), and magnetic resonance imaging (MRI) are anatomically oriented. 
These are highly sensitive and sophisticated, yet lack specificity for infection, especially in 
early phases, when anatomic structures have not been altered. Furthermore, in presence of 
distortion of the normal anatomy, i.e. postsurgical changes, scarring, or the presence of im-
plants and/or vascular grafts, the diagnostic role of these techniques is limited. Visualization 
of fungal infections with fluorine 18- (18F)-fluoro-2-deoxy-D-glucose (18F-FDG) by positron 
emission tomography (PET) and PET/CT procedures in patients with malignancy has been 
reported [9]. However, this tracer suffers from serious drawbacks, including its high radiation 
burden for patients and medical personnel, the requirement of a dedicated imaging equip-
ment (PET scanner), and its short half life (110 min) puts strains on the infrastructure and 
logistics. No imaging technique that specifically and accurately assesses the presence of 
Candida spp. (or other yeasts/fungi) at different anatomical locations in the human body 
is currently available to assist clinical decision making. Scintigraphic detection of fungal 
infections would have the advantage of a whole body image. Thus, nuclear medicine could 
contribute to fungal infection imaging provided that good tracers are available [10]. The 
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ideal tracer for fungal infection imaging should fulfill the following criteria: i) rapid uptake 
at sites of fungal infection with little or no accumulation at sites of sterile inflammation and 
bacterial infections; ii) good stability of the labeled complex under physiological conditions; 
iii) preservation of binding activity upon labeling; iv) rapid clearance from the circulation 
with little or no accumulation in unaffected tissues, and v) little or no adverse effects, such 
as toxicity and immunological reactions [11]. Unfortunately, none of the currently available 
radiopharmaceuticals, e.g., gallium-67-citrate (67Ga), indium-111 (111In), and technetium-99m 
(99mTc)-labeled polyclonal human immunoglobulins or monoclonal antibodies, and 111In- or 
99mTc-labeled autologous leukocytes discriminates between infection and sterile inflamma-
tion [12-14]. Nevertheless, the visualization of radiolabeled leukocytes has taken a central 
role in infection imaging during the last decades in clinical practice, resulting in high ac-
curacy for infection diagnosis in selected clinical settings. For obvious reasons, novel tracers 
for fungal infection imaging are urgently needed.
This review encompasses the current knowledge and future promises as well as the 
limitations of radiolabeled antimicrobial peptides, antifungals and chitin-binding agents for 
scintigraphic imaging of invasive fungal infections.
antimicrobial peptides
Antimicrobial peptides are important components of innate immune system of all living 
organisms. They are evolutionarily ancient molecules that fend off a wide range of infec-
tions. They often contain hydrophobic and cationic amino acids, which are organized in an 
amphipatic structure. Most antimicrobial peptides interact through their cationic (positively 
charged) domains with the (negatively charged) surface of microorganisms [15, 16]. Differ-
ently from mammalian cells, where the negatively charged lipids are segregated into the in-
ner leaflet facing the cytoplasm, microorganisms expose the negatively charged headgroups, 
e.g., lipopolysaccharide (LPS), lipoteichoic acids, mannoproteins, to the outer world. Main 
features of antimicrobial peptides are described in Box 1 and an online catalogue on cationic 
peptides can be consulted at: http://www.bbcm.univ.trieste.it/~tossi/antimic.html.
Difficulties in purifying natural antimicrobial peptides from various sources have prompted 
the recombinant production of antimicrobial peptides by genetically engeneered bacteria 
[35] or by peptide synthesis [36, 37]. Sufficient amounts of antimicrobial peptides can be 
produced under good laboratory practice conditions. The latter is essential for future ap-
proval to employ the (radiolabeled) peptides in clinical practice. Peptide synthesis offers the 
possibility to make chemical variants, such as D-enantiomers, peptides having amino acid 
substitutions at various positions, peptides in which chelators can be introduced on desired 
positions to enable labeling via a bifunctional ligand. On the basis of the chemical character-
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istics (amino acid sequence and secondary structure), and the biological features of domains 
present in natural antimicrobial peptides/proteins, various potential domains within intact 
antimicrobial proteins, such as human lactoferrin (hLF) and ubiquicidin (UBI), have been 
identified [22, 38-40]. Promising candidates for fungal infection detection were selected 
on the basis of in vitro binding studies showing a preferential binding of these peptides to 
microorganisms over activated human leukocytes, detection of infectious over inflammatory 
processes in mice, and favorable pharmacokinetics. Further investigations were performed 
regarding other properties, like immunological adverse effects, toxicology, and antimicrobial 
activity [41].
To overcome the disadvantage that UBI-derived and lactoferrin-derived peptides (as well 
as other antimicrobial peptides) exerting their antimicrobial activities and thus destroying 
their targets for infection imaging, these peptides were used for scintigraphic studies at 
doses lacking microbicidal activity [42].
Box 1. 
Key features of antimicrobial peptides 
 Antimicrobial peptides usually contain < 50 amino acids with a net positive charge owing  
to an excess of basic residues, such as lysine and arginine, and ~ 50% hydrophobic amino acids. 
 The majority of antimicrobial peptides are derived from larger precursors harboring a  
signal sequence, whereas other peptides are generated by proteolysis from larger proteins (such 
as lactoferricin). 
 Antimicrobial peptides are part of the chemical barrier against the constant microbial  
assault found at various anatomical sites, such as epithelia [17].  
 The expression of antimicrobial peptides by cells may be constitutive or induced upon  
contact with microorganisms or their products, like LPS, or pro-inflammatory cytokines.  
 Most antimicrobial peptides can affect both planktonic bacteria and those residing in biofilms [18, 
19], viruses such as HIV [20], and fungi [21] in vitro [22-25] and in laboratory animals [26,28].  
 In addition to their antimicrobial actions, antimicrobial peptides such as - and - 
defensins, cathelicidins (LL-37), and lactoferrin-derived peptides, participate at the  
interface of innate and adaptive immunity by modulating cytokine and chemokine  
production by a range of cell types, chemoattracting various immune effector cells [29]  
and mesenchymal stem cells [30], regulating autophagy in conjunction with vitamin D  
[31], modulating the differentiation of monocytes to macrophages [32] and dendritic  







Fluconazole is the most frequently employed among the triazole antifungal agents in 
treating Candida infections in individuals with severe immunodeficiency. It inhibits the 
ergosterol biosynthesis pathway and, in particular, the cytochrome P450-dependent lanos-
terol 14α-demethylase, encoded by the ERG11 gene. Drug-treated cells display a reduction 
in ergosterol content, the major component of fungal membrane, and accumulation of 
methylated sterol precursors, such as lanosterol. Such change in sterol composition disturbs 
membrane function and results in growth inhibition and death of the fungal cells. Indeed, 
ergosterol contributes to a variety of cellular functions, including fluidity and integrity of 
the membrane and the proper function of membrane-bound enzymes, such as proteins as-
sociated with nutrient transport and chitin synthesis. Ergosterol is also a major component 
of secretory vesicles in Saccharomyces cerevisiae, and has an important role in mitochondrial 
respiration. Indeed, mutants defective in ergosterol biosynthesis and yeasts treated with 
azole compounds are induced to a respiratory deficient “petite” status at a high frequency 
[43]. A further role of ergosterol can be found in mating conditions as demonstrated by muta-
tions in ERG4, encoding the enzyme that catalyzes the last step of ergosterol biosynthesis 
that impair both shmoo formation and cell fusion [44].
Radiolabeling of antimicrobial peptides and fluconazole
Obligatory conditions for adequate radiolabeling include the firm attachment of radionu-
clide or its incorporation into the antimicrobial peptide/antifungal molecule. Furthermore 
the labeling yield and the stability of the tracer should be high to allow the visualisation of 
the infection. The chosen labeling conditions should not affect the binding activity of the 
peptide/antifungal to the microorganism. The radiolabel is also very important. Technetium-
99m is the radiolabel of choice since it is readily available from a molybdenum generator as 
99mTc-pertechnetate, at low cost. In addition, its relatively short half-life (6 hours) results in 
low radiation burden for the patient. Various methods of labeling peptides with 99mTc, such as 
the indirect labeling using the preformed chelate approach or bifunctional chelating agents 
and the direct labeling method, have been extensively discussed [11, 45]. The radiolabeled 
tracer obtained with the preformed chelate approach is chemically well-defined as the 99mTc 
is bound to the specific chelating moiety before incubation with the peptide, thereby not 
exposing the compound to harsh labeling conditions. The drawbacks of this method are 
that it is complex and not well-suited for kit formulation. The use of bifunctional chelating 
agents incorporated into the peptide molecules, like HYNIC, N3S, DADT, amongst others, is 
chemically well-defined. However, introduction of a chelator may alter the lipophilicity of 
the peptide and thus its pharmacokinetics. Moreover, the large amounts of these chelating 
agents used to achieve high peptide-chelator conjugation yields require a time-consuming 
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purification step. The direct labeling method is, however, a simple procedure that has been 
used to successfully label an array of peptides and antibiotics, e.g. ciprofloxacin [46] and 
fluconazole [47], while keeping their biological functions intact [48]. This labeling method is 
performed under reducing conditions at a final pH 5-6 and requires a relatively short labeling 
time of approximately 10-20 min, resulting in a high labeling yield over 95% [41]. The stabil-
ity of the 99mTc-peptide/fluconazole complex in diluted human serum was excellent, and the 
peptides/anti-infectives retained their antimicrobial activity towards microorganisms in in 
vitro killing assays [41, 42, 49, 50]. In the reaction mixtures no colloids or free radioactive 
pertechnetate exceeding 5% of the total 99mTc-activity were observed [41].
In vitro binding studies and scintigraphic detection of infections by 99mTc-labeled antimicrobial 
peptides/fluconazole
A first selection of peptides displaying a preferential binding to fungi and bacteria over acti-
vated human leukocytes was performed by testing in vitro an array of 99mTc-labeled synthetic 
peptides derived from natural human antimicrobial peptides, e.g. UBI and hLF [40, 49, 50]. 
The most promising peptides were 99mTc-UBI29-41 and 99mTc-hLF1-11. In an attempt to fulfill 
all the previously mentioned criteria 99mTc-labeled fluconazole has also been considered for 
fungal infection imaging [47]. The results of in vitro binding studies of the selected peptides 
and 99mTc-fluconazole to Aspergillus fumigatus, Candida albicans, Staphylococcus aureus, Kleb-
siella pneumoniae, and activated leukocytes are shown in Table 1.
Following these investigations, 99mTc-peptides and 99mTc-fluconazole were injected into mice 
with a bacterial or fungal infection or sterile inflammatory process in order to study whether 
they could discriminate infections from sterile inflammatory lesions using scintigraphic 
techniques. Scintigraphic analysis revealed that these 99mTc-tracers accumulated at sites of 
infection, but not inflammation (Figure 1). The results are expressed as the ratio between 
Table 1. In vitro binding studies of 99mTc-compounds to microorganisms and activated leukocytesa












99mtc-hLf 1-11 55±6 26±2 20±4 2±1 10±1
99mtc-uBI 29-41 52±3 17±1 38±4 11±3 2±0.4
99mtc-fluconazole 18±2 38±3 3±0.4 6±0.1 13±5
99mtc-IgG 17±1 17±1 58±2 36±1 8±1
In vitro binding of 99mTc-labeled compounds to 107 CFU of Aspergillus fumigatus, C. albicans, S. aureus, K. pneumoniae and activated leukocytes 
is expressed as the percentage of added radioactivity. Activation of human leukocytes was accomplished after incubation of the cells with a 
combination of LPS and formyl-Met-Leu-Phe for 1 h at 37°C [Welling 04]. Values are means±SEM of at least eight observations.
aFrom Lupetti et al. [Current Drug Targets]
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the amount of radioactivity in the infected or infl amed (target) and the non-infected or 
non-infl amed (non-target) thighs, further referred as to target-to-non-target (T/NT) ratio. 
99mTc-human polyclonal IgG, which accumulates nonspecifi cally at sites of both infection and 
infl ammation, was used as positive control. The radiolabeled antimicrobial peptides accumu-
lated rapidly (within 30 min) in the target (infected) tissues (1-2% of the injected dose) with 
little accumulation at sites of sterile infl ammation, indicating that fungal and bacterial infec-
tions can be distinguished from sterile infl ammation by these tracers [47, 50]. After killing 
the animals, the number of viable microorganisms was assessed in homogenized infected 
thigh muscles using microbiological techniques. Target-to-non-target ratios for the diff erent 
tracers are shown in Figure 1.
In contrast to 99mTc-peptides, which detected both C. albicans and bacterial infections in 
immunocompetent mice, and A. fumigatus in immunocompromised mice, 99mTc-fl uconazole 
accumulated poorly in bacterial and A. fumigatus infected thigh muscles [47]. In contrast, a 
correlation (R2=0.864, P<0.05; n=12) was found between T/NT ratios at 2 hours after injec-
tion of 99mTc-fl uconazole and the number of viable C. albicans present in the infected thigh 
muscles [47]. In previous studies a correlation was seen between the accumulation of 99mTc-
UBI peptides in C. albicans-infected thigh muscles in mice and the number of viable yeasts. In 
Figure 1. Mean T/NT ratio of infected/infl amed thigh muscles after injection of 99mTc-labeled compounds.
 
Legend: Accumulation of 99mTc-labeled compounds in thigh muscles infected with A. fumigatus, C. albicans, bacteria (S. aureus and K. 
pneumoniae), or infl amed with lipopolysaccharide (LPS). Values represent mean±SEM observed at 30, 60, and 120 min after injection of tracer. 
* T/NT is signifi cantly higher (P<0.05) than T/NT in mice injected with LPS.
133





addition, the possibility that 99mTc-UBI peptides can monitor the efficacy of antifungal therapy 
against C. albicans infection was investigated. The effect of the various concentrations of 
fluconazole on the accumulation of 99mTc-UBI29-41 in a fluconazole-sensitive C. albicans 
thigh muscle infection was quantified [51]. The results revealed decreasing amounts of 99mTc-
UBI29-41 at the site of infection with increasing doses of this antifungal agent (R= -0.605; 
P< 0.017). As expected, an inverse correlation (R= -0.788; P<0.001) between the number of 
viable C. albicans and the concentration of fluconazole was observed. These data indicate 
that 99mTc-UBI29-41 scintigraphy can successfully monitor the efficacy of fluconazole in mice 
with a disseminated C. albicans infection, the lower detection limit being 103 colony forming 
unit (CFU).
Biodistribution
Kinetic studies using intravenously injected 99mTc-hLF1-11, 99mTc-UBI29-41, and 99mTc-flucon-
azole into C. albicans infected mice revealed that the former highly accumulates in the gall 
bladder and intestines, making it unfavorable for infection detection, whereas 99mTc-UBI29-41 
and 99mTc-fluconazole are rapidly cleared from the circulation (half-life approximately 30-60 
min) via kidneys and urinary tract with low activity in the liver and no intestinal deposits 
(Table 2). That the activity is mainly cleared through the kidneys is an advantage over 
hepatobiliary clearance because high activity in the liver and especially in the bowel would 
have made 99mTc-tracers less suitable for the imaging of infectious foci in the abdomen (intra-




abdominal abscesses). In agreement, a previous study which reported on fungal imaging 
with 18F-fluconazole and PET suffered from rather poor accumulation at sites of infection 
and high amounts of radioactivity were deposited in the liver [52]. Due to the very different 
labeling methods 18F-fluconazole is more lipophilic than 99mTc-fluconazole, and thus is more 
readily taken up by the liver [53].
Clinical trials with 99mTc-labeled antimicrobial peptide UBI29-41
Unfortunately, to our knowledge no clinical studies that investigated imaging of fungal infec-
tions in patients by radiolabeled tracers have been reported. However, scintigraphic studies in 
a small series of 18 patients with suspected bacterial bone or soft-tissue infections of the limbs 
(including prosthesis) showed that 99mTc-UBI29-41 discriminates between bacterial infections 
and sterile inflammations in patients and confirmed that this tracer is without adverse effects. 
Human biodistribution studies showed rapid clearance of 99mTc-UBI29-41 through the kidneys 
with gradual accumulation in the urinary bladder in time [54, 55]. Approximately 85% of the 
injected activity was eliminated by renal clearance 24 hours after injection of the tracer. Accu-
mulation at the site of infection of 99mTc-UBI29-41 reached the maximum value already from 
30 min [55] to 2 hours [56] after intravenous injection. Both in bone and soft tissue infections 
[55] and in suspected mediastinitis after cardiac surgery [56] the specificity and sensitivity 
resulted to be around 80% and 100%, respectively. No accumulation of 99mTc-UBI29-41 was in 
agreement with negative microbiological results in culture. On the other hand, in most cases, 
the positive 99mTc-UBI29-41 scintigraphic images were beneficial for determining the pres-
ence of infection and confirmed in microbiological culture. Overall, 99mTc-UBI29-41 is a highly 
sensitive and specific agent for localizing bacterial infected foci in various body districts and 
discriminating them from sterile inflammatory processes.
Newer radioligands
In the attempt to develop new tracers that specifically detect fungal infections, components 
of fungal cell wall have been considered highly selective targets. Since chitin is a component 
of fungal cell wall, which is absent in mammalian cells, a radiolabeled marker for chitine, 
123I-chitinase was developed in order to bind specifically to fungal cells. The results revealed 
that this radioiodine labeled enzyme accumulates in C. albicans and A. fumigatus infections 
in mice; these infections can be visualized at 24 hours after injection of the tracer and its 
accumulation correlates with the number of viable fungal cells [57] without visualizing bacte-
rial infections or sterile inflammations. Since radioiodinated peptides are rapidly dehaloge-
nated in vivo, 123I was rapidly taken up by thyroid and stomach, resulting in quite disturbed 
scintigraphic imaging. Furthermore chitinase, which is a protein of ~60 kDa, is not retained 
in kidneys. To this respect a smaller fragment like the chitin binding domain of this protein 
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could show better characteristics for in vivo imaging, such as rapid uptake, faster blood clear-
ance and therefore faster visualization of fungal infection. Thus, the chitin-binding protein 
(CBP21; 21kDa) produced by Serratia marcescens, which binds chitin with high affinity, has 
been labeled with 99mTc via the bifunctional chelating agent HYNIC as a novel radiophar-
maceutical for fungal infection imaging [58]. The maximum uptake of 99mTc-HYNIC-CBP21 
was found between 5 and 7 hours postinjection of the tracer. T/NT ratios for A. fumigatus 
were significantly higher than T/NT ratios for C. albicans, maybe related to a different chitin 
percentage in their cell wall or difference in the accessibility of the chitin. Similar results were 
found in in vitro binding studies. T/NT ratios for fungal infection were higher than T/NT ratios 
for bacterial infections and sterile inflammation between 5 and 7 hours postinjection but 
not earlier. Clearance was via kidneys and urinary bladder but the uptake in stomach was 
high up till 7 hours after injection of the tracer. Since it is generally understood that stomach 
uptake is due to 99mTc-O4
- and the tracer was > 97% pure, these data point to instability of the 
tracer in vivo [58]. Potential limitations of these newer tracers are the following. First, since 
chitin is an abundant substance in nature, chitinase or a chitin binding protein might be 
non specific for fungal cells. In addition, Guan et al. have been recently demonstrated that 
the chitinase BjCHI1, identified to possess two chitin-binding domains, inhibits not only the 
growth of fungi but also the growth of gram negative bacteria (Escherichia coli, Pseudomonas 
aeruginosa) more effectively than Gram-positive bacteria (Micrococcus luteus, Bacillus mega-
terium) through its agglutination activity [59]. Therefore, depending on the bacteria causing 
the infection, 123I-chitinase as well as 99mTc-HYNIC-CBP21 could result in non specific tracers 
for fungal infections. Second, it has been recently demonstrated that acidic mammalian 
chitinase is produced by lung epithelial cells, macrophages and eosinophils at sites of Th2 
inflammation [60], being expressed in an exaggerated fashion in epithelial and inflammatory 
cells in tissues from patients with moderate-severe asthma. Furthermore, the serum level of 
the chitinase-like protein YKL-40, that was elevated in patients with asthma, was correlated 
with severity, thickening of the subepithelial basement membrane, and pulmonary function 
[61]. Therefore, injection of these tracers in humans could have important immunological 
side effects.
Conclusions
Newer tracers, i.e. radiolabeled antimicrobial peptides, fluconazole and agents targeting 
chitin, may be useful for imaging of fungal infections. The main limitation of radiolabeled 
antimicrobial peptides - that discriminate between infections and sterile inflammatory 
processes - is that they can not distinguish fungal infections from bacterial infections. How-
ever, radiolabeled antimicrobial peptides were successful in monitoring antifungal therapy 
in C. albicans-infected mice. Moreover, radiolabeled fluconazole distinguished C. albicans 
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infections from bacterial infections/sterile inflammatory processes, but failed to image A. 
fumigatus infections. In addition, 99mTc-UBI29-41 and 99mTc-fluconazole are eliminated from 
the circulation mainly via the urinary tract, thus showing a favorable pharmacokinetics. Fi-
nally, radiolabeled agents that target chitin may be an interesting option for fungal infection 
imaging at later time points. Further studies exploring novel radioligands able to distinguish 
invasive fungal infections from bacterial infections as well as from sterile inflammatory pro-
cesses are needed.
137






 1. Pennisi M, Antonelli M. Clinical aspects of invasive candidiasis in critically ill patients. Drugs 2009; 
69(Suppl 1): 21-28.
 2. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of 
candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 
503-535.
 3. Shoham S, Marwaha S. Invasive fungal infections in the ICU. J Intensive Care Med 2010; 25: 78-92.
 4. Zilberberg MD, Shorr AF. Fungal infections in the ICU. Infect Dis Clin North Am 2009; 23: 625-642.
 5. Koh AY, Köhler JR, Coggshall KT, Van Rooijen N, Pier GB. Mucosal damage and neutropenia are 
required for Candida albicans dissemination. PLoS Pathog 2008; 4: e35.
 6. Dalle F, Wächtler B, L’Ollivier C, et al. Cellular interactions of Candida albicans with human oral 
epithelial cells and enterocytes. Cell Microbiol 2010; 12: 248-271.
 7. Pemán J, Zaragoza R. Current diagnostic approaches to invasive candidiasis in critical care set-
tings. Mycoses 2009. [Epub ahead of print]
 8. Wheat LJ. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med 
2009; 30: 367-377.
 9. Igai H, Gotoh M, Yokomise H. Computed tomography (CT) and positron emission tomography 
with 18F-fluoro-2-deoxy-D-glucose (FDG-PET) images of pulmonary cryptococcosis mimicking 
lung cancer. Eur J Cardiothorac Surg 2006; 30: 837-839.
 10. Lupetti A, Welling MM, Pauwels EKJ, Nibbering PH. Radiolabelled antimicrobial peptides for infec-
tion detection. Lancet Infect Dis 2003; 3: 223-229.
 11. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers 
and other diseases. Med Res Rev 2004; 24: 357-397.
 12. Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis 
2001; 1: 326-333.
 13. Kumar V. Radiolabeled white blood cells and direct targeting of micro-organisms for infection 
imaging. Q J Nucl Med Mol Imaging 2005; 49: 325-338.
 14. Palestro CJ. In vivo leukocyte labeling: the quest continues. J Nucl Med 2007; 48: 332-334.
 15. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395.
 16. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic 
strategies. Nat Biotechnol 2006; 24: 1551-1557.
 17. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive 
bacterial infection. Nature 2001; 414: 454-457.
 18. Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin 
family of antimicrobial peptides. Biochim Biophys Acta 2006; 1758: 1408-1425.
 19. Overhage J, Campisano A, Bains M, et al. Human host defense peptide LL-37 prevents bacterial 
biofilm formation. Infect Immun 2008; 76: 4176-4182.
 20. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Söderlund J. The antimicrobial peptide LL-37 
inhibits HIV-1 replication. Curr HIV Res 2007; 5: 410-415.
Chapter 8
138
 21. López-García B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their poten-
tial role in Candida albicans skin infection. J Invest Dermatol 2005; 125: 108-115.
 22. Brouwer CP, Bogaards SJ, Wulferink M, Velders MP, Welling MM. Synthetic peptides derived from 
human antimicrobial peptide ubiquicidin accumulate at sites of infections and eradicate (multi-
drug resistant) Staphylococcus aureus in mice. Peptides 2006; 27: 2585–2591.
 23. Nibbering PH, Ravensbergen E, Welling MM, et al. Human lactoferrin and peptides derived from 
its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Im-
mun 2001; 69: 1469-1476.
 24. Lupetti A, Paulusma-Annema A, Welling MM, et al. Candidacidal activities of human lactoferrin 
peptides derived from the N terminus. Antimicrob Agents Chemother 2000; 44: 3257-3263.
 25. Lupetti A, van Dissel JT, Brouwer CPJM, Nibbering PH. Human antimicrobial peptides’ antifungal 
activity against Aspergillus fumigatus. Eur J Clin Microbiol Infect Dis 2008; 27: 1125-1129.
 26. Lupetti A, Brouwer CPJM, Bogaards SJP, et al. Human lactoferrin-derived peptide’s antifungal 
activities against disseminated Candida albicans infection. J Infect Dis 2007; 196: 1416-1424.
 27. Ciornei CD, Sigurdardóttir T, Schmidtchen A, Bodelsson M. Antimicrobial and chemoattractant 
activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of 
human cathelicidin LL-37. Antimicrob Agents Chemother 2005; 49: 2845-2850.
 28. Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM. Antimicrobial peptides: 
mediators of innate immunity as templates for the development of novel anti-infective and im-
mune therapeutics. Curr Pharm Des 2004; 10: 2891-2905.
 29. Yang D, Chertov O, Bykovskaia SN, et al.β-defensins: linking innate and adaptive immunity 
through dendritic and T cell CCR6. Science 1999; 286: 525-528.
 30. Coffelt SB, Marini FC, Watson K, et al. The pro-inflammatory peptide LL-37 promotes ovarian tu-
mor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad 
Sci U S A 2009; 106: 3806-3811.
 31. Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 induces autophagy in human monocytes/macro-
phages via cathelicidin. Cell Host Microbe 2009; 6: 231-243.
 32. van der Does AM, Bogaards SJP, Ravensbergen B, et al. Antimicrobial peptide hLF1-11 directs 
granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward 
macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Che-
mother 2010; 54: 811-816.
 33. Davidson DJ, Currie AJ, Reid GS, et al. The cationic antimicrobial peptide LL-37 modulates 
dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004; 172: 
1146-1156.
 34. Mookherjee N, Hancock RE. Cationic host defence peptides: innate immune regulatory peptides 
as a novel approach for treating infections. Cell Mol Life Sci 2007; 64: 922-933.
 35. Piers KL, Brown MH, Hancock RE. Recombinant DNA procedures for producing small antimicrobial 
cationic peptides in bacteria. Gene 1993; 134: 7-13.
 36. Rao AG, Rood T, Maddox J, Duvick J. Synthesis and characterization of defensin NP-1. Int J Pept 
Protein Res 1992; 40: 507-514.
 37. Aumelas A, Mangoni M, Roumestand C, et al. Synthesis and solution structure of the antimicrobial 
peptide protegrin-1. Eur J Biochem 1996; 237: 575-583.
139





 38. Bellamy W, Takase M, Yamauchi K, et al. Identification of the bactericidal domain of lactoferrin. 
Biochim Biophys Acta 1992; 1121: 130-136.
 39. Hiemstra PS, van den Barselaar MT, Roest M, Nibbering PH, van Furth R. Ubiquicidin, a novel 
murine microbicidal protein present in the cytosolic fraction of macrophages. J Leukoc Biol 1999; 
66: 423-428.
 40. van Berkel PHC, Welling MM, Geerts M, et al. Large scale production of recombinant human 
lactoferrin in the milk of transgenic cows. Nat Biotechnol 2002; 20: 484-487.
 41. Welling MM, Mongera S, Lupetti A, et al. Radiochemical and biological characteristics of 99mTc-UBI 
29-41 for imaging of bacterial infections. Nucl Med Biol 2002; 29: 413-422.
 42. Welling MM, Nibbering PH, Paulusma-Annema A, et al. Imaging of bacterial infections with 99mTc-
labeled human neutrophil peptide-1. J Nucl Med 1999; 40: 2073-2080.
 43. Kenna S, Bligh HF, Watson PF, Kelly SL. Genetic and physiological analysis of azole sensitivity in 
Saccharomyces cerevisiae. J Med Vet Mycol 1989; 27: 397-406.
 44. Aguilar PS, Heiman MG, Walther TC, et al. Structure of sterol aliphatic chains affects yeast cell 
shape and cell fusion during mating. Proc Natl Acad Sci USA 2010; 107: 4170-4175.
 45. Blok D, Feitsma RI, Vermeij P, Pauwels EKJ. Peptide radiopharmaceuticals in nuclear medicine. Eur 
J Nucl Med 1999; 26: 1511-1519.
 46. Hall AV, Solanki KK, Vinjamuri S, Britton KE, Das SS. Evaluation of the efficacy of 99mTc-Infecton, a 
novel agent for detecting sites of infection. J Clin Pathol 1998; 51: 215-219.
 47. Lupetti A, Welling MM, Mazzi U, Nibbering PH, Pauwels EKJ. Technetium-99m labelled fluconazole 
and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections. 
Eur J Nucl Med Mol Imaging 2002; 29: 674-679.
 48. Pauwels EKJ, Welling MM, Feitsma RI, Atsma DE, Nieuwenhuizen W. The labeling of proteins and 
LDL with 99mTc: a new direct method employing KBH4 and stannous chloride. Nucl Med Biol 1993; 
20: 825-833.
 49. Welling MM, Paulusma-Annema A, Balter HS, Pauwels EKJ, Nibbering PH. Technetium-99m 
labelled antimicrobial peptides discriminate between bacterial infections and sterile inflamma-
tions. Eur J Nucl Med 2000; 27: 292-301.
 50. Welling MM, Lupetti A, Balter HS, et al. 99mTc-labeled antimicrobial peptides for detection of bacte-
rial and Candida albicans infections. J Nucl Med 2001; 42: 788-794.
 51. Lupetti A, Welling MM, Pauwels EKJ, Nibbering PH. Detection of fungal infections using radiola-
beled antifungal agents. Curr Drug Targets 2005; 6: 945-954.
 52. Fischman AJ, Alpert NM, Livni E, et al. Pharmacokinetics of 18F-labeled fluconazole in rabbits with 
candidal infections studied with positron emission tomography. J Pharmacol Exp Ther 1991; 259: 
1351-1359.
 53. Welling MM, Visentin R, Lupetti A, et al. Radiochemical and biological characteristics of Tech-
netium-99m labelled fluconazole. In: Technetium, rhenium and other metals in chemistry and 
nuclear medicine. Edited by M. Nicolini, U. Mazzi, SGE Editoriali, Padova, pp.655-659, 2002. ISBN 
88-86281-73-0.
 54. Melendez-Alafort L, Rodriguez-Cortes J, Ferro-Flores G, et al. Biokinetics of 99mTc-UBI 29-41 in 
humans. Nucl Med Biol 2004; 31: 373-379.
Chapter 8
140
 55. Akhtar MS, Qaisar A, Irfanullah J, et al. Antimicrobial peptide 99mTc-ubiquicidin 29-41 as human 
infection-imaging agent: clinical trial. J Nucl Med 2005; 46: 567-573.
 56. Vallejo E, Martinez I, Tejero A, et al. Clinical utility of 99mTc-labeled ubiquicidin 29-41 antimicrobial 
peptide for the scintigraphic detection of mediastinitis after cardiac surgery. Arch Med Res 2008; 
39: 768-774.
 57. Siaens R, Eijsink VGH, Dierckx R, Slegers G. 123I-labeled chitinase as specific radioligand for in vivo 
detection of fungal infections in mice. J Nucl Med 2004; 45: 1209-1216.
 58. Siaens R, Eijsink VGH, Vaaje-Kolstad G, et al. Synthesis and evaluation of a 99mTechnetium labeled 
chitin-binding protein as potential specific radioligand for the detection of fungal infections in 
mice. Q J Nucl Med Mol Imaging 2006; 50: 155-166.
 59. Guan Y, Chye ML. A Brassica juncea chitinase with two-chitin binding domains show anti-
microbial properties against phytopathogens and Gram-negative bacteria. Plant Signal Behav 
2008; 3: 1103-1105.
 60. Zhu Z, Zheng T, Homer RJ, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and 
IL-13 pathway activation. Science 2004; 304: 1678-1682.
 61. Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and 




GeNeraL dIsCussION aNd summary

145





General discussion and summary
Pneumocystis pneumonia (PCP) and invasive aspergillosis (IA) are the most prevalent oppor-
tunistic pulmonary fungal infections occurring post transplantation. About both pathogens, 
but in particular about the in-vitro unculturable P. jirovecii, a high level of uncertainty exists 
with respect to transmission patterns and the dynamics of exposure. In the near future - for 
PCP as well as for invasive aspergillosis - the detailed assessment of the clinical risk factors 
(including the genetic make-up of the host) is of major importance and the single path to 
selective prevention strategies. Where exposure is inevitable and prevention strategies fail, 
the next line of defense is formed by the application of sensitive and specific non-invasive 
tests to allow early diagnosis and/or monitoring for disease. With regard to the above, the ob-
servations and results of the studies described in the Chapters 2 through 8 are summarized 
and concisely discussed in the sections below.
Transmission of Pneumocystis jirovecii and identification of factors that cause the occurrence 
of an outbreak of Pneumocystis pneumonia in kidney – and possibly other – transplant 
populations.
Triggered by a sudden rise in the incidence of PCP among kidney transplant recipients in 
our institution, we set out to investigate the underlying cause. The outbreak investigation 
and the systematic literature review described in Chapters 2 and 3 were performed to 
elucidate the origin of the outbreak as well as the mode of transmission of P. jirovecii. From 
the presented epidemiological data alone the presence of an environmental source could 
neither be confirmed nor excluded. The same was true for possible interhuman transmission. 
For example: the communal presence of patients in the outpatient department might imply 
that they acquired PCP through interhuman transmission just as easily as it can indicate that 
they were infected by a local environmental source. The genotyping shows that patient-to-
patient transmission cannot be excluded, but still allows the possibility of a single strain that 
infects patients from its environmental niche. Also, the statistical approach to the outbreak 
data described in chapter 2 yields ambiguous results. The analysis of outpatient visits of PCP 
patients and frequency of encounters with patients who later developed PCP showed the 
strongest association with the number of times that a patient visited the outpatient depart-
ment (Cox conditional regression model). Since statistical models represent an abstraction of 
reality, it is uncertain whether these calculations can reliably assess the likelihood of either 
interhuman transmission or a common environmental source. However, in the greater evolu-
tionary context of the commensal relation that likely exists between P. jirovecii and humans, 
there is only one preferred model of transmission of P. jirovecii and development of PCP as 
pointed out in the following paragraph [1, 2].
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The discovery of the linkage of each species of Pneumocystis to a specifi c mammalian host 
and the phenomenon of common asymptomatic carriage in the airways of both healthy and 
immunocompromised hosts strongly attest to the hypothesis that the human population 
forms the primary – if not the only – source [3, 4]. With the human population identifi ed as 
a reservoir, P. jirovecii circulates among both immunocompromised and healthy individuals 
by interhuman airborne transmission (panel 1A-B). Immunocompromised individuals, upon 
contracting P. jirovecii, may, or may not, develop symptomatic disease (i.e., PCP). This depends, 
among other factors, on the specifi c state of their cell mediated immunity and yet unknown 
virulence factors of P. jirovecii (panel 1C). In contrast to the emergence of solitary cases of 
PCP in kidney transplant recipients explained by this model, a set of specifi c additional fac-
tors (e.g., crowding) leading to increased exposure and/or enhanced susceptibility probably 
needs to co-exist in order to give rise to a PCP outbreak among an immunocompromised 
population (panels 1D-E). Exposure is probably increased through frequent contact or 
crowding of individuals at increased risk for either carriage of P. jirovecii or development of 
PCP, as was convincingly demonstrated to be the case in a large number of outbreak studies 
included in the systematic review (chapter 3).
Figure 1. Model of transmission of Pneumocystis jirovecii within the human population and occurrence of Pneumocystis pneumonia outbreaks 
in populations at risk.
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Clinical risk factors and approach to chemoprophylaxis for Pneumocystis Pneumonia in HIV- 
negative immunocompromised hosts.
Individual cases and outbreaks of PCP that occur in the absence of adequate chemopro-
phylaxis are still regularly reported in the medical literature [5, 6]. Transplant physicians 
sometimes abstain from a prescribing chemoprophylaxis for a variety of reasons including 
anticipation on adverse effects e.g. increase in serum creatinine, hyperkalemia, Stephen-
Johnson’s syndrome, interstitial nephritis and interactions with other medication [7-9]. The 
pros and cons of this approach were heavily debated by experts in the field [10, 11]. In the 
absence of well-designed trials, kidney transplant guidelines recommend the prescription 
of chemoprophylaxis for ‘at least 3-6 months after transplantation’ [12]. The alternative of a 
selective, i.e. more individualized approach towards the prescription was not yet explored. In 
chapter 4 we demonstrate by multivariate analysis that age older than 55 years at the time 
of transplantation, CMV infection and treatment for rejection were the main independent 
risk factors for development of PCP in kidney transplant recipients. When these variables 
are incorporated in a hypothetical risk factor and time dependent prophylaxis strategy, the 
expected effects for the Leiden kidney transplantation cohort were estimated. The model 
showed that by use of several selective strategies the use of chemoprophylaxis within the 
first two years post transplantation could be decreased by 60 to 70% while maintaining the 
PCP incidence at <1.0 %.
The implementation of the results of these findings is complicated by some limitations. First, 
PCP remains a relatively rare diagnosis and validation of a chemoprophylactic strategy may 
take years. In addition, the population characteristics (e.g., age or the frequency of rejec-
tion treatment) may change over time. Furthermore there is an increased ‘physician failure 
hazard’ since it has to be specifically determined whether a patient needs, or does not need 
a prescription for PCP chemoprophylaxis. A certain strategy may work for years but will 
finally become redundant or inappropriate due to changes in the standard immunosuppres-
sive regimen, new treatments for treatment for rejection or development of new virulence 
factors by P. jirovecii. At present however, our study provides substantial support for a risk-
factor-based, differentiated approach towards PCP chemoprophylaxis, comprising the first 6 
months for all- and for the first year post transplantation limited to patients over 55 years of 
age and those treated for graft rejection. This recommendation adds to current European and 
other kidney transplantation guidelines [13]. It should be noted that prolonged prescription 
of prophylaxis, even over years post transplantation, may sometimes be necessary for those 
patients at increased risk due to accompanying conditions [14].
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Biological determinants of invasive aspergillosis and the potential influence of genetic 
polymorphisms in the innate immune system on host susceptibility to disease.
To be at risk for development of IA, a profoundly immunocompromised state, such as observed 
after immune-ablative chemotherapy, allogeneic stem cell transplantation (ASCT) condition-
ing regimens or chronic corticosteroid treatment, is needed. Study of the influence of host 
genetics on susceptibility to IA in ASCT recipients represents a challenge while both donor 
and recipient genotype will invariably exert their influence on function of the immune cells 
post transplantation. It is uncertain when chimerism is achieved at the level of the pulmonary 
macrophages, which cells constitute the frontline in the immune response to invasive fungal 
infection (IFI). For the activation of this immune response, recognition of fungal antigens by 
pattern recognition receptors (PRRs), which include C-type lectin receptors like the Dectin-1 
receptor, is pivotal [4]. Recently, a functional single nucleotide polymorphism in this receptor 
(Y238X), which resulted in diminished expression of the Dectin-1 receptor on immune cells, 
was described [6].
In the study presented in chapter 6 we found that Y238X status of the ASCT recipient 
was associated with a modest trend towards susceptibility to IA. After multivariate adjust-
ment, the Y238X status was no longer significant as a risk factor for IA. The increased Y238X 
allele frequency of 19.0% in non-ASCT recipients with IA (as compared to other reference 
populations: range 6.9-7.7%) suggest that heterozygosity for the Y238X SNP potentially has 
a moderate association with acquisition of IA in patients at-risk in some populations. In-vitro 
experiments demonstrated a decreased response to Aspergillus antigens in monocytes ho-
mozygous for the Dectin-1 Y238X mutation. No in-vitro data was generated with regard to 
the response in macrophages heterozygous for the Dectin-1 Y238X mutation since the in 
vitro assays were only performed to find a mechanistic explanation of the limited influence 
of this Dectin-1 polymorphism on susceptibility to IA. Nonetheless, whether a diminished 
function after exposure to Aspergillus would also occur in a patiente heterozygote for the 
Y238X mutation would be interesting to study in the in-vitro setting. In general, previous 
research on the effects of mutations in genes encoding cell surface receptors showed that a 
decrease or increase in function can be also expected in the heterozygotes [15, 16].
Other polymorphisms in genes coding for components of the innate immunity to Aspergil-
lus infections have been recently reported to increase susceptibility to disease caused by this 
pathogen: TLR1, TLR4, TLR6, IL1 and the IL10 promoter region [17-20]. In all of these studies, 
the polymorphism of interest was studied in isolation and not in association with each other. 
Thus, the relative influence of combinations of polymorphisms was not addressed. Simulta-
neous presence of two or more of these polymorphisms in a patient may further enhance the 
risk profile to IA. In the case-control investigation described in chapter 7, we found that the 
TLR4 1063A>G polymorphism was associated with increased susceptibility to IA, when pres-
ent in the donors DNA of ASCT recipients (alone or in combination with TLR6 745C>T or IFNG 
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874T>A SNPs). The IFNG 874T>A SNP appeared to enhance the risk conferred by two of the 
TLR polymorphisms. Although carriers of this genetic variation produce suboptimal levels of 
IFN-γ, putting them at increased risk for perhaps manifest mycobacterial infection [16], the 
isolated presence in either donor or recipient did not increase the risk for IA. Remarkably, 
SNPs that affect the production of IL-10, one of the most important broad-acting negative 
modulators of the TLR to IL-12 and IFN-γ macrophage-activating pathway, were not associ-
ated with IA.
Compared to other risk factors, the absolute risk conferred by relevant SNPs in PRR- and 
cytokine genes seems limited. Healthy individuals carrying these SNPs do not develop IA 
unless a profound immune deficiency is present. It is more probable that specific patterns of 
genetic polymorphisms rather than a single genetic variation in TLRs or subsequent cytokine 
pathways that activate macrophages may be associated with IA in patients at risk. The obser-
vation of the association between the TLR4 1063A>G plus IFNG 874T>A SNP combination in 
our study fits this hypothesis.
On the other hand, probable associations of IA with conditional combinations of mutations 
may also attest to the complex immuno-pathogenesis of IA. As a consequence of neutropenia 
limiting the redundancy in the immune response to IA, the role of key components within the 
innate immune response could be more prominent in the remaining defense against inva-
sive fungal infection and thus facilitate linkage to TLR- in combination with cytokine SNPs. 
Assuming that the studied SNPs have an effect on the functioning of the innate immune 
system, different SNPs may also be working at different time points to modulate resistance to 
IA and eventually constitute the overall genetic signature of susceptibility (figure 2).
The potential of (future) serum markers for the diagnosis of pulmonary fungal infection.
In the prospective study described in chapter 5, we demonstrated that serum 1,3-β-D-glucan 
(β-D-glucan) - but not serum S-adenosylmethionine (AdoMet) - was an accurate diagnostic 
tool for the diagnosis of PCP in HIV-negative immunocompromised adults. In HIV-infected in-
dividuals, the clinical relevance of serum β-D-glucan has already been investigated in larger 
studies [21]. These studies showed a sensitivity and specificity that was not surpassed by 
other potential markers, except may be by AdoMet [22, 23]. Several major concerns preclude 
transposing the results found in HIV-positive populations with PCP to the HIV-negative popu-
lation at risk for PCP. First of all, autopsy studies reported lower loads of P. jirovecii in the lungs 
of immunocompromised patients without HIV as compared to HIV-positive patients with PCP 
[24, 25]. With a lower pulmonary fungal burden, the amount of cell wall components of the 
Pneumocysts that enter the circulation are probably smaller. In addition, patients at risk for 
PCP, but with a relatively more fit immune system may have a less slow decrease of circulating 
β-D-glucan [26]. In an observational study performed by Nakamura et al., serum β-D-glucan 
levels were confirmed to be significantly lower in patients with PCP due to other underlying 
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causes than HIV [27]. Secondly, HIV-negative patients at risk for PCP – and the population of 
patients with hematologic disorders in particular – generally have a higher a priori chance to 
develop other invasive pulmonary fungal infections, e.g. invasive aspergillosis or candidemia. 
Due to the presence of β-D-glucan in the cell wall of these organisms, a false positive test 
result may be obtained when only the 1 β-D-glucan test is used to diagnose PCP. Hence, 
the use of the β-D-glucan assay as a single test for the purpose of diagnosing PCP is clearly 
limited [28]. Thus, a primary suspicion of PCP above other fungal infections (supported by 
clinical signs and symptoms as well as chest imaging) seems warranted. Careful assessment 
of the clinical presentation and chest imaging, remain to play an important role in the di-
agnostic work up. Furthermore, we found that follow-up levels of β-D-glucan significantly 
decreased over relatively short time during treatment. However, the values measured after a 
median of 3 days of treatment still remained far above the upper limit of normal in >90% of 
cases, indicating that for now the clinical follow up is of is of at least equal importance when 
determining the response to treatment.





























































Legend: Line A, B and C represent individual hosts susceptible to IA. Diagram I-IV shows the spectrum of mechanisms that can be involved. 
Genetic polymorphisms may affect the functioning of the remaining lung macrophages and epithelial cells at the start of neutropenia (I); 
influence the level of colonization of the airways and alveoli with Aspergillus prior to the neutropenic period (II); influence actions of lung 
epithelial cells and macrophages or neutrophils throughout the period at risk (III); or affect factors that regulate the development of symptoms 
(IV). Modified after: human variations in susceptibility to infection by S.typhi: evidence from the distribution of incubation periods in single-
exposure epidemics. van Dissel J.T . & van Furth R. (1993); In: Cabello F, ed. The Biology of Salmonella; Proceedings of NATO ASI. (pp 385-389).
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Despite of previous reports claiming AdoMet to be both a highly sensitive and a specific 
marker for PCP in HIV-positive patients, this could not be confirmed in our study in a HIV-
negative population with PCP. Concerns similar to those expressed above on the reliability 
of the β-D-glucan test exist with regard to AdoMet. The suggested mechanism by which 
AdoMet would be useful as a marker for PCP is its depletion from the serum during infection 
with P. jirovecii [29]. Since lower pulmonary fungal loads are present in HIV-negative patients 
with PCP, this may adversely influence the serum AdoMet level in a way that its reliability as 
a diagnostic test for PCP becomes compromised. Moreover, AdoMet is the product of the 
human body’s own metabolism and other factors, e.g., malnourishment, general clinical 
condition and other variables are known to affect the level of serum S-adenosylmethionine 
[30]. Our study is the first that assessed the reliability of this marker in HIV-negative patients. 
Unfortunately, we found that it failed to discriminate between HIV-negative immunocompro-
mised patients with and without PCP.
As described in chapter 8 specific tracers, i.e. radiolabeled antimicrobial peptides, flucon-
azole and agents targeting chitin, may prove useful for the diagnosis of invasive fungal infec-
tions in the near future. The main limitation of usage of radiolabeled antimicrobial peptides 
- that appear to discriminate between infections and sterile inflammatory processes - is their 
inability to distinguish fungal infections from bacterial infections. However, these markers 
may be suitable for other purposes. For example, radiolabeled antimicrobial peptides were 
successful in monitoring antifungal therapy in C. albicans-infected mice. One step further, 
radiolabeled fluconazole distinguished C. albicans infections from bacterial infections and 
sterile inflammatory processes, and failed to image A. fumigatus infections. The challenge 
now is to bring promising markers through the phase I to III clinical trials that ensure their 
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Ten gevolge van de toepassing van orgaan- en stamceltransplantatie als behandeling voor 
ziekten waarvoor eerder geen therapeutische opties meer bestonden, neemt het aantal per-
sonen met een ernstig in kwaliteit verminderd afweersysteem wereldwijd toe. De aantasting 
van het afweersysteem wordt bij deze patiënten veroorzaakt door de medicatie die wordt 
toegediend ter voorkoming van afstoting van het getransplanteerde orgaan of door de be-
handeling met intensieve chemotherapie voorafgaand aan stamceltransplantatie. Hierdoor 
ontstaat gedurende langere tijd een verhoogde vatbaarheid voor infecties. In een dergelijke 
situatie kunnen complicerende infecties ook veroorzaakt worden door zogenaamde op-
portunistische pathogenen. Dit zijn micro-organismen die alleen in staat zijn om ziekte te 
veroorzaken als het immuunsysteem ernstig is verzwakt.
De in dit proefschrift beschreven studies gaan over het optreden van opportunistische 
schimmelinfecties van de longen na transplantatie. Deze infecties gaan gepaard met een 
hoge sterfte. In West-Europa zijn Pneumocystis jirovecii (box 1) en Aspergillus soorten (box 2) 
de meest voorkomende verwekkers van een dergelijke infectie. Welk type schimmelinfectie 
zich voordoet - en op welk tijdstip - wordt grotendeels bepaald door de aard van onderlig-
gende aandoening en de voorafgaande behandeling van de patiënt. Deze twee factoren 
bepalen namelijk zowel de aard als de ernst van de ontstane gebreken in het afweersysteem. 
In geval van uitschakeling van de door T-lymfocyten gegenereerde afweerrespons is de pa-
tiënt vooral vatbaar voor het ontwikkelen van een pneumonie (longontsteking) veroorzaakt 
door Pneumocystis jirovecii. Bij langer durende afwezigheid van neutrofiele granulocyten 
(een subtype witte bloedcellen) treden vooral longinfecties op met Aspergillus als verwekker.
Box 1 Pneumocystis
Het micro-organisme Pneumocystis werd gedurende lange tijd na zijn beschrijving (in ratten) 
door Delanoe & Delanoe in 1912, geclassificeerd als een protozoa. Pas kort na de 2e wereldoorlog 
ontdekten artsen dat Pneumocystis in staat was tot het veroorzaken van een ernstige interstitiele 
longontsteking bij mensen met een verstoorde afweer (door bijvoorbeeld ernstige ondervoeding, 
of chemotherapie of orgaantransplantatie). Ten gevolge van de HIV-epidemie, en de daarmee 
samenhangende stijging van het aantal patienten met een Pneumocystis pneumonie, kwam het 
onderzoek in een stroomversnelling. Er bestaan meerdere soorten Pneumocystis, en elk afzonder-
lijke soort heeft zijn eigen gastheer. De soort die longontsteking bij de mens veroorzaakt was 
voorheen bekend als Pneumocystis carinii of Pneumocystis carinii f. sp. hominis, maar is recent omge-
doopt tot Pneumocystis jirovecii. Het bleek ondermeer dat Pneumocystis jirovecii ook de longen kan 
‘koloniseren’ van gezonde personen zonder evident ziekte te veroorzaken. Alleen in geval van het 
dysfunctioneren van de T-lymfocyt gerelateerde immunteit kan een ernstige interstitiele longont-
steking ontstaan. Op basis van DNA-analyse en op grond van met elektronenmicroscopie nieuw 





In hoofdstuk 2 beschrijven we het onderzoek dat werd verricht naar een Pneumocystis-pneu-
monieuitbraak onder niertransplantatiepatiënten in het Leids Universitair Medisch Centrum 
(figuur 1). Hierin komen alle facetten van een klassiek epidemiologisch onderzoek naar een 
uitbraak van een infectieziekte aan bod. Er waren al langere tijd zowel directe aanwijzingen 
(dierexperimenteel onderzoek) als indirecte aanwijzingen dat dit micro-organisme van pa-
tiënt naar patiënt kan worden overgedragen. Nu deed zich de mogelijkheid voor om dit in de 
praktijk te onderzoeken met behulp van nieuwe pathogeen genotyperingsmethoden en aan 
de hand van nauwkeurige epidemiologische gegevens. De resultaten van de genotypering 
laten zien dat het overgrote deel van de patienten een Pneumocystis pneumonie doormaakte 
die werd veroorzaakt door hetzelfde Pneumocystis genotype (d.w.z.: met hetzelfde DNA pro-
fiel). Tevens bleken de patienten op dezelfde momenten de polikliniek nierziekten bezocht te 
hebben, of tegelijkertijd met een andere patiënt opgenomen te zijn geweest op de klinische 
afdeling. Dit is suggestief voor de overdracht van het pathogeen van patiënt naar patiënt.
Ter verdere exploratie werden de beschikbare epidemiologische gegevens met statistische 
modellen geanalyseerd. Hiermee kon overdracht van P. jirovecii van patiënt tot patiënt wel 
aannemelijk gemaakt worden, maar een externe bron kon niet worden uitgesloten. Nadeel 
van dergelijke modellen blijft dat zij slechts een zeer abstracte weergave zijn van de werke-
lijkheid.
Box 2. Aspergillus en ‘invasive aspergillose’
De term ‘invasieve aspergillusinfectie’ verwijst naar weefselinvasie door de filamenteuze schimmel 
Aspergillus. Er bestaan diverse ondersoorten, waarvan A. fumigatus, A. flavus, A. niger en A. ter-
reus het meest frequent verantwoordelijk zijn voor ziekte bij de mens. Aspergillus is wereldwijd op 
grote schaal aanwezig in de bodem, in voedsel en in vochtige omgevingen. De sporen (conidia) 
worden verspreid via de lucht en kunnen na inademing direct aanleiding geven tot verschillende 
aandoeningen van de luchtwegen. Invasieve infecties van de longen komen echter alleen voor bij 
patienten met een ernstig gestoord functioneren (of bij afwezigheid-) van de witte bloedcellen, in 
het bijzonder de neutrofiele granulocyten. De longen of het KNO-gebied zijn de primaire locatie 
van de infectie (in 90-95% van alle gevallen). Via de bloedsomloop kan Aspergillus dissemineren 
naar andere organen, met name ook naar de hersenen. 
De erkenning als één van de belangrijkste infectieuze complicaties na een stamceltransplantatie is 
een belangrijke drijvende kracht achter het klinische en experimentele onderzoek naar Aspergil-
lus. Veel risicofactoren zijn inmiddels bekend en er zijn een aantal markers beschikbaar om een 
invasieve aspergillusinfectie vroegtijdig te diagnosticeren. Ondanks dit alles  heeft de huidige 
incidentie van deze ziekte zich gestabiliseerd op ongeveer 5-8% van alle patiënten die behandeld 








Verder werd een systematisch literatuuronderzoek verricht naar het ontstaan van Pneu-
mocystis pneumonie uitbraken onder patienten met een niertransplantaat (hoofdstuk 3). Er 
werden 15 wetenschappelijke artikelen geïncludeerd. Uit de analyse bleek ondermeer dat in 
de medische centra waar de epidemieen vanaf 1980 plaatsvonden geen chemoprofylaxe ter 
voorkoming van Pneumocystis pneumonie werd voorgeschreven. Verder was er bijna altijd 
sprake van contacten tussen de patienten in de periode voorafgaande aan de diagnose. 
Bij opname werden de patienten met een Pneumocystis pneumonie niet geïsoleerd. De 
gerapporteerde klinische risicofactoren verschilden niet van de risicofactoren die gevonden 
werden in twee case-controle onderzoeken waarbij geen sprake was van een epidemie. Per 
10 jaar daalde de gerapporteerde mortaliteit aanzienlijk van gemiddeld 38% voor 1990 naar 
19% tussen 1990 en 2000, en vervolgens naar een gemiddelde van 13% tussen 2000 en 2010. 
Dit heeft meerdere oorzaken. Ten eerste heeft sinds circa 1990 het toevoegen van steroïden 
aan het behandelingsschema de overleving van patienten met een Pneumocystis pneumonie 
sterk verbeterd. Daarnaast zijn een betere bekendheid van het ziektebeeld en een door de 
tijd heen verbeterende intensive care zorg waarschijnlijk belangrijke bijdragende factoren. 
Het moment van ontstaan van de epidemieen was niet evident gerelateerd aan een bepaald 
jaargetijde. De combinatie van de epidemiologische gegevens en de resultaten van de ge-
notypering van de aangetroffen Pneumocystis pleitte in bijna alle studies voor de overdracht 
van P. jirovecii van patiënt naar patiënt. Hoewel dergelijke uitbraken zeldzaam zijn, dient 




men om deze (maar ook individuele gevallen) te voorkomen, antibiotische profylaxe voor 
te schrijven. De optimale duur van deze antibioticaprofylaxe gerekend vanaf het moment 
van transplantatie is onbekend. De huidige van toepassing zijnde richtlijnen geven hierover 
uiteenlopende adviezen.
In hoofdstuk 4 wordt getracht een antwoord te vinden op de vraag hoe lang een indi-
viduele patiënt na niertransplantatie ter voorkoming van een Pneumocystis pneumonie 
antibioticaprofylaxe zou moeten innemen. Er kleven ook nadelen aan het innemen hiervan, 
zoals bijwerkingen, beïnvloeding van de nierfunctie, maar ook het in de hand werken van 
antibioticaresistentie bij verscheidene micro-organismen is een punt van zorg. Dit onderzoek 
voltrok zich in twee fasen. Als eerste werd in een case-controle onderzoek onderzocht welke 
klinische factoren de kans op een Pneumocystis pneumonie vergroten. De onderzochte groep 
patiënten bestond uit 50 niertransplantatiepatiënten met Pneumocystis pneumonie en 99 
niertransplantatiepatiënten zonder Pneumocystis pneumonie. In een multivariate analyse 
werd vervolgens ook de samenhang van de gevonden risicofactoren bestudeerd. Het bleek 
dat op het moment van transplantatie een oudere leeftijd (55+) een iets meer dan 2,5-maal 
extra kans gaf op het ontwikkelen van een Pneumocystis pneumonie. Verder waren ook 
behandeling voor afstoting van het niertransplantaat (met hoge dosis prednison of anti-
thymocyten globuline) en CMV infectie geassocieerd met het ontwikkelen van een Pneumo-
cystis pneumonie (respectievelijk c.a. 6x en 3x zo vaak in vergelijking met de controlegroep). 
De wijze waarop het immuunsuppressieve medicatieprofiel was samengesteld bleek niet 
van invloed. Dit is in tegenstelling tot wat eerder in de literatuur op basis van case-series 
en op grond van onderzoek bij ratten werd gesuggereerd. Een belangrijke bevinding was 
verder dat 85% van de patienten met een Pneumocystis pneumonie zich presenteerde tus-
sen de 2e en 24e maand na niertransplantatie. Bij nadere studie bleek dat in de overige 15% 
van de patienten er vrijwel altijd een bijzondere omstandigheid aanwezig was waardoor de 
vatbaarheid voor het krijgen van Pneumocystis pneumonie ook na de 24e maand verhoogd 
was. De verkregen gegevens werden vervolgens in het 2e deel van de studie gebruikt in een 
rekenmodel waarmee de effectiviteit van een aantal profylaxestrategieën (gebaseerd op de 
geïdentificeerde risicofactoren) werd geschat. Hieruit bleek dat voor patienten zonder risico-
factoren een behandelduur tot 6 maanden na transplantatie voldoende is. Indien sprake is 
van een leeftijd ouder dan 55 jaar ten tijde van transplantatie, of indien rejectiebehandeling 
moet worden toegepast, is verlenging van de duur van de profylaxe tot 1 jaar na transplan-
tatie aan te bevelen. Het is van belang te realiseren dat deze schattingen gebaseerd zijn op 
retrospectief verkregen gegevens. De effectiviteit van deze strategieën moet daarom ook 
verder prospectief worden onderzocht.
Het vroegtijdig stellen van de diagnose Pneumocystis pneumonie is van groot belang. Voor 
het met zekerheid stellen van de diagnose moet - volgens de huidige standaarden - materiaal 








olaire lavage of een longbiopsie. Dit materiaal wordt dan onderzocht op de aanwezigheid 
van P. jirovecii door middel van directe microscopie en toepassing van PCR-technieken. Beide 
onderzoeksprocedures ter verkrijging van het materiaal zijn belastend voor de patiënt en 
geven een niet te verwaarlozen kans op complicaties. In hoofdstuk 5 beschrijven we het 
onderzoek dat werd verricht naar het toepassen van een patiëntvriendelijkere methode om 
de diagnose Pneumocystis pneumonie te stellen: namelijk door het meten van zogenaamde 
‘markers’ in het bloed. Twee chemische verbindingen kwamen hiervoor in aanmerking: S-
adenosylmethionine (AdoMet) en 1,3-β -D-glucan (β-D-glucan).
Het S-adenosylmethionine is een lichaamseigen stof die door de cellen van het lichaam 
wordt gebruikt bij diverse metabole processen. Onderzoek bij ratten laat zien dat tijdens een 
infectie met P. jirovecii de concentratie van deze stof in het serum fors daalt. De hypothese 
bestaat dat P. jirovecii niet in staat is tot het zelf aanmaken van AdoMet en afhankelijk is van 
opname uit de omgeving. Enkele uitzonderingen daargelaten zijn verder alle parasieten, 
schimmels en bacterien wel in staat tot de synthese van AdoMet. In tegenstelling tot AdoMet 
is het β-D-glucan niet een lichaamseigen stof, maar een belangrijk onderdeel van de celwand 
van P. jirovecii. Bij het uit elkaar vallen van het micro-organisme komt het β-D-glucan vrij in 
de bloedcirculatie. Een detecteerbare concentratie van β-D-glucan in het serum zou derhalve 
wijzen op de diagnose Pneumocystis pneumonie.
De door ons uitgevoerde studie was gericht op de evaluatie van de hierboven beschreven 
markers bij HIV-negatieve patienten met een mogelijke Pneumocystis pneumonie. Uit autop-
siestudies is gebleken dat in deze groep patienten de hoeveelheid Pneumocystis relatief lager 
is - en de inflammatie in de longen heviger - in vergelijking met Hiv-geïnfecteerde patiënten 
met een Pneumocystis pneumonie. Eerdere studies beoordeelden de diagnostische waarde 
van de genoemde serum markers slechts bij Hiv-positieve patiënten. Deze resultaten zijn 
dus niet zondermeer toepasbaar op patienten met bijvoorbeeld een solide orgaan trans-
plantaat en een verdenking op Pneumocystis pneumonie. Uit onze studie bleek dat de serum 
AdoMet waarden niet goed discrimineerden tussen het hebben van wel of geen Pneumo-
cystis pneumonie op het moment van presentatie in het ziekenhuis. Daarentegen was het 
onderscheidende vermogen van de β-D-glucan serum marker wel zeer goed. De hoogte van 
de concentratie gemeten β-D-glucan hing tevens significant samen met de surrogaatwaarde 
voor de hoeveelheid Pneumocystis DNA in de long, de zogenaamde Ct-waarde. Nadeel van de 
β-D-glucan test blijft dat deze ook in het geval van sommige andere schimmelinfecties een 
positieve uitslag geeft. Dit maakt dat deze test alleen als diagnosticum voor Pneumocystis 
pneumonie gebruikt kan worden als hierop een hoge klinische verdenking bestaat op basis 
van zowel het onderliggende lijden en de radiologische beeldvorming (bij voorkeur CT-scan).
Het 2e deel van dit proefschrift bevat de beschrijving van twee onderzoeken naar de genetische 
predispositie voor het ontwikkelen van een invasieve aspergillusinfectie bij patienten die een 
allogene stamceltransplantatie hebben ondergaan. Bij afwezigheid of slecht functioneren 
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van de witte bloedcellen na de voorbereidende chemotherapie voor stamceltransplantatie is 
de patiënt kwetsbaar voor invasieve schimmelinfecties. Een afweerbarrière die dan nog wel 
kan worden opgeworpen is die van de zogenaamde ‘innate immunity’ (aangeboren afweer). 
Onderdeel hiervan zijn de in de long aanwezige macrofagen (een bepaald type afweercellen) 
die met behulp van receptoren binnenkomende schimmelkiemen (conidia) herkennen en 
afbreken. Ook kunnen zij door uitscheiding van signaalstoffen (cytokines) andere afweercel-
len uit de omgeving aantrekken om de ontstekingreactie te intensiveren.
In het onderzoek beschreven in hoofdstuk 6 onderzochten we of een defecte Dectin-1-
receptor functie, ten gevolge van de stopcodon mutatie ‘Y238X’, het risico op het ontwikkelen 
van invasieve aspergillusinfectie verhoogd. De dectin-1 receptor is een eiwit dat dient voor 
het herkennen van β-D-glucan in de wand van een schimmel. Afweercellen van patienten die 
de Y238X-mutatie van zowel vaders als moederszijde hebben geërfd bezitten deze receptor 
niet. Het klinische belang van de aanwezigheid van deze mutatie werd geëvalueerd in een 
groep van 71 patiënten die een allogene stamceltransplantatie hadden ondergaan, en in 
een aparte groep van 21 patiënten die een invasieve aspergillus-infectie ontwikkelden na 
chemotherapie zonder stamceltransplantatie. De controlegroep bestond uit 108 patiënten 
die allen een allogene stamceltransplantatie hadden ondergaan. Tevens werd bestudeerd of 
de aanwezigheid van de Y238X-mutatie was gerelateerd met het beloop van de aspergillus-
infectie. Bij patienten die een allogene stamceltransplantatie hadden ondergaan en hete-
rozygoot waren voor de Y238X-mutatie bleek een trend aanwezig tot een hoger risico voor 
het ontwikkelen van een invasieve aspergillus-infectie. Het genotype van de stamceldonor 
was niet van invloed. Een opvallende bevinding was dat Y238X allelfrequentie hoger was 
bij niet-getransplanteerde hematologiepatiënten met een invasieve aspergillus-infectie 
(19.0%) ten opzichte van het wél getransplanteerde patiëntencohort en een steekproef uit 
de Nederlandse bevolking (bereik 6.9%-7.7%, pH-waarde <0.05). Uit laboratoriumtesten 
bleek dat uit het bloed gewonnen cellen met een volledig defect in Dectin-1 functie minder 
efficiënt reageerden tegen Aspergillus. Echter, gekweekte macrofagen met dezelfde defi-
ciëntie, bleken ondanks de gebrekkige Dectin-1 functie wel een adequate reactie te kunnen 
genereren tegen Aspergillus. Dit laat zien dat het aangeboren afweersysteem vermoedelijk 
beschikt over alternatieve oplossingen in geval van het disfunctioneren van één of enkele 
afzonderlijke componenten.
hoofdstuk 7 beschrijft het onderzoek naar de invloed van de gemeenschappelijke 
aanwezigheid van mutaties in Toll-like receptor- en cytokine genen op het risico voor het 
ontwikkelen van een invasieve aspergillus-infectie. De genoemde genen zijn allen betrokken 
bij de regulatie van de activiteit van longmacrofagen. Vierenveertig patienten die een al-
logene stamceltransplantatie ondergingen en bij wie een invasieve aspergillus-infectie werd 
gediagnosticeerd, werden in het onderzoek geïncludeerd. De controlegroep bestond uit 64 
allogeen getransplanteerde patienten zonder invasieve aspergillus-infectie. Alle patienten 








mutatie in Toll-like receptor 4 bleek alleen geassocieerd met het ontstaan van een invasieve 
aspergillus-infectie indien deze mutatie aanwezig was bij de donor van de getransplanteerde 
patiënt. In een multivariate analyse was de gecombineerde aanwezigheid van de Toll-like 
receptor 4 1063 A>G en de Interferon-γ 874 T>A of de gecombineerde aanwezigheid van 
de Toll-like receptor 6 745 C>T met de Interferon-γ 874 T>A mutatie, geassocieerd met het 
optreden van invasieve aspergillus-infectie. Hoewel de resultaten ook na correctie voor 
aanwezigheid van graft-versus-host ziekte en de duur van de neutropenie significant waren 
of een duidelijke trend lieten zien, is er een aantal beperkingen aan deze studie. Vooral door 
de relatief kleine aantallen patienten kunnen de resultaten vertekend zijn. De bevindingen 
wijzen op de relevante immunologische routes die betrokken zijn bij afweer tegen invasieve 
aspergillus-infectie van de longen en rechtvaardigen verdere studie naar de effecten van 
Toll-like receptor en cytokine mutaties.
hoofdstuk 8 geeft een overzichtsbeschrijving van de huidige stand van zaken ten aan-
zien van de ontwikkeling van radioactiefgelabelde antimicrobiële moleculen die mogelijk 
gebruikt kunnen worden voor het diagnosticeren van invasieve schimmelinfecties. Dit 
onderzoek is grotendeels nog in een experimentele fase. De belangrijkste studies in mui-
zen laten vooral zien dat Technetium-99 gelabeld fluconazol een selectieve tracer kan zijn 
voor het detecteren van Candida albicans infecties. Voor Aspergillus zijn dergelijke proeven 
tot op heden niet erg succesvol gebleken. In de toekomst zouden nieuwe antimicrobiele 
medicamenten, bijvoorbeeld de echinocandines, voor dit doel geëvalueerd kunnen worden. 
Uiteindelijk zullen de in klinische studies onderzochte reproduceerbaarheid en veiligheid, 
van deze nieuw te ontwikkelen markers bepalen of zij kunnen worden toegevoegd aan het 
diagnostisch armamentarium.
Conclusies
Het onderzoek uit het eerste deel van het proefschrift toont aan dat de overdracht van Pneu-
mocystis jirovecii meest waarschijnlijk plaats vindt van persoon tot persoon. In de engelse 
samenvatting en discussie worden de achterliggende overwegingen ten aanzien van de 
factoren die een rol spelen in het ontstaan van een uitbraak/epidemie uitgebreid uiteenge-
zet. Verder benadrukken de bevindingen het belang van het toepassen van een profylaxe-
strategie ter voorkoming van een Pneumocystis pneumonie bij niertransplantatiepatienten. 
De resultaten ondersteunen ook het eerder veronderstelde nut van isolatiemaatregelen bij 
patienten die worden opgenomen met een Pneumocystis pneumonie.
Ten aanzien van de duur van de profylaxe zijn er meerdere benaderingen mogelijk. Om de 
incidentie van Pneumocystis pneumonie onder niertransplantatiepatienten laag te houden 
(beneden de 1 per 100 transplantaties) kan gekozen worden voor een duur tot 12 maanden 
na transplantatie voor iedere patiënt, of voor een risicoprofiel geleid algoritme. In het meest 
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optimale algoritme krijgen alleen de relatief oudere patienten (55+) en diegenen die be-
handeld worden voor afstoting van het transplantaat tot 12 maanden na transplantatie co-
trimoxazol. Alle overige patienten behoeven slechts profylaxe te gebruiken tot 6 maanden 
na transplantatie.
Het onderzoek naar het gebruik van serummarkers voor de diagnose Pneumocystis pneu-
monie bij niet Hiv-geinfecteerden laat zien dat β-D-glucan het meest geschikt is voor dit 
doel. Een juiste beoordeling van de à a-priori kans op basis van de klinische en radiologische 
gegevens is van groot belang om de uitslag juist te kunnen interpreteren. Het gebruik van 
radioactief gelabelde stoffen voor het diagnosticeren van invasieve schimmelinfecties is nog 
in het stadium van dierexperimenteel onderzoek. Een aantal vorderingen zijn veelbelovend, 
maar behoeven in de toekomst verdere evaluatie in klinische trials.
Uit de studies naar de genetische predispositie voor het ontwikkelen van een invasieve 
aspergillus-infectie na stamceltransplantatie blijkt dat geen enkele mutatie in het innate 
immuunsysteem van essentieel klinisch belang is. Aanwezigheid van de Dectin-1 Y238X mu-
tatie heeft bijvoorbeeld slechts een beperkte invloed op de kans op het ontstaan van een 
invasieve aspergillus-infectie. Combinatie van verscheidene mutaties zoals hierboven 
beschreven lijken, met name indien aanwezig in het DNA van de stamceldonor, wel degelijk 
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geleidelijk duidelijk dat Interne Geneeskunde de specialisatie van keuze was. Na het behalen 
van het artsexamen (cum laude) aan de Rijks Universiteit Leiden in 2001, begon hij als arts-
assistent op de afdeling Interne Geneeskunde van het Leids Universitair Medisch Centrum. Na 
aanname voor de opleiding tot internist (opleiders Prof. dr. A.E. Meinders, dr. J.W. van ’t Wout 
en Prof. dr. J.A. Romijn) volgde in 2008 de registratie in het specialistenregister. Gedurende de 
periode van 2004 tot 2007 was hij bestuurslid van de Jonge Nederlandse Internistenvereni-
ging (JNIV) en lid van het Forum Visitatorum. De vanaf het begin af aan gekoesterde interesse 
voor infectieziekten leidde in 2006 tot de keuze voor het betreffende aandachtsgebied (op-
leider Prof. dr. J.T. van Dissel), waarvoor hij registreerde in september 2008. Het onderzoek 
dat aanleiding gaf tot de totstandkoming van dit proefschrift nam in 2005 een aanvang, toen 
een uitbraak van Pneumocystis pneumonie onder niertransplantatiepatienten (beschreven in 
hoofdstuk 2) samenviel met een stage op de afdeling klinische epidemiologie onder leiding 
van Prof. dr. J.P. Vandenbroucke. Voor veel verkregen vaardigheden die nodig zijn voor het 
verrichten van klinisch onderzoek werd in deze periode de grondslag gelegd. Het onderzoek 
liep naast de klinische werkzaamheden van de auteur voort tot eind 2010. Behalve de spe-
ciale interesse in infecties veroorzaakt door Pneumocystis jirovecii en Aspergillus sp., heeft de 
auteur zich verder toegelegd op de behandeling van patienten die geïnfecteerd zijn met HIV. 








Dit proefschrift zou zonder de medewerking en inspanningen van velen niet zijn huidige 
vorm hebben bereikt.
Frank, ik weet nog goed de eerste keer dat ik op je werkkamerdeur klopte, ‘of ik wat 
onderzoek mocht doen…?’ Bedankt voor alles wat je me sindsdien leerde. Luc, ook mede 
dankzij jouw opgewekte aanmoediging en introductie in de ‘Pneumocystologie’ is het zover 
gekomen. Daarnaast dank ik de vele andere artsen, wetenschappers en overige medewer-
kers voor de fijne en vriendschappelijke samenwerking in de afgelopen jaren. Ook veel dank 
uiteraard aan alle patienten die deelnamen aan het onderzoek.
Een bijzonder woord van dank wil ik richten aan mijn ouders, die mij in staat stelden te 
studeren en het beroep te kiezen dat ik ambieerde.
Lieve Evelyne, Rozemarijne en Pheline, jullie zijn het geluk in mijn leven. Bedankt voor alle 
tijd, inspiratie en kracht die jullie mij gaven om dit project succesvol af te ronden. Laten we 
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